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The amyloid cascade hypothesis suggests that overproduction and 
accumulation of the neurotoxic amyloid beta (Aβ) peptide plays a central role 
in Alzheimer’s disease (AD). Aβ is generated from the sequential cleavage of 
the amyloid precursor protein (APP) through the β-secretase pathway. Several 
isoforms of APP exist: APP695, APP751, and APP770, generated through 
alternative splicing of exons 7 and 8. Alternative splicing to produce APP695 
involves exclusion of exon 7, encoding the Kunitz protease inhibitor (KPI), and 
exon 8. Studies show up-regulation of KPI-containing APP isoforms (APP770 
and APP751) in AD and increase Aβ deposition, whereas APP695 is down-
regulated. Furthermore, the AICD (Amyloid Intracellular Domain) which is 
preferentially produced from APP695 can translocate to the nucleus and act 
as a transcription factor for genes such as Neprilysin which acts to degrade 
Aβ. Therefore, APP695 is theorised to be protective against AD, with its loss 
coinciding with disease progression. 
This study sought to design Phosphorodiamidate morpholino oligomers 
(PMOs) specific to exons 7 and 8 of APP, targeting exonic splicing enhancer 
(ESE) sites, sterically hindering their binding, and modulating alternative 
splicing, thus increasing APP695 levels. In addition, this study assessed the 
efficacy of these PMOs and examined the protective effects of APP695 and 
its cleavage products by analysing downstream effects of splicing modulation. 
Results demonstrate that PMOs successfully induced alternative splicing 
events, modulating APP at the RNA and protein level, and significantly 
increasing APP695. Western blotting data confirmed the presence of the AICD 
peptide in protein samples from PMO transfected cells. Following this, qPCR 
data confirmed that PMO transfected cells show increased expression of key 
Aβ clearing proteins such as Neprilysin. The data collected in this thesis 
reinforces the theory that APP695 is protective against AD through the effects 
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1  Introduction 
1.1 Alzheimer’s disease: An overview 
Alzheimer’s disease (AD) was first defined in 1907 by Alois Alzheimer 
(Stelzmann et al. 1995). AD is a debilitating age-related progressive 
neurodegenerative disorder which leads to major cognitive and behavioural 
deficits, and is the most prevalent of all neurodegenerative disorders affecting 
10% of over 65 year olds and over 50% of those above the age of 85 years 
(Hebert et al. 1995; Zhang et al. 2011; Nalivaeva & Turner 2013). AD is part 
of a subset of neurological disorders known as dementias. Dementias are 
characterised by a loss in memory and/or cognitive ability, and AD is the most 
common form of dementia, making up over 60% of total cases worldwide 
(Bekris et al. 2010; Erk et al. 2011; Holtzman et al. 2011). With its incidence 
growing in recent years, it is predicted that AD will affect over 65 million people 
by 2030, and over 100 million by 2050 (Holtzman et al. 2011; Karran et al. 
2011; Bandyopadhyay & Rogers 2014). This increasing incidence is placing 
increasing pressure on healthcare systems globally and becoming a major 
burden on the economy, costing an estimated 817 billion US dollars globally 
in 2015 (Holtzman et al. 2011; Wimo et al. 2017). As of now, there are no 
available cures or preventative medications for AD, and the majority of clinical 
trials targeting AD have proven unsuccessful, and therefore greater 
understanding and potential therapeutics for AD treatment are needed (Coric 
et al. 2012; Doody et al. 2013; Egan et al. 2018; Honig et al. 2018). 
As AD is a disease of aging, the pathological process begins many years prior 
to the development of the disease. This implies that there are transitional 
phases between the process of normal aging, and AD. The first transitional 
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state between normal aging and AD, is called pre-clinical phase. The pre-
clinical phase is characterised by changes in AD related biomarkers that can 
be detected in the cerebrospinal fluid (CSF) and through positron emission 
tomography (PET) or magnetic resonance imaging (MRI) of the brain 
(Hansson et al. 2006; Rowe et al. 2007; Buchhave et al. 2012; Schoonenboom 
et al. 2012). The first biomarker changes that are observed in the brains of 
pre-clinical individuals are related to the formation of amyloid beta (Aβ) 
plaques and neurofibrillary tangles (NFTs) of tau protein, the two pathological 
hallmarks of AD (Seppälä et al. 2012). Structural brain changes such as 
atrophy and decreased hippocampus volume appear next and can be 
detected by MRI . All of these AD markers appear before the first symptoms 
of cognitive decline (Phelps et al. 1979; Hoffmann et al. 2000; Vemuri et al. 
2009). Studies in cognitively normal individuals have shown that increased Aβ 
plaque abundance in the brain, as measured by Pittsburgh compound B (PiB)-
PET, slightly decrease cognitive performance, impair episodic memory, 
reduce hippocampus volume and accelerate cortical atrophy compared with 
individuals that are PiB PET negative (Rentz et al. 2010; Pontecorvo et al. 
2019).  
Progression from the pre-clinical to the prodromal phase of AD, also known as 
mild cognitive impairment (MCI), is not well understood. It is possible that all 
individuals with pre-clinical AD will eventually progress to MCI and 
subsequently AD if they were to live long enough, however research has also 
shown that cognitively normal subjects with an Aβ load that is indistinguishable 
from patients with AD, can remain cognitively stable (Morris et al. 2009; 
Sperling et al. 2011; Villemagne et al. 2011; Vlassenko et al. 2011). Therefore, 
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it is possible that some patients have compensatory mechanisms that are 
efficient enough to prevent the progression to AD. In a recent study by Roberts 
et al. individuals without dementia were randomly selected and evaluated both 
clinically and cognitively at baseline and then every 15 months for 10 years 
(Roberts et al. 2018). The results of this study showed that 14.5% of 
individuals with preclinical AD developed MCI within the 3.7 year mean follow-
up period, and 3.2% developed AD dementia within 4.2 years of follow-up 
(Roberts et al. 2018). The progression from the pre-clinical phase to MCI is 
caused by progressive Aβ plaque deposition, tau NFT build up and cortical 
atrophy which are associated with a decline in cognitive and behavioural 
functions (Balducci et al. 2010; Holtzman et al. 2011; Johnson et al. 2012). 
Individuals with MCI are said to be at increased risk of developing AD later in 
life, and MCI is therefore said to be a prodromal state. The characterization of 
MCI includes the following criteria:  First, a subjective complaint of a memory 
disorder (preferably corroborated by an informant); second, an intact ability to 
carry out everyday activities such as meal preparation; third, preserved 
general cognitive abilities; fourth, objective evidence of a memory deficit; and 
fifth, the absence of dementia (Libon et al. 2014). In patients with MCI, atrophy 
first manifests in the medial temporal lobe, with structures such as the 
entorhinal cortex, hippocampus and amygdala being among the first to be 
affected (Scahill et al. 2002; Spulber et al. 2013). This stage is the MCI stage, 
and as previously stated, is the transitional state between normal aging and 
AD. 
Two studies by Roberts et al. and Ye et al. showed that 32.7% and 70.0% of 
individuals with MCI developed AD dementia within 3.2 years and 3.6 years of 
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follow-up, respectively (Roberts et al. 2018; Ye et al. 2018). In these patients 
that progress to AD we see the first symptomatic presentation of AD, episodic 
and spatial memory deficits, which include short-term memory deficits (Frisoni 
et al. 2009; Zhang et al. 2011). Further progression of AD as the disease 
spreads is known as mild stage AD and involves spread of the disease to brain 
regions such as the lateral temporal and parietal lobes leading to deficits in 
semantic memory, memory of facts or events (Frisoni et al. 2009; Zhou et al. 
2010; Rami et al. 2012). Cortical atrophy as well as atrophy of the precuneus 
and posterior cingulate gyrus, frontal and temporal cortices, hippocampus, 
amygdala and enlargements of the temporal horn are also typically seen in AD 
patients (Zhou et al. 2010; Apostolova et al. 2012; Rami et al. 2012). Other 
cognitive deficits associated with early mild stage AD include: changes in 
attention, problem solving ability, language dysfunction, visuospatial difficulty, 
and personality changes (Holtzman et al. 2011; Zhang et al. 2011). 
Progression to the moderate stage of AD involves progressive atrophy of the 
brain regions that  lead to impairment of procedural memory, which involves 
memories of how to perform and learning of normal everyday tasks, as well as 
changes in behaviour, and deficits in problem solving and language. Further 
to this, the disease is able to spread to other brain regions, with potential 
occipital lobe atrophy leading to visual impairment (McDonald et al. 2009). 
These symptoms worsen over time as the disease progresses, and atrophy 
spreads further throughout the brain, however the severity and the variety of 
these symptoms are dependent on each patient. This eventually leads to 
complete dependency of patients on caregivers for all aspects of daily life and 
impacts both the patients and their families greatly. At this stage of the disease 
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individuals can also become mute, and unable to walk, swallow or control 
bladder and bowel function; these final stages of the disease can also be fatal 
(Holtzman et al. 2011). This atrophy that is central to AD progression is due to 
losses of synapses, and neuronal death which lead to brain shrinkages. 
In 1992, Cummings and Benson described three clinical stages of 
symptomatic AD. The first stage involves memory impairment, while 
personality and social skills are preserved. The second stage involves 
worsening of memory impairment, aphasia and apraxia, restlessness, and 
occasional incontinence. In the third stage, all cognitive functions deteriorate. 
There is sometimes limb rigidity present associated with a loss of mobility, and 
patients are incontinent of urine and faeces. Death in patients usually occurs 
from infection (Cummings & Benson D.F 1992). 
 
1.2 Histopathological hallmarks of Alzheimer’s disease 
AD is characterised by the presence of two pathological hallmarks; 
intraneuronal neurofibrillary tangles (NFTs) and extracellular plaques of Aβ 
(figure 1.1) (Hardy & Higgins 1992; Bierer et al. 1995; Ingelsson et al. 2004; 
Galimberti & Scarpini 2010; Carrera et al. 2013). Isolation and purification of 
these extracellular plaques from AD patient brains identified a small peptide 
(36-43 amino acids) called β-amyloid (Aβ) as a major constituent of the 
plaques (Glenner & Wong 1984). The intraneuronal NFTs on the other hand 
were labelled with tau specific antibodies, which revealed that they were 
formed of aggregated hyperphosphorylated filaments of the microtubule 
associated tau protein (Grundke-Iqbal et al. 1986). These findings strongly 
associated accumulation of both Aβ, and tau protein in the pathogenesis and 
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progression of AD. Both of these are seen as diagnostic markers of AD, and 
can be used to diagnose AD in the brains of AD patients pre- and post-mortem 
(Guillozet et al. 2003; Buchhave et al. 2012; Jansen et al. 2015).  The accumulation 
and dysregulation of these proteins are seen to be a major factor in neuronal 
death and therefore brain atrophy (Balducci et al. 2010; Holtzman et al. 2011).  
Although these are the two most common, pathophysiological hallmarks of AD, 
there are other pathophysiological features that present in patients with AD. 
One of these is cerebral amyloid angiopathy (CAA). CAA and AD have overlap 
as Aβ is pathogenic in both of these conditions (Kalaria & Ballard 1999). In AD 
extracellular Aβ deposits are common and are able to aggregate, forming 
amyloid plaques. Aβ peptides also has the ability to deposit in cerebral blood 
vessels, causing CAA. Research has shown that up to 98% of patients with 
AD have some degree of cerebral amyloid angiopathy (Kalaria & Ballard 
1999). The predominant form of Aβ present in CAA is the Aβ40 variant, and 
affects small arteries, arterioles, and capillaries (Greenberg & Vonsattel 1997; 
Perl 2010; Serrano-Pozo et al. 2011). Research has shown that the parietal 
and occipital cortices are more vulnerable to CAA than the frontal and temporal 
lobes, and leptomeningeal arteries are more vulnerable than parenchymal 
vessels (Greenberg & Vonsattel 1997; Serrano-Pozo et al. 2011). Severe CAA 
can impair blood flow and lead to spontaneous ischemic lesions or vascular 
ruptures leading to accumulation of blood in the brain (Perl 2010). These 
haemorrhages tend to occur in the white matter of the frontal and occipital 
lobes rather than around the lenticular nuclei and thalamus. These are often 
small and CAA can present with multiple at once (Perl 2010). 
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Granulovacuolar degeneration (GVD) is another change that is present in AD 
patients. In addition to AD, it is detected in other neurodegenerative diseases. 
GVD presents as 3– 5 μm vacuoles with a central 0.5–1.5 μm dense granule 
which are considered to be autophagic (Hirano et al. 1968; Funk et al. 2011). 
They are most frequent in the cytoplasm of pyramidal neurons in the 
hippocampus. Recent research has suggested that the presence of 
granulovacuolar bodies correlate with neurofibrillary tangle density, 
suggesting they may be a cellular response to damage in neurons (Hou et al. 
2018). GVDs are seen in brains of elderly individuals with normal cognition, 
but studies have reported that GVDs correlate well with a diagnosis of AD, and 
that brains of AD patients present with large numbers of GVDs in the 
hippocampus (Tomlinson & Kitchener 1972; Lo 1977).   
Hirano bodies are another pathophysiological change that is present in AD 
patients. These were first described in Parkinson’s disease patients and found 
in the presence of NFTs and GVDs, but not amyloid plaques (Hirano et al. 
1968; Hirano 1994). Hirano bodies form rod-like inclusions located in neuronal 
dendrites and are rich in F-actin and actin binding proteins. Hirano bodies have 
been reported in elderly normal individuals and are more frequent and 
numerous in AD patients than in normal patients (Gibson & Tomlinson 1977). 
Their role in AD pathogenesis is unclear, however, recent animal models 
expressing mutant actin binding proteins suggest Hirano bodies are 
associated with impaired synaptic responses and decreased spatial working 
memory (Furgerson et al. 2014). 
Astrogliosis is a non-specific feature that can occur in response to injury to the 
CNS and involves the activation and proliferation of different types of glial cells. 
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Under physiological conditions, glial cells, such as astrocytes, function to 
respond to CNS damage which can be caused by infection, trauma, ischemia 
or even neurodegenerative diseases. They respond to this damage by a 
process commonly referred to as reactive astrogliosis, which involves changes 
in their molecular expression and morphology, and is also responsible for 
scare formation in response to severe damage (Sofroniew 2005). Astrogliosis 
is marked by increased proliferation and activation of microglia and reactive 
astrocytes near the sites of amyloid plaques deposits (Olabarria et al. 2010). 
The process of an astrocyte becoming reactive usually takes place in response 
to Inflammatory mediators released by microglia, neurons, endothelial cells, 
leucocytes and other astrocytes. Reactive astrocytes surround amyloid beta 
plaques and contribute to the local inflammatory response by releasing pro-
inflammatory cytokines and modulate calcium signalling (Frost & Li 2017). The 
impact of reactive astrogliosis in disease is complex: reactive astrocytes can 
be both harmful and beneficial to surrounding cells and may worsen or resolve 
the initial CNS injury (Sofroniew & Vinters 2010). Notably, reactive astrocytes 
are necessary for scar formation, which helps to contain the spread of 
inflammatory cells, and also for repairing insults to the blood–brain barrier 
(Sofroniew 2005; Wanner et al. 2013). Conversely, reactive astrocytes may be 
neurotoxic when producing reactive oxygen species and inflammatory 







Figure 1.1: Photomicrographs of the temporal cortex of a patient with Alzheimer’s 
disease highlighting the presence of the pathological hallmarks of AD. A) using a 
modified Bielschowski stain at 40x magnification. B) using a modified Bielschowski stain at 
100x magnification. C) using an immunohistochemical preparation using the TG-3 antibody 
directed against abnormally phosphorylated tau. Senile plaques are highlighted with black 





Clinical diagnosis of AD is very difficult due to the progression of the disease 
which takes place over multiple decades. The current clinical diagnosis of AD 
combines both biomarker testing and neuropsychological testing (McKhann et 
al. 1984). Clinical diagnosis is often made in accordance with the criteria from 
the National Institute of Neurological and Communicative Disorders and 
Stroke—Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) (McKhann et al. 1984; McKhann et al. 2011), These criteria are 
centred on attempting to exclude other dementias or disorders that could 
account for cognitive deterioration, and result at best in a diagnosis of probable 
AD. Patients are assessed by clinicians and classified into groups based on 
whether they patients show cognitive or behavioural deficits that match any of 
the following statements as taken from Mckhann et al 2011: Interfere with the 
ability to function at work or at usual activities; and 
1. Represent a decline from previous levels of functioning and performing; 
and 
2. Are not explained by delirium or major psychiatric disorder. 
3. Cognitive impairment is detected and diagnosed through a combination 
of (1) history-taking from the patient and a knowledgeable informant 
and (2) an objective cognitive assessment, either a “bedside” mental 
status examination or neuropsychological testing. Neuropsychological 
testing should be performed when the routine history and bedside 
mental status examination cannot provide a confident diagnosis. 
4. The cognitive or behavioural impairment involves a minimum of two of 
the following domains: 
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a. Impaired ability to acquire and remember new information—
symptoms include: repetitive questions or conversations, 
misplacing personal belongings, forgetting events or 
appointments, getting lost on a familiar route. 
b. Impaired reasoning and handling of complex tasks, poor 
judgment—symptoms include: poor understanding of safety 
risks, inability to manage finances, poor decision-making ability, 
inability to plan complex or sequential activities. 
c. Impaired visuospatial abilities—symptoms include: inability to 
recognize faces or common objects or to find objects in direct 
view despite good acuity, inability to operate simple implements, 
or orient clothing to the body. 
d. Impaired language functions (speaking, reading, writing)—
symptoms include: difficulty thinking of common words while 
speaking, hesitations; speech, spelling, and writing errors. 
e. Changes in personality, behaviour, or comportment—symptoms 
include: uncharacteristic mood fluctuations such as agitation, 
impaired motivation, initiative, apathy, loss of drive, social 
withdrawal, decreased interest in previous activities, loss of 
empathy, compulsive or obsessive behaviours, socially 
unacceptable behaviours. 
Following this, if the patients meets any of the above statements, they 
are assessed for probable AD. Probable AD is determined by a clinician 
when the patient:  
30 
 
Meets criteria for dementia described earlier in the text, and in addition, 
has the following characteristics: 
a. Insidious onset. Symptoms have a gradual onset over months to 
years, not sudden over hours or days. 
b. Clear-cut history of worsening of cognition by report or 
observation; and 
c. The initial and most prominent cognitive deficits are evident on 
history and examination in one of the following categories. 
i. Amnestic presentation: It is the most common syndromic 
presentation of AD dementia. The deficits should include 
impairment in learning and recall of recently learned 
information. There should also be evidence of cognitive 
dysfunction in at least one other cognitive domain, as 
defined earlier in the text. 
ii. Nonamnestic presentations: 
• Language presentation: The most prominent 
deficits are in word-finding, but deficits in other 
cognitive domains should be present. 
• Visuospatial presentation: The most prominent 
deficits are in spatial cognition, including object 
agnosia, impaired face recognition, 
simultanagnosia, and alexia. Deficits in other 
cognitive domains should be present. 
• Executive dysfunction: The most prominent 
deficits are impaired reasoning, judgment, and 
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problem solving. Deficits in other cognitive 
domains should be present. 
Clinical diagnosis of probable AD based on the above criteria alone has been 
shown to achieve an average sensitivity 81% and an average specificity of  
70% (Knopman et al. 2001) .In persons who meet the core clinical Criteria for 
probable AD, dementia biomarker evidence can be assessed to increase the 
confidence and accuracy of AD diagnosis (McKhann et al. 2011). Confirming 
the presence of biomarkers that reflect the pathology of AD is a beneficial step 
towards ascertaining a patients AD status, and as these biomarkers show 
abnormal concentrations even in the pre-clinical, early stages of AD, this 
allows for AD to be diagnosed early (De Meyer et al. 2010). In terms of 
biomarkers, CSF biomarkers are preferred over blood or plasma biomarkers 
as they reflect the pathophysiology of the brain, as the brain and the CSF are 
in direct contact (Albert et al. 2011; Sperling et al. 2011). CSF biomarkers are 
measured via a lumbar puncture (LP), which when performed correctly has a 
low complication rate, a high diagnostic yield and are generally considered to 
be well tolerated by patients (Duits et al. 2016). CSF biomarkers are related to 
the three major pathological changes that occur in the brain of AD patients: Aβ 
plaques, NFTs and neuronal loss. When assessing CSF Aβ levels, generally 
Aβ42 levels decrease in the CSF in response to greater deposition of Aβ42 in 
the brain of the patient (Jansen et al. 2015). This is because as more of the 
insoluble Aβ42 aggregates and forms plaques, there is less free Aβ42, 
resulting in a detectable decrease in of Aβ42 in the CSF. Research has shown 
that this Aβ plaque deposition can occur at least 10 years prior to the first 
symptoms of AD appearing, meaning that decreases Aβ42 should be 
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detectable in the CSF early in the progression of AD, providing a promising 
method of diagnosing early AD, which could be beneficial in a clinical setting 
(Buchhave et al. 2012; Jansen et al. 2015). 
Tau is present in the cytosol of neurons, and in AD, imbalances between 
kinases and phosphatases result in tau hyperphosphorylation, leading to tau 
detachment from microtubules and its accumulation as NFTs. During this 
process, tau proteins are also released into the extracellular space, which 
leads to an increase in detectable CSF tau, and CSF phosphorylated tau 
concentrations in AD (Buchhave et al. 2012). Research has shown that CSF 
tau levels are more strongly correlated with cognitive decline than CSF Aβ42, 
making this a very useful biomarker for the diagnosis of AD (Savva et al. 2009). 
Changes in these biomarkers allow diagnosis of AD in its prodromal phase, 
and therefore could be used to diagnose and begin AD treatment early in the 
cycle of disease progression (Hansson et al. 2006). The concentration of CSF 
Aβ42 decreases over time in AD patients whereas the levels of tau and 
phosphorylated tau increase compared to healthy controls (Sunderland et al. 
2003). Having all three biomarkers in the normal range rules out AD, whereas 
combining these three biomarkers, has the highest diagnostic power to 
discriminate between cognitively healthy and AD patients with a sensitivity of   
(Sunderland et al. 2003; Engelborghs et al. 2008). 
Aside from CSF biomarkers, imaging-based biomarkers can also be assessed 
for AD diagnosis. These biomarkers are imaged using a technique called PET. 
For AD, PET utilizes ligands specific to biomarkers of AD, and the binding of 
these ligand to their associated biomarkers will allow for visualization of 
biomarker levels and localization (Kapoor et al. 2004). These imaging-based 
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biomarkers include PET with amyloid-specific probes. After injection of a 
radiolabelled tracer agent, patients undergo a specialized PET scan which 
detect regions of Aβ deposition and plaque formation. One such amyloid-
specific probe is the PiB labelled with C-11 (Klunk et al. 2004). This compound 
is derived from thioflavin-T which has a high affinity to Aβ plaques, binding 
strongly to these plaques allowing for visualizing and making it useful as both 
a diagnostic tool and as a reference for other Aβ PET tracers (Klunk et al. 
2004). This tracer is useful for both AD diagnosis and in a research setting, 
however the short half-life of the C-11 compound makes its utility limited (Choi 
et al. 2009). As a result of this, an F-18 based Aβ tracer has been developed, 
which has a longer half-life, and is therefore more clinically relevant. As of now, 
there are three F-18 labelled Aβ PET tracers approved by the FDA for clinical 
use (Choi et al. 2009; Nelissen et al. 2009; Wolk et al. 2012). Other imaging-
based biomarkers look for markers of neuronal injury, these include tau tracers 
such as the 18F flortaucipir tracer, the use of fluorodeoxyglucose PET imaging 
to quantify the decreased glucose metabolism in affected brain regions, and 
the analysis of magnetic resonance imaging (MRI) for determination of 
hippocampal or medial temporal lobe atrophy (Phelps et al. 1979; Hoffman et 
al. 2000; Vemuri et al. 2009; Pontecorvo et al. 2019).  
Evidence from memory clinic-based studies which include autopsy-confirmed 
dementia patients showed that the accuracy of CSF biomarkers as a 
diagnostic tool were comparable in accuracy to the clinical diagnostic work-up 
which is performed by clinicians in patients (Le Bastard et al. 2010; 
Niemantsverdriet et al. 2018). This work-up consists of an interview with the 
patient and caregiver, physical and clinical exam blood analysis, extensive 
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neuropsychological examination, and brain imaging. However, LPs to assess 
CSF biomarkers are invaluable in cases where the clinical diagnostic work-up 
for a patient is unable to differentiate between AD, or another type of dementia, 
and in patients with early-onset AD (EOAD) (Le Bastard et al. 2010). This 
allows for accurate and early disease diagnosis and could also allow for 
suitable AD treatment to be initiated early. 
  
1.3 Alzheimer’s disease genetics and risk factors 
There are 2 main subtypes of AD, these are classified based on their age of 
onset, EOAD, also known as familial AD (fAD) or Late-onset AD (LOAD), also 
known as sporadic AD (sAD). fAD form is far rarer, in that it contributes only 
2-5% of AD cases, whereas sAD is far more common  (Campion et al. 1999; 
Brickell et al. 2006; Bekris et al. 2010; Holtzman et al. 2011; Wu et al. 2012). 
The fAD form is inherited in an autosomal dominant manner and refers to 
patients which demonstrate AD related symptoms before the age of 65. On 
the other hand, sAD shows no causative factors, but rather risk factors. This 
form consists of patients who demonstrate AD symptoms much later in life, 
with age of onset greater than 65 years (Guerreiro et al. 2012). The sAD form 
is considered to have strong links to genetics with there being multiple genome 
wide association studies (GWAS) undertaken which have identified 21 genes 
which are associated with an altered risk of sAD (figure 1.1) (Karch & Goate 
2015). According to these GWAS studies, the main genetic determinant of AD 
risk was the APOE gene, encoding the apolipoprotein E protein (APOE). The 
gene locus for APOE is polymorphic, existing as three distinct alleles ε2, ε3, 
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and ε4, which are present at ~7%, 79%, and ~14% respectively in the 
population (Sing & Davignon 1985; Fernandez et al. 2019).  
The ε4 allele of APOE has been identified to confer the greatest risk for sAD. 
The risk for AD is said to be three-fold greater for heterozygous carriers of ε4, 
while homozygous carriers are said to have an 8-12 fold increased risk (Corder 
et al. 1993; Carrera et al. 2013). The ε4 allele is also estimated to reduce the 
age of onset from 85 years with no ε4 alleles, to 75 years with one ε4, and 68 
years with two ε4 alleles (Corder et al. 1993). Research has shown that the ε4  
allele confers risk through significantly increasing the burden of Aβ on the 
brain, suggesting that the ε4 allele of APOE interacts with Aβ increasing its 
propensity to form plaques (Schmechel et al. 1993; Reitz 2012). In contrast, 
the ε2 allele has been associated with a decreased risk for AD, indicating that 
it is neuroprotective, whereas the ε3 allele is neutral, neither conferring risk or 
protection (Corder et al. 1994; Karran et al. 2011; Frieden & Garai 2012). 
Research has also identified multiple other APOE isoform-dependent effects, 
Including  differences in lipid and cholesterol metabolism, neuroinflammation 
regulation and neuronal growth (Schmechel et al. 1993; Kim et al. 2014; 
Mahley & Huang 2012). 
There have also been environmental factors associated with sAD, these 
include aging, injuries to the brain, exposure to metals such as aluminium, 
poor education, lack of exercise and infection with certain viruses such Herpes 
simplex virus type 1 (HSV-1) (Grant et al. 2002; Itzhaki 2014; Reitz 2012; 
Armstrong 2013). 
The fAD form is far rarer than sAD, and mutations within genes associated 
with fAD are likely to be causative of AD rather than conferring risk for AD 
36 
 
(Bekris et al. 2010; Guerreiro et al. 2012). Mutations have been identified in 
genes encoding Presenilin 1 (PSEN1), Presenilin 2 (PSEN2) and Amyloid 
Precursor Protein (APP) which are sufficient to cause fAD (figure 1.2) (Karch 
& Goate 2015; Lanoiselée et al. 2017). A duplication in the APP gene locus 
has also been reported to be causative of AD (Chartier-Harlin et al. 1991; 
Sleegers et al. 2006). The mutations in PSEN1 are the most common of these 
mutations, with 221 mutations reported as pathogenic (Lanoiselée et al. 2017). 
APP is the second most commonly involved gene with 32 pathogenic 
mutations described, while 17 pathogenic mutations have been described for 
PSEN2 (Cai et al. 2015; Lanoiselée et al. 2017). These causative mutations 
either alter the proteolytic processing of APP in favour the production of the 
longer forms of Aβ, as in the case of PSEN1 and PSEN2, or lead to increased 
levels of Aβ, as is seen with the mutation causing APP duplication (Sleegers 
et al. 2006; Lanoiselée et al. 2017). The importance of these three genes and 
the ability of mutations within these genes to cause AD through increasing 
levels of Aβ have solidified the importance of Aβ as one of the key factors in 
AD progression and pathogenesis. 
Other key mechanisms which were implicated by GWAS studies to be involved 
in the progression of AD include immune response regulation, endocytosis 
regulation, epigenetic regulation, and regulation of cytoskeleton/axon 
development. Polymorphisms in genes which are associated with the 
regulation of these mechanisms have been implicated to increase the risk of 
Alzheimer’s disease (Karch & Goate 2015).  
Neuroinflammation and dysregulation of the immune response is central to the 
pathology of AD (Heneka et al. 2015). In a healthy human brain, the microglia 
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and astrocytes are the main immunological cells. The microglia are 
responsible for housekeeping functions, as well as immunological 
surveillance. As part of immunological surveillance microglia function to sense 
pathological and inflammatory signals and produce inflammatory signals in 
response to these (Heneka et al. 2015; Bachiller et al. 2018). Similar to 
microglia, astrocytes play multiple roles in organizing and maintaining brain 
structure and function, however the role of astrocytes in the immune response 
is still poorly understood (Sofroniew & Vinters 2010). Variants have been 
detected in several genes that are associated with AD and the immune 
response in GWAS. The Triggering receptor expressed on myeloid cells 2 
(TREM2) gene is one such example and has been implicated through GWAS 
studies to confer increased risk of AD through immune response dysregulation 
(Karch et al. 2016). This gene encodes a single-transmembrane protein, and 
in the brain is expressed selectively by microglia (Gratuze et al. 2018). TREM2 
has been implicated in anti-inflammatory signalling through the inhibition of 
toll-like receptor signalling and promotion of phagocytosis of apoptotic cell 
membranes. A loss of function mutation in TREM2 known as the TREM2 
RH7H allele has been shown confer AD risk and decrease AD age of onset by 
through the loss of this immune response regulation (Pottier et al. 2013; 
Korvatska et al. 2015). 
GWAS studies have also identified polymorphisms in and around genes 
related to epigenetic regulation (Karch et al. 2016). Polymorphisms in these 
genes, such as the Zinc finger CW-type and PWWP domain containing 1 
(ZCWPW1) gene have been shown to increase the risk of AD through 
dysregulation of epigenetic control (He et al. 2010; Lambert et al. 2013; Karch 
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et al. 2016; Gao et al. 2016). Epigenetic mechanisms determine how and when 
genes are expressed and are being increasingly recognised as having the 
ability to exert lasting effects on genes. These lasting effects on gene 
expression can lead to the long-term, progressive abnormalities characteristic 
of diseases such as AD (Tsankova et al. 2007). Evidence supporting the role 
of epigenetic mechanisms in the development of AD include the detection of 
abnormal methylation pathways in the brains of people afflicted with dementia 
(Yokoyama et al. 2017). These changes are detectable much earlier than the 
pathophysiological changes of AD can be observed. Thus, epigenetic 
mechanisms are implicated in AD progression. DNA methylation is the most 
well understood epigenetic mechanism. This occurs through the covalent 
addition of a methyl group to cytosine (Alagiakrishnan et al. 2012). Methylation 
of cytosine hinders the binding of transcription factors and is therefore 
associated with gene silencing (Alagiakrishnan et al. 2012). Histone 
modification is another very well understood epigenetic mechanism and 
involves the reversible post-translational modification of histones. Since 
histones play a role in DNA packaging these modifications exert a great 
influence on the overall DNA structure (Alagiakrishnan et al. 2012). Histone 
modifications can influence both transcriptional activation and gene silencing.  
Another mechanism which has been implicated by GWAS studies in the 
progression of AD is the dysregulation of endocytosis. In neurones, 
endocytosis plays an important role, enabling neurons to modify or degrade 
molecules from the cell surface into intracellular compartments. These 
intracellular compartments are known as the central vacuolar system and 
consists of endosomes and lysosomes that have different abilities proteolytic 
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processing (Cataldo et al. 2000). These are classified as early or late 
endosomes. During endocytosis primary vesicles leave the plasma membrane 
and fuse with early endosomes to deliver the content that they contain (Dunn 
& Maxfield 1992). These early endosomes function to sort their protein 
contents into recycling and degradative components (Huotari & Helenius 
2011). Plasma membrane proteins are recycled back to the cell membrane, 
and proteins which are to be degraded are sorted to cisternal parts of early 
endosomes which mature into late endosomes (Dunn et al. 1989). These late 
endosomes can either fuse with lysosomes, or mature into lysosomes in order 
to degrade the proteins which are held within (Dunn & Maxfield 1992). A direct 
link between Aβ and dysregulations in the endosomal pathway can be seen in 
the case of genes such as the neuronal sortilin-related receptor gene 
(SORL1), where SNPs determined through GWAS studies have been linked 
to AD development and progression (Lee et al. 2008; Reitz et al. 2011). 
Research has shown that functional SORL1 binds to APP and differentially 
regulates its sorting into the endocytic or recycling pathways. In the absence 
of SORL1, APP is released into late endosomal pathways, where the acidic 
pH promotes the processing of APP by both β- and γ-secretase, leading to 
increased Aβ production (Van Acker et al. 2019). Multiple GWAS studies have 
determined both common and rare SNPs in SORL1, contribute to increase Aβ 
deposition, and have been linked with both EOAD and LOAD (Lee et al. 2008; 
Reitz et al. 2011; Lambert et al. 2013; Holstege et al. 2017). Recent GWAS 
studies have confirmed these SNPs function to reduce SORL1 expression 
levels, and contribute to increased AD risk through this loss of SORL1 




Figure 1.2: Graph showing the risk loci associated with Alzheimer’s Disease and the 
frequency of these within the population. Through GWAS and meta-analysis studies 21 
genes have been identified in which polymorphisms are associated with an increased risk of 
AD. These gene variants in the population vary in terms of the risk associated with them, 
conferring either low, medium or high risk. There have also been gene polymorphisms which 
are said to be causative of AD, rather than just conferring risk. The frequency of these genes 
also vary from being rare (present in less than 3% of the population) to being common (present 
in over 20% of the population). This graph demonstrates that the highest risk for AD is 
conferred by 2 copies of the APOE4 gene, however there are also polymorphisms in the 
PSEN1, PSEN2 and APP genes. These genes are all directly associated with APP 
metabolism and therefore demonstrates the importance of APP in the onset and subsequent 







1.4 The Amyloid Precursor Protein Function and Proteolytic 
Processing 
The Amyloid precursor protein (APP) gene is located on chromosome 21q21.3 
and is made up of 18 exons which code for the full-length APP protein. APP is 
an integral type I membrane glycoprotein, that exists as 8 distinct isoforms of 
APP generated through alternative splicing of exons 7, 8 and 15. Alternative 
splicing of APP exon 15 was first discovered in peripheral mononuclear 
leukocytes and microglial cells, therefore isoforms which do not include exon 
15 were denoted as leukocyte-derived APP (L-APP) (Bergsdorf et al. 2000). 
There are five L-APP isoforms and expression studies have shown ubiquitous 
expression of L-APP isoforms throughout the body, but an absence of these 
in the brain (Bergsdorf et al. 2000). Therefore, the major APP isoforms in the 
brain contain exon 15, and their genetic diversity is based solely on the 
alternative splicing of APP exons 7, and 8. This alternative splicing of exons 7 
and 8 leads to the expression of three major alternatively spliced isoforms: 
APP770, APP751, and APP695 (figure 1.3) (Bekris et al. 2010; Guerreiro et 
al. 2012). APP isoforms 770 and 751 are expressed highly throughout the 
body, but are also present at lower levels in neurones (Selkoe 2001). APP695 
on the other hand is found in high abundance within neurones in the central 
nervous system (CNS) and at much lower levels in other cell types (Kang & 
Müller-Hill 1990; Sisodia et al. 1993). Alternative splicing to produce APP695 
leads to the exclusion of both exon 7, which encodes for a 56 amino acid 
Kunitz protease inhibitor (KPI), and exon 8, which codes for the 19- amino-
acid putative glycosylation domain that shares sequence identity with the OX-
2 antigen of thymus-derived lymphoid cells (Belyaev et al. 2010). APP isoform 
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770 is the full-length APP splice variant and contains all 18 exons, whereas 
APP751 is the splice variant which has had exon 8 excluded but does contain 
APP exon 7. The KPI containing isoforms (APP770 and 751) are extremely 
abundant in platelets and there has been evidence which suggests that they 
play a role in the coagulation cascade, affecting wound healing through 
regulating serine proteases. (Van Nostrand et al. 1991; Selkoe 2001; Dawkins 
& Small 2014). Studies have shown that APP695 preferentially undergoes 
processing via the amyloidogenic APP processing pathway, which 
subsequently leads to production of high levels of Aβ (Cordy et al. 2003; 
Ehehalt et al. 2003; Belyaev et al. 2010). However, KPI containing isoforms 
have also been shown to promote amyloidogenic processing of APP (Ho et al. 
1996). 
 
Figure 1.3 Schematic representation of the human APP isoforms. The figure shows the 
schematic of each of the three major APP isoforms and shows the position of the KPO and 
OX2 domains, as well as the Aβ and AICD regions. Taken and adapted from (Nalivaeva & 




Over the years members of the APP family of proteins have emerged as taking 
part in diverse biological processes which range from transcriptional regulation 
to synaptic functions (Octave et al. 2013). They are able to mediate their 
effects from the cell surface, or through their secreted proteolytic fragments, 
however the precise function of APP is still not fully understood. One important 
neuronal function of APP which has recently been described is its role in the 
maintenance of neuronal calcium homeostasis, a process which is essential 
for synaptic transmission and neuronal networking (Berridge 1998; Octave et 
al. 2013). APP also plays an important role in neuronal growth and viability; 
this has been demonstrated in studies of neurones from APP deficient mice 
(Perez et al. 1997). In these neurones, diminished cell viability and reduction 
in outgrowth of neurites was observed, which is subsequently restored when 
neurons were cocultured with astrocytes secreting soluble APP (Perez et al. 
1997). 
APP has also been implicated to play an important role in learning and 
memory. In vivo studies have demonstrated that the APPsα proteolytic product 
of APP promote learning and memory in mouse models (Meziane et al. 1998). 
APP has also been suggested to play important roles in the restoration of 
neuronal functions after traumatic brain injury. In Drosophila head injury 
models, studies have shown that APP is up-regulated up to 7 days after a head 
injury (Leyssen et al. 2005). This observation has also been confirmed in APP 
overexpressing mice which show more efficient nerve regeneration after an 
injury, and decreased neuropathic pain as a result of APP overexpression 
(Kotulska et al. 2010). Many processing pathways have been suggested 
involving multiple secretases, but the two most researched processing 
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pathways are the amyloidogenic and non-amyloidogenic pathways (figure 
1.4). Both of these pathways involve sequential cleavage, with the initial 
secretase cleavage step being the distinguishing factor between the two, 
leading to generation of different cleavage products.  
The non-amyloidogenic pathway processes the majority of APP and involves 
initial cleavage by α-secretase within the Aβ domain (at the Lys16-Lys17 
bond), disrupting this domain and preventing Aβ formation. This initial 
cleavage produces an N-terminal APP fragment termed APPsα that is 
released into the extracellular space, as well as a membrane bound C terminal 
fragment (α-CTF) (Alves et al. 2016). Studies have provided evidence 
indicating that several members of the ADAM (a disintegrin and 
metalloprotease) family possess α-secretase activity, these include ADAM9, 
ADAM10 and ADAM17 (Zhang et al. 2011). ADAM10 has been implicated as 
the major α-secretase, as RNAi knockdown and mutations in this protein have 
shown reduced formation of APPsα, and overexpression of ADAM10 has led 
to increased levels of APPsα (Kuhn et al. 2010; Endres & Deller 2017). Studies 
have shown that APPsα is beneficial to neurones as it protects neurones 
against oxygen and glucose deprivation, protects against excitotoxicity by 
stabilising the resting membrane potential and plays an important role in 
neuronal plasticity and survival (Gakhar-Koppole et al. 2008; Chow et al. 2010; 
Zhang et al. 2011). APPsα also promotes neurite outgrowth, synaptogenesis 
and cell adhesion (Gakhar-Koppole et al. 2008; Chow et al. 2010). APPsα is 
very important during brain damage as well as during brain development as 
they are present in embryonic brains (Chasseigneaux et al. 2011). The 
subsequent step in the non-amyloidogenic pathway involves cleavage of the 
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α-CTF by the γ-secretase complex. γ-secretase is an aspartyl protease and is 
unique as it is able to regulate intramembrane proteolysis (RIP) for many type 
1 membrane proteins (Kerridge et al. 2014). Processing of α-CTF by γ-
secretase  yields p3, a 3kDa protein with no known biological function, and the 
APP intracellular domain (AICD) (Chow et al. 2010).  
In the amyloidogenic pathway, APP is initially cleaved by β-secretase within 
the N-terminal domain. Beta-secretase 1 (BACE1) has been confirmed as the 
major β-secretase, this is a membrane-bound aspartyl protease with a 
characteristic type I transmembrane domain near the C-terminus. BACE1 
cleavage generates a small N-terminal fragment (APPsβ) which is smaller 
than APPsα, as well as a membrane bound C-terminal fragment (β-CTF) 
which has a non-disrupted Aβ domain. APPsβ only differs from sAPPa by 
lacking the Aβ 1-16 region at its carboxyl-terminus and has been associated 
with pruning of the synapses during development of central and peripheral 
neurones via acting as a ligand to the death receptor 6 (DR6) (Nikolaev et al. 
2009; Chow et al. 2010; Zhang et al. 2011). The β-CTF is subsequently 
cleaved by the γ-secretase complex generating the Aβ peptide, as well as the 
AICD. The Aβ peptide produced via γ-secretase cleavage can vary in length 
between 39-43 amino acids due to the unprecise nature of the γ-secretase, 
cleaving in at least 3 different sites: V636, A638 and L645 (ε-cleavage site) 
(Murphy & Levine 2010; Pardossi-Piquard & Checler 2012; Dawkins & Small 
2014). These different sized peptides are named for the number of residues 
they are formed from. Under physiological conditions the most common form 
of Aβ is 40 amino acids in length (aa) and is termed Aβ40, levels of the longer 
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forms of the Aβ peptide are low under physiological conditions (Tamaoka et 
al. 1998).  
The γ-secretase complex is made up of four major components; nicastrin, 
anterior pharynx defective homolog (aph-1), presenilin enhancer 2 (pen-2) and 
Presenilin (PS, either PSEN1 or PSEN2)  (Edbauer et al. 2003; Krishnaswamy 
et al. 2009).  Nicastrin is a membrane protein which plays an important role in 
γ-secretase assembly (Francis et al. 2002). Aph-1 exists in two homologous 
forms, aph-1a and aph1-1b, and has a similar function to nicastrin (Francis et 
al. 2002). Pen-2 is the smallest component of the γ-secretase complex and 
functions to activate presenilin endoproteolysis (Francis et al. 2002; Luo et al. 
2003; Krishnaswamy et al. 2009). The Presenilin components are 
transmembrane proteins which have enzyme catalytic activity and therefore 
form the catalytic subunit of the γ-secretase complex (De Strooper et al. 1998; 
De Strooper 2007). There have been over 150 mutations observed in PSEN1 
and 17 mutations observed in PSEN2 which may be pathogenic, and lead to 
fAD  (De Strooper 2007; Cai et al. 2015). Research has determined that these 
PSEN mutations which are causative of fAD also lead to increases in the 
production of Aβ peptides which are longer than are normally present under 
normal physiological conditions, at 42aa in length (Aβ42) (Singleton et al. 
2000; De Strooper 2007; Bekris et al. 2010; Mills & Janitz 2012).  Further 
research gave rise to the discovery that longer Aβ peptides such as Aβ42 
aggregate more readily and are also the primary form of Aβ found in senile 
amyloid plaques, even though this longer form of Aβ is the minority of the total 
Aβ population. This evidence further supported the importance of Aβ42 in AD 
progression (Jarrett et al. 1993). These discoveries together led to the 
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formulation of the amyloid cascade hypothesis in 1992 (Hardy & Higgins 
1992). 
 
Figure 1.4: Proteolytic processing of APP. Image showing the two alternative processing 
pathways of APP. Taken from (Alves et al. 2016). The figure shows the cleavage of APP via 
either α- or β -secretase, followed by sequential cleavage by γ-secretase in both cases. 
Processing via α-secretase is non-amyloidogenic as it cleaves APP in the Aβ region and 
therefore doesn’t lead to the production of Aβ. α-secretase cleavage of APP leads to the 
formation of the α-CTF C83 and APPsα (secreted APP- α). Sequential cleavage via γ-
secretase results in formation of p3, and the AICD (amyloid intracellular domain). Processing 
via β-secretase is amyloidogenic as it directly leads to the formation of Aβ. Cleavage of APP 
by β-secretase leads to the production of the β-CTF C99, as well as APPsβ. Subsequent 










1.5 The amyloid cascade hypothesis 
The amyloid cascade hypothesis was formulated in 1992 in order to describe 
the progression of AD, and proposes a central role for Aβ42 in disease 
pathology (Hardy & Higgins 1992). The original hypothesis stated that 
deposition of Aβ42 was the first step of AD and the accumulation of this 
principal toxic agent triggers the onset of the disease (Hardy & Higgins 1992; 
Selkoe & Hardy 2016). The hypothesis was formed based on the observation 
that Aβ42 was the main constituent of senile amyloid plaques, and that 
mutations in APP as well as the presenilin genes (PSEN1 and PSEN2) which 
make up the active site of γ-secretase result in the overproduction of Aβ42 and 
are seen to be causative of fAD (Karran et al. 2011; Reitz 2012). It was later 
shown that the Aβ42/ Aβ40 ratio, rather than the absolute levels of Aβ42 that 
are pathogenic and lead to the onset of disease pathology (Pimplikar 2009). 
The biggest change to the amyloid cascade in recent years was made to 
address the accumulation of soluble oligomers of Aβ42 which have been 
shown to be more toxic than Aβ42 plaques, and correlate better with AD 
progression (Pike et al. 1991; Pike et al. 1993; Walsh et al. 2002; Walsh & 
Selkoe 2004; Walsh & Selkoe 2007). These studies have supported the 
neurotoxic role of Aβ42 oligomers by demonstrating that Aβ42 oligomers are 
able to induce neuronal death and therefore reduce neuronal viability (Pike et 
al. 1991; Pike et al. 1993).  
Over the years, although there have been many objections to this hypothesis, 
it has been widely accepted. Many of the objections to this hypothesis focus 
on highlighting that Aβ independent factors also contribute to AD progression, 
and the fact that Aβ plaque load alone does not correlate well with AD 
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progression (Reitz 2012). It has also been suggested that increased APP 
expression and therefore Aβ may be a response to the AD process in order to 
maintain cellular function rather than a cause of the disease (Crdenas-Aguayo 
et al. 2014).  
However, since this time, there has been much research that has further 
supported the amyloid cascade hypothesis and act as counterarguments to 
these objections. It has been shown that fAD mutations in APP, PSEN1 and 
PSEN2, which lead to Aβ deposition may mediate the deregulation of tau 
(Selkoe & Hardy 2016). To this end, Jin et al treated cultured rat neurones with 
soluble Aβ42 oligomers which resulted in neuritic dystrophy and tau 
hyperphosphorylation (Jin et al. 2011). However when this same experiment 
was performed but with tau having been knocked down first, no dystrophy was 
seen (Jin et al. 2011). This indicates that Aβ42 accumulation can lead to 
progressive tau dysregulation, but the converse is not possible, indicating a 
role for Aβ42 in triggering an NFT related AD pathology. 
Another piece of evidence supporting this hypothesis was the discovery of a 
missense mutation in the Aβ region of the APP gene which is protective of AD 
as it decreases the processing of APP by the amyloidogenic pathway, this 
mutation is termed A673T (Jonsson et al. 2012). These A673T carriers show 
lower levels of Aβ production and aggregation as senile plaques as well as a 
lower risk of clinical AD and age related cognitive decline (Jonsson et al. 
2012). These reduced levels of amyloid deposition and the subsequently 
lowered AD risk resulting from the protective A673T mutation strongly support 
the amyloid cascade hypothesis (Kero et al. 2013; Maloney et al. 2014). 
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1.6 Aβ42 oligomer neurotoxicity  
Aβ42 is able to rapidly aggregate and has the ability to form oligomers, 
protofibrils and fibrils which spread throughout the brain and culminate in the 
impairment of neurones and induce the atrophy which is characteristic of AD 
(Caughey & Lansbury 2003; Lyketsos et al. 2011). Previously, amyloid 
plaques were the form of this peptide which were implicated be the most toxic, 
and most strongly associated with AD (Ahmed et al. 2010; Kuperstein et al. 
2010). However, in recent years Aβ42 oligomers have been demonstrated to 
be more neurotoxic than Aβ42 plaques, and correlate better with AD 
progression (Walsh & Selkoe 2004; Walsh & Selkoe 2007). Oligomers of Aβ42 
have been shown to play roles in causing synaptic dysfunction, disrupting long 
term potentiation and impairing memory in AD (Hsia et al. 1999; Walsh et al. 
2002; Ahmed et al. 2010).  
Synapse loss and synaptic dysfunction are among the first features seen 
during the progression of AD  (Shankar & Walsh 2009). This loss of synapses 
strongly correlates with a decline in cognitive function, and leads to further 
memory deficits (Umeda et al. 2014; Marsh & Alifragis 2018). The mechanisms 
behind this synaptic dysfunction in AD are not well understood despite 
extensive research, however there is clear evidence which implicate Aß42 
oligomers as among the major causes. One such study implicating soluble Aβ 
oligomers used AD transgenic mice with the E683 Δ mutation in APP (termed 
the Osaka mutation) (Tomiyama et al. 2008; Umeda et al. 2014). This mutation 
is seen to cause AD by enhancing the oligomerisation of Aβ without plaque 
formation (Tomiyama et al. 2008; Umeda et al. 2014). It was demonstrated 
that this model showed significant intraneuronal accumulation of Aβ oligomers 
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and increased loss of synapses which was demonstrated by immunostaining, 
resulting in increased memory impairment  (Umeda et al. 2014). This solidifies 
a potential role for Aβ oligomers as one of the earliest mediators of the synaptic 
dysfunction which is characteristic of AD. 
Memory impairments which are observed as a result of Aβ oligomer 
accumulation indicate that these peptides may also interfere with synaptic 
mechanisms such as synaptic plasticity which involves long term potentiation 
(LTP) and long term depression (LTD) (Walsh & Selkoe 2004; Umeda et al. 
2014). LTP and LTD are important processes which underlie the ability to learn 
and the ability to form memories (Walsh & Selkoe 2004). There is mounting 
evidence implicating these Aβ oligomers in the disruption of LTP and LTD, and 
it has been demonstrated that microinjections of naturally occurring Aβ 
oligomers contained within cell medium into WT rats resulted in significant 
inhibition of LTP tested via electrophysiology (Walsh & Selkoe 2004). 
Therefore, it can be assumed that Aβ oligomers can contribute to the cognitive 
defects which are characteristic of AD through the disruption of synaptic 
plasticity. 
Aβ42 oligomers have also been linked with synaptic toxicity and the 
progression of AD through the deregulation of tau (Umeda et al. 2014). The 
hyperphosphorylation of the microtubule associated protein tau forms NFTs 
that are neurotoxic, and characteristic of AD. Research has demonstrated that 
this hyperphosphorylation of tau is facilitated by soluble Aβ oligomers, which 
then initiate neuritic dystrophy and disruption of the microtubule network (Jin 
et al. 2011). This effect on hyperphosphorylation of tau as a result of Aβ 
oligomer accumulation has been demonstrated in AD-transgenic mice bred to 
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contain genes for WT human tau and the APP Osaka mutation (E693Δ) which 
prevents Aβ plaque formation (Umeda et al. 2014). The results of this study 
showed clear signs of tau hyperphosphorylation, and suggests that this was 
as a result of Aβ oligomers (Jin et al. 2011). These findings together implicate 
Aβ oligomers as mediators of synaptic dysfunction through various 
mechanisms, and supports the fact that Aβ42 oligomers are key toxic agents 
















1.7 The role of Aβ in sAD 
Causal mutations in APP and the presenilin (PSEN1 and PSEN2) genes 
provide a clear mechanism as to how Aβ42 is able to accumulate in fAD, 
however these mutations are not present, and therefore unable to explain the 
accumulation of Aβ42 in sAD. This increase in Aβ42 is involves defective 
clearance and breakdown of the peptide (Selkoe & Hardy 2016). There have 
been several proteases implicated in the regulation of Aβ levels, among these 
the two most researched and most important are neprilysin (NEP) and insulin 
degrading enzyme (IDE) (Murphy & Levine 2010). 
NEP is a membrane bound type II zinc endopeptidase and is responsible for 
the extracellular degradation of a variety of peptides including Aβ. Research 
has indicated that NEP is a major Aβ42 degrading enzyme in particular, with 
the ability to degrade monomeric as well as oligomeric Aβ42 (Iwata et al. 
2000). Therefore, a decrease in NEP levels should correlate with an increase 
in Aβ levels, with research confirming this, Iwata et al demonstrated that NEP 
deficient mice showed significant increases in Aβ levels in a dose dependent 
manner (Iwata et al. 2001). Conversely, NEP overexpression in vitro and in 
vivo has been demonstrated to lead to a reduction in Aβ levels in the brain in 
a dose-dependent manner (Caccamo et al. 2005; Grimm et al. 2013; Kerridge 
et al. 2014).  
IDE is a thiol metallo-endopeptidase which is effective both intra- and 
extracellularly and degrades small peptides such as insulin and Aβ. IDE 
exclusively degrades soluble monomeric but not oligomeric forms of Aβ (Qiu 
et al. 1998). Research has shown that neuronal overexpression of IDE 
reduces Aβ42 levels and greatly lowers cerebral plaque formation  in  
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transgenic  mice  expressing  APPswedish (APPsw) and Indiana mutations 
which lead to excessive Aβ accumulation in plaques. This reduction in Aβ 
levels was shown to rescue the premature lethality present in this model 
(Caccamo et al. 2005). Research has shown that levels of both NEP and IDE 
enzymes decrease under normal aging conditions, but also that levels of NEP 
in particular are decreased in brain regions which show Aβ plaque deposition 
(Caccamo et al. 2005). This highlights a potential critical role that NEP and 
IDE play in regulating levels of Aβ, which are lost overtime during aging and 
hence alongside other mechanisms lead to sAD.  
Defective clearance of Aβ is another potential link between sAD and Aβ. Under 
normal physiological conditions, Aβ is cleared from the brain by crossing 
through the blood brain barrier (BBB) through interactions with a number of 
transport proteins such as the low-density lipoprotein receptor (LDLR) family 
(Kang et al. 2000; Bell et al. 2007). Several factors have been implicated to 
interfere with the clearance of Aβ at the BBB in AD. 
The low-density lipoprotein receptor–related protein (LRP) is part of the LDLR 
(low density lipoprotein receptor) family and has been implicated in AD (Kang 
et al. 2000). LRP is a multi- functional receptor that mediates internalization 
and degradation of ligands involved in metabolic pathways of lipoproteins. 
These ligands include α2-macroglobulin (α2M), apoE and KPI containing 
forms of APP, all of which are genetically associated with AD and variants in 
these have been associated with accumulation of Aβ. Therefore, these 
variants potentially increase the risk of AD by adversely affecting Aβ 
clearance. The risk associated with polymorphisms in α2M may promote the 
production of a truncated protein that is still able to bind to Aβ, but is unable to 
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interact with LRP1 preventing the transcytosis of Aβ through the BBB, and 
therefore lead to decreased Aβ clearance (Blacker et al. 1998; Kovacs 2000). 
Although associations between α2M and AD have been suggested, there have 
also been studies which have disputed these association (Blennow et al. 
2000). The effect of apoE on Aβ is another that has been extensively 
researched. Studies have revealed that apoE2 and apoE3 bind more 
efficiently to Aβ than apoE4, therefore the risk apoE4 confers to AD may be 
due to apoE4 being an ineffective chaperone for Aβ removal from the brain 
compared to apoE2 and apoE3 (Deane et al. 2008). Research has also shown 
that different isoforms of apoE bind with differing affinity to LRP1 or the very-
low density lipoprotein receptor (VLDLR) (Deane et al. 2008). These indicate 
that the accumulation in Aβ leading to sAD progression could be at least in 
part due to a reduction in the clearance of Aβ mediated by LRP1.  
Research has also suggested that the increases detected in Aβ levels in sAD 
could be due to the interactions between apoE and APP which leads to 
increased APP transcription, and subsequent processing and Aβ deposition 
(Huang et al. 2017). This regulation of APP by apoE is in an isoform dependent 
manner, with apoE4, the isoform that is considered the biggest risk factor for 
AD, demonstrating the largest increase in APP and Aβ, followed by apoE3 and 
apoE2 respectively (Huang et al. 2017). The combination of these factors 
provides a clear mechanism as to how dysregulation of Aβ production and 







1.8 APP695 and amyloid intracellular domain  
The Aβ peptide and its oligomers have been demonstrated to be the principal 
neurotoxic agents which underpin the progression of AD and the pathological 
changes which are observed (Hardy & Higgins 1992; Walsh et al. 2002; 
Kerridge et al. 2014). Aβ production is facilitated by the sequential proteolytic 
processing of APP via the amyloidogenic pathway which involves cleavage 
steps by β-secretase, followed by the presenilin dependent γ-secretase 
(Menéndez-González et al. 2006; Zhang et al. 2012). The non-amyloidogenic 
pathways of APP processing involves α-secretase, followed by γ-secretase 
and cleaves APP within the Aβ region, disrupting and preventing the formation 
of Aβ. All isoforms of APP undergo processing through both of these 
pathways. Research has suggested that Aβ accumulation in AD could be due 
to the increased production of Aβ due to alterations in APP metabolism and 
expression.(Smith, Al Hashimi, Girard, Delay & Sébastien S. Hébert 2011; 
Zhang et al. 2011). Analysis of APP protein and mRNA levels in AD revealed 
that there is an increase in the levels of KPI positive APP isoforms (APP770 
and APP751), and a decrease in levels of APP695 compared to a healthy brain 
(Siman et al. 1989; Johnson et al. 1990; Heuvel et al. 2000; Menéndez-
González et al. 2006). This change in APP isoform expression pattern 
correlates with increased deposition of Aβ, providing a potential contribution 
of dysregulated APP splicing in increasing Aβ load, and pathogenesis of AD 
(Johnson et al. 1990). This change in APP isoform expression decreasing 
APP695 expression levels in neurones and the fact that this correlates with 
increased Aβ deposition gave rise to the hypothesis that the APP695 is 
somehow protective against AD, and loss of protection is one of the factors 
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contributing to AD. A possible mechanism for these protective effects is 
mediated through one of the many cleavage fragments of APP, the carboxy 
terminal fragment termed the amyloid intracellular domain (AICD) (Słomnicki 
& Leśniak 2008; Belyaev et al. 2010). It has been demonstrated that both the 
amyloidogenic and non-amyloidogenic pathways of APP processing are able 
to generate the AICD, and as these pathways are localized to different 
subcellular compartments this provides insight into why there exist multiple 
different sized AICD peptides (Bukhari et al. 2017). The generation of AICD 
takes place through γ-secretase cleavage of either the α- or β-CTF, the α-CTF 
is produced during non-amyloidogenic processing APP which typically takes 
place at the cell membrane, whereas the β-CTF results from amyloidogenic 
processing of APP which has been linked to endosomes and the lysosomal 
membrane (Sisodia 1992; Annaert et al. 1999; Cupers et al. 2001; Carey et al. 
2005; Vingtdeux et al. 2007). Research has suggested that the AICD is 
generated by γ-secretase cleavage at the endosomes (Vingtdeux et al. 2007). 
This could explain the process of preferential production of the AICD from the 
APP695, as this isoform of APP is predominantly processed by amyloidogenic 
pathway which involves γ-secretase and is localized to these endosomes. 
 The diversity of the AICD peptide can also be attributed to the imprecise 
nature of γ-secretase, which cleaves at multiple sites , producing fragments of 
different sizes, similar to the processing of the Aβ peptide(Grimm et al. 2015). 
AICD57 and AICD59 encompass the 47 amino acid APP cytoplasmic region 
and either 10 or 12 amino acids of the transmembrane domain, and cleavage 
at the ε-cleavage site (Leu49-Val50) produces AICD50 and AICD51 (Kerridge 
et al. 2014). The main species of AICD that is produced is the AICD50, and 
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this is considered the typical form of the AICD (Chow et al. 2010; Pardossi-
Piquard & Checler 2012).The proteolytic events which are involved in the 
formation of the AICD via γ-secretase are termed regulated intramembrane 
proteolysis (RIP), and are commonly associated with important cellular 
signalling pathways (Müller et al. 2008; Kerridge et al. 2014). The involvement 
of the ε-cleavage site, and presenilin via RIP is reminiscent of Notch 
processing, a core component of an important signalling pathway (Hébert et 
al. 2006; Słomnicki & Leśniak 2008). Notch proteolysis involves ADAMs (α-
secretases) and γ-secretase. ADAMs induce ectodermal shedding of Notch, 
followed by processing with γ-secretase which results in the release of the 
Notch intracellular domain (NICD) which is critical in the notch signalling 
cascade (Selkoe & Kopan 2003; Kerridge et al. 2014). NICD has been 
implicated to be capable of translocating to the nucleus and regulating gene 
transcription, and research has shown that the NICD has the ability to regulate 
genes critical to development (Selkoe & Kopan 2003; Zhang et al. 2011; 
Kerridge et al. 2014). In fact, the AICD was first named as such because it was 
deemed to be analogous with the NICD. As the NICD is able to translocate to 
the nucleus and regulate gene expression, the theory was proposed that the 
AICD acted in the same manner, having the same ability (Pardossi-Piquard & 
Checler 2012; Kerridge et al. 2014). Endogenous AICD isoforms are not often 
detected due to their rapid degradation in the cytosol by insulin degrading 
enzyme (IDE), the proteasome and cathepsin (Grimm et al. 2013; Kerridge et 
al. 2014; Andrew et al. 2016). Rapid binding of AICD to adaptor proteins such 
as Fe65 have been shown to stabilize released AICD peptides, thereby 
enabling the translocation of AICD to the nucleus and to form trimeric protein 
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complex with the histone acetyltransferase Tip60 (Murphy & Levine 2010; 
Grimm et al. 2015). It has recently been shown that the AICD which is 
produced through the processing of different APP isoforms function differently 
in their ability to translocate and act to alter gene expression (Belyaev et al. 
2010). Research has suggested that AICD that is preferentially from the 
processing of APP695 is able to translocate to the nucleus of cells and 
regulate transcription of multiple genes, as well as signal transduction (Müller 
et al. 2008; Belyaev et al. 2009).Most important among these are Neprilysin 
(NEP) and Transthyretin (TTR) (Schmidt et al. 2009; Belyaev et al. 2010; 
Kerridge et al. 2014). NEP is the major Aβ degrading enzyme, which makes it 
of great importance to AD (Belyaev et al. 2010). It has been shown that AICD 
produced from APP695 is able to bind to the NEP promoter causing its 
transcriptional activation and an increase in NEP mRNA protein and activity 
levels (Belyaev et al. 2009; Belyaev et al. 2010; Kerridge et al. 2014). TTR is 
a transporter of thyroid hormone and retinol, it is able to bind to Aβ preventing 
its accumulation into plaques (Kerridge et al. 2014). This prevention of plaque 
formation is protective against AD as it allows the clearance of Aβ before it 
aggregates into its toxic forms. Belyaev et al. and Kerridge et al. have shown 
that the different isoforms of APP (695, 751, and 770) differ in their ability to 
regulate NEP and TTR (Belyaev et al. 2010; Kerridge et al. 2014). They 
concluded that AICD is preferentially produced through γ-secretase activity 
from APP695, and that the AICD produced from this isoform specifically is able 
to upregulate NEP (Belyaev et al. 2010; Kerridge et al. 2014).  
Similarly, it was shown that TTR is upregulated in an APP695 and AICD-
dependent manner, with increased mRNA levels of both NEP and TTR 
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corresponding to increased occupancy of AICD on their respective promoters 
(Kerridge et al. 2014).  This increase of NEP and TTR showed a significant 
drop in Aβ levels in SH-SY5Y cells as these are both related to Aβ degradation 
and clearance (Grimm et al. 2013; Kerridge et al. 2014). The impact of the Aβ 
peptide has been repeatedly demonstrated and the ability for AICD-dependent 
up-regulation of amyloid- clearing proteins raises a potential role for APP 
based therapies in the treatment of AD (Ghosal et al. 2009). In particular, one 
of the genes regulated by the AICD, TTR has been specifically shown to target 
the Aβ42 peptide, which is the more toxic form of Aβ which is central to the 
pathology of AD (Garai et al. 2018; Cao et al. 2019). Therefore, the APP695 
isoform is central to Aβ clearance, and is therefore a significant target 
considering AD treatment. 
 
1.9 AD therapeutics   
Despite the years of research and the significant pharmaceutical investment 
there are no therapies available at this moment in time that are able to cure or 
significantly hinder the progression of AD (Graham et al. 2017). Despite the 
testing of multiple potential disease modifying therapeutics for AD, only four 
drugs have gained FDA approval for the treatment of AD. Three of these 
drugs, Donepezil, Galantamine, and Rivastigmine act on the central nervous 
system (CNS) cholinergic pathways and function through anticholinesterase 
activity (Graham et al. 2017). The fourth licensed drug for AD is Memantine 
which is an N-methyl-D-aspartate (NMDA) antagonist which acts to protect 
neurones from excessive glutamatergic excitotoxicity (Galimberti & Scarpini 
2010; Graham et al. 2017). All four of these drugs provide some level of 
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symptomatic relief and are generally administered as palliative therapy to 
improve the quality of life of patients, however there is no clear evidence that 
these therapies are able to modify the pathological processes underlying the 
disease and therefore do not impact disease progression (Yiannopoulou & 
Papageorgiou 2013; Graham et al. 2017). 
There are a variety of other potential disease modifying agents which either 
have been tested or are currently being tested for their ability to provide 
significant modulation of the pathological processes underlying AD. The 
majority of these drugs target Aβ, either directly in order to increase its 
clearance, or indirectly by inhibiting BACE or γ-secretase lowering overall Aβ 
production (Cummings et al. 2014; Graham et al. 2017).  
γ-secretase targeting therapies have a history of failure in part due to the 
complexity of the γ-secretase complex. As this complex is made up of four 
main subunits: nicastrin, PSEN-1, APH-1 and PSEN-2, each of these subunits 
is regarded as a potential therapeutic target (Mendiola-Precoma et al. 2016). 
However, as this complex is known to process up to 50 different protein 
substrates including Notch and APP, identification of an inhibitor specific to 
only the γ-secretases ability to process APP is a major drug-development 
target and is a key factor in the failure of this complex as a target for AD 
therapy (Graham et al. 2017). The effects of γ-secretase inhibitors on Notch 
processing can lead to toxic effects which include gastrointestinal bleeding, 
and immunosuppression, this interaction between Notch and γ-secretase is a 
key reason why a number of γ-secretase inhibitors have failed in the past 
(Graham et al. 2017). The most studied γ-secretase inhibitor, semagacestat, 
showed dose dependent decreases in the generation of Aβ in the CSF of 
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healthy people, but later showed detrimental effects on cognition in patients 
receiving the drug vs a placebo in a large phase III clinical trial, these 
detrimental effects were attributed to inhibition of Notch processing, continuing 
the trend of promising AD therapeutics failing in clinical trials (Yiannopoulou & 
Papageorgiou 2013). 
As an alternative to γ-secretase inhibitors which up to now have failed to show 
any significant reduction in AD progression, BACE1 inhibitors have been 
heavily researched. As BACE1 is the enzyme responsible for the first 
processing step in the pathway which leads to the production of Aβ, this was 
considered a key therapeutic target. The first generation of BACE1 inhibitors 
failed due to low oral bioavailability, and low BBB penetration (Yiannopoulou 
& Papageorgiou 2013; Graham et al. 2017). Second generation BACE1 
inhibitors were designed to overcome these limitations, however failed in 
clinical trials due to high levels of liver toxicity (Graham et al. 2017). Despite 
this, there were promising results shown by various third generation BACE1 
inhibitors such as Verubecestat which reached phase III clinical trials and 
showed encouraging data and satisfactory pharmacokinetics (Graham et al. 
2017). The Verubecestat clinical trial has since been discontinued after an 
external data monitoring committee concluded that the drug was unlikely to 
provide a positive benefit compared to risk (Kish 2018).  
Various immunotherapies have also been trialled for their ability to directly 
clear Aβ, with the first report of an immunotherapy treatment published in 1999 
(Morgan et al. 2000). This report demonstrated that active immunisation 
achieved by using synthetic human Aβ42 significantly reduced Aβ plaque 
formation and the prevention of memory deficits in animal models. These 
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benefits did not translate to patients however and demonstrated severe side 
effects resulting in the halting of this study (Holmes et al. 2008). As a result of 
the failure of active immunisation, passive immunisations directed against 
various  Aβ  domains were developed as an alternative therapy, and showed 
the potential to prevent Aβ oligomerisation and fibril formation (Legleiter et al. 
2004; Yiannopoulou & Papageorgiou 2013). There were three main 
immunotherapies trialled for AD treatment; Bapineuzumab, Solanezumab and 
Crenezumab (Salloway et al. 2014; Doody et al. 2013; Honig et al. 2018; 
Yoshida et al. 2020). Bapineuzumab involves passive immunization with an 
Aβ N-terminal directed monoclonal antibody. Phase II clinical trials with 
Bapineuzumab did not attain statistical significance on any of the primary 
efficacy endpoints, however it later appeared that both the therapeutic and 
adverse effects of Bapineuzumab treatment were dependent on the APOE4 
allele (Salloway et al. 2009). APOE4 carries showed no improvement and 
developed severe vasogenic edema. In non-APOE4 carriers, however, the 
drug was well tolerated and cleared cerebral Aβ in a dose dependent manner. 
Phase III clinical trials of Bapineuzumab were disontinued due to these safety 
concerns and a lack of the clinical end points being met (Salloway et al. 2014).  
Solanezumab is an IgG1 anti-amyloid monoclonal antibody that recognizes 
and binds to a central epitope on Aβ. Pre-clinical studies have shown that 
solanezumab increases the clearance of soluble Aβ (Siemers et al. 2010; 
Farlow et al. 2012). This therapy showed a more promising safety profile in 
clinical trials compared with previous immunotherapies, and showed 
significant reductions in Aβ42 levels (Siemers et al. 2010; Farlow et al. 2012). 
This drug reached phase III clinical trials but was later discontinued due to 
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failure to meet primary and secondary endpoints (Doody et al. 2013; Honig et 
al. 2018). Crenezumab is another immunotherapy which targets the central 
epitope region of Aβ, and importantly contains a human IgG4 backbone 
leading to reduced inflammatory activation. Initial clinical data suggested good 
penetration of the brain-blood barrier, affinity for amyloid beta monomers, 
oligomers, and fibrils, no induction of vasogenic oedema as seen with both 
Bapineuzumab and Solanezumab (Cummings et al. 2018; Salloway et al. 
2018). However, as with other immunotherapies, this drug was discontinued 
as it was unable to meet its primary endpoint of slowing the decline of AD 
symptoms and restoring cognitive function (Guthrie et al. 2020).  
To date, research into AD therapy has failed in terms of developing disease 
modifying therapies but has succeeded in terms of developing therapies which 
are at least able to provide symptomatic relief. Therefore, there is a great need 
to identify therapies which have the potential to slow the progression of the 
disease and improve cognitive function rather than just provide symptomatic 
relief.  Gene therapy utilising Antisense Oligonucleotides (ASOs) has emerged 
as a potential strategy by which to accomplish this, and there have been at 
least two ASO based therapies which have previously been researched in 








1.10 Antisense oligonucleotides    
1.10.1 Overview of Antisense oligonucleotides   
Since the splicing of APP appears vital to the progression of AD, one likely 
avenue for a therapy would be to regulate the alternative splicing. One such 
method of regulating alternative splicing is through the use of Antisense 
oligonucleotides (ASOs). These are synthetic single stranded nucleic acids 
and are usually between 8 and 50 nucleotides in length. They bind to pre-
mRNA through Watson-Crick base pairing in a sequence-dependent manner. 
ASOs interfere with gene expression as they are able to alter RNA function. 
ASOs can alter RNA function through several mechanisms depending on their 
sequence and modifications. ASO mediated gene inhibition was first used  in 
1978 by Stephenson and Zamecnik utilising a DNA molecule of 13 nucleotides 
in length (Stephenson & Zamecnik 1978; Evers, Toonen, et al. 2015). This first 
generation of DNA oligonucleotide was used for the specific knockdown of 
gene expression in the Rous sarcoma virus. These DNA oligonucleotides 
worked by binding to the RNA to form DNA/RNA hybrids which activated 
RNase H. This enzyme cleaves the double-stranded mRNA preventing 
translation into protein, and therefore decreases protein expression. These 
ASOs were successful but were very susceptible to degradation by 
endonucleases and exonucleases. Since this, modifications to the backbone 
and sugar component of these ASOs has improved the stability, binding 




1.10.2 Functional mechanisms of ASOs  
ASOs can modulate gene expression in multiple ways depending on the 
outcome required and the chemistry of the target site (Chan et al. 2006; Evers 
et al. 2015). Formation of the ASO-mRNA heteroduplex can modulate gene 
expression in one of 3 ways.  
The first method of modulating gene expression is through triggering RNase 
H mediated breakdown of RNA which can be used to knock down expression 
of genes. To exploit RNase H, ASOs known as gapmers have been 
developed. These ASOs consist of 2’-modified flanking sequences 
complementary to the target RNA surrounding central sequences of DNA. 
These ASOs are able to recruit endogenous RNase H to the complex, and 
lead to gene knockdown through degradation of RNA (figure 1.5) (Chan et al. 
2006; Evers et al. 2015). 
Another approach that has been utilised has been the use of ASOs in inducing 
disruptions of RNA processes through steric hindrance (figure 1.5). This 
method is able to lower protein levels by inhibiting translation. Due to the 
dependence of RNA processes on recognition sites or secondary structures 
of RNA molecules the addition of short complementary sequences of 
oligonucleotides which have been modified are able to disrupt these 
processes. The highly specific nature of ASOs allow them to be directed to 
specific regions of the RNA transcript. One application of steric hindrance 
which has been well researched is in the modulation of splicing events 
(Verhaart & Aartsma-rus 2012; Aartsma-Rus, Fokkema, et al. 2009). By 
blocking sequences associated with either splice enhancers or splice 
silencers, ASOs can promote exon skipping or exon inclusion, respectively. 
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ASOs utilising steric hindrance and exon skipping have been successfully 
utilised in the treatment of Duchenne Muscular Dystrophy (DMD). By targeting 
ASOs to sequences which are involved in recruitment of the spliceosome 
preventing its action, these ASOs were able to induce exon skipping of exons 
which contain mutations associated with DMD producing a truncated protein 
that was functional, and alleviated the disease phenotype (Popplewell et al. 
2009). Various ASOs have now been approved for the treatment of DMD. 
These include Eteplirsen, Golodirsen and Viltolarsen (Aartsma-Rus, Fokkema, 
et al. 2009; Mendell et al. 2016; Lim et al. 2017; Roshmi & Yokota 2019; 
Aartsma-Rus & Corey 2020; Dhillon 2020).  
Aside from RNase H mediated breakdown of mRNA or steric hindrance of 
ribosomal subunits, ASO strategies also involve inhibiting the maturation of 
pre-mRNA, and hence lowering the expression of mRNA and subsequent 
protein. ASOs in this case act to destabilise the pre-mRNA in the nucleus 
through inducing RNase H, binding to the 5’ cap region and preventing cap 
formation, or even by preventing RNA splicing, resulting in downregulation of 
mRNA and target protein. These approaches are targeted at lowering protein 
expression levels using ASOs, however applications which are targeted at 


















Figure 1.5: Functional mechanisms of ASOs. (1) Without the addition of ASOs there is 
normal gene and protein expression. The ASO is taken up by endocytosis and hybridises 
with the mRNA in the cytoplasm leading to formation of the ASO-mRNA heteroduplex which 
induces (2) activation of RNase H and degradation of mRNA or (3) steric hindrance of 
ribosomal subunits, both of which lead to protein downregulation. The ASO can also enter 
the nucleus and regulate mRNA maturation by (4) inhibiting 5’ cap formation, (5) inhibiting 















1.10.3 Spliceosome assembly 
As previously discussed, ASOs have been used to block the recruitment of the 
spliceosome, preventing its action and inducing exon skipping.  
A ribonucleoprotein (RNP) complex termed the spliceosome mediates this 
pre-mRNA splicing. The spliceosome is formed of small nuclear 
ribonucleoproteins (snRNPs) and a multitude of auxiliary proteins which act to 
recognize splice sites and catalyse the two transesterification steps of the 
splicing reaction (Roca et al. 2005; Will & Lührmann 2011). Each 
transesterification step involves a nucleophilic attack on terminal 
phosphodiester bonds of the intron and results in removal of the intronic 
sequence from spliced mRNA (Chen & Manley 2009; Lee & Rio 2015).  
Spliceosome assembly begins with the recognition and binding of snRNP U1 
to the 5’ splice site. Splicing factor 1 (SF1) binds to the branch point, this forms 
the E’ complex (Chen & Manley 2009). Recruitment of the U2 auxiliary 
complex (U2AF) (which is a heterodimer of U2AF65/U2AF35) to the 3’ splice 
site converts the E’ complex to the E complex. The ATP-independent E 
complex is converted into the ATP-dependent pre-spliceosome A complex by 
the replacement of SF1 by U2 snRNP at the branch point (Chen & Manley 
2009). Further recruitment of the U4/U6–U5 tri-snRNP leads to the formation 
of the B complex, which contains all spliceosome subunits in order to carry out 
pre-mRNA splicing. The B complex carries out the first of the two 
transesterification reactions with a nucleophilic attack at the branch point 
(Chen & Manley 2009). Following this conformational changes and 
remodelling, including the loss of U1 and U4 snRNPs result in the formation of 
the C complex, which is the catalytically active spliceosome (Chen & Manley 
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2009). Complex C carries out the second transesterification reaction at the 3’ 
splice site and results in the removal of the intron from the mature spliced 
mRNA (Chen & Manley 2009).  
The splicing mechanism has been elucidated in great detail however, it is not 
fully understood just how splicing sites are selected by the spliceosome (De 
Conti et al. 2013). The first step in selection of splicing sites is for the splicing 
machine to separate and define the difference between introns and exons. 
There are two possible ways in which the splicing machinery is able to 
determine this, exon definition and intron definition. Exon definition is more 
common in human genes which are characterised by short exons (average 
size of 145 nt) separated by considerably larger introns (average size of 3365 
nt) and involves the splicing machinery communicating over an exon, this 
allows for recognition of exons which are to be ligated together (De Conti et 
al. 2013). When exons are small and introns are long the splicing machinery 
is more likely to form over exons than across introns (De Conti et al. 2013). 
Intron definition involves the splicing machinery spreading out over the intron 
and therefore allows recognition of intronic regions which are to be spliced out 
of the pre-mRNA but also limits the length of these intronic regions (De Conti 
et al. 2013). Intronic definition is an ancient mechanism as single celled 
organisms have been shown to have short introns no longer than 350 bp (De 
Conti et al. 2013; Ram & Ast 2007).  
Splice sites can be either strong or weak and are ranked depending on their 
similarity to the consensus sequence; the more similar they are the more likely 
they are to be spliced (Roca et al. 2005). The consensus sequence is a 
sequence of 9 bases at the 5’ splice site and 15 bases at the 3’ splice site that 
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ensure splicing takes place. The consensus sequence for the 5’ splice site is 
the complementary sequence for the U1 snRNP required for spliceosome 
assembly, whereas the 3’ and branch point consensus sequences are not as 
defined (Roca et al. 2005). The presence of pseudo splice sites which are 
sequences that are similar to the consensus but do not undergo splicing, as 
well as cryptic splice sites which are sites that become spliced when natural 
splice sites are inactivated, support the idea that similarity to the consensus 
sequence is not the most important factor when it comes to pre-mRNA splicing 
(Roca et al. 2005).  Due to 5’ and 3’ splice site consensus motif degeneration 
it is difficult for the spliceosome to identify genuine splice sites from pseudo 
splice sites in the pre-mRNA transcript (Roca et al. 2005). It has been 
observed that a number of splice sites that are normally recognised by splicing 
machinery do not adhere to the optimal consensus sequence but are seen to 
possess more divergent sequences, it would be expected that these are poorly 
recognised, but research has shown that this is not the case (De Conti et al. 
2013) . In one study, 5000 constitutively expressed exons were examined and 
the results showed that only 5% of these perfectly matched the consensus 
sequences, with the other 95% showing partial matches or divergent 
sequences (Chasin 2007). 
Other factors which influence whether splice sites are selected are referred to 
as splice regulatory elements and can be either cis-acting or trans-acting . Cis-
acting elements are regulatory sequences in the RNA which recruit RNA-
binding factors to enhance or inhibit exon-intron recognition (Gamazon & 
Stranger 2014). If they act to enhance inclusion of an exon, they are termed 
exon splicing enhancers (ESE) or intronic splicing enhancers (ISE) depending 
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on where they are found. However, if they repress exon inclusion, they are 
termed exonic splicing silencers (ESS) or intronic splicing silencers (ISS), 
again depending on their localisation (Gamazon & Stranger 2014). Originally 
it was thought that these were only important when it came to alternative 
splicing, but recent studies have shown that they are necessary in 
constitutively spliced exon recognition processes (De Conti et al. 2013). ESEs 
localise close to splice sites and are able to compensate for a weak splice site 
by promoting exon inclusion. ESEs act by assisting in the early steps of the 
spliceosome complex formation by interacting with U1 snRNP and U2AF 
resulting in recognition and stability of the branch point (De Conti et al. 2013). 
Trans-acting factors are the aforementioned RNA-binding elements which 
bind to cis-acting factors and facilitate their effects (WANG et al. 2015). There 
are two main families of trans-acting regulators that can determine splicing, 
SR proteins (serine/arginine rich family of nuclear phosphoproteins) which are 
positive trans-acting factors and generally bind to ESEs and ISEs to enhance 
splicing, and heterogenous nuclear ribonuclear proteins (hnRNPs) which bind 
to ESS and ISS and are negative regulators of splicing and act antagonistically 
to SR proteins (Gamazon & Stranger 2014). The collaboration between the cis 
and trans-acting factors is what ultimately results in the promotion or inhibition 
of spliceosome assembly at weak splice sights (Chen & Manley 2009; Will & 
Lührmann 2011; WANG et al. 2015). 
Some exons are constitutively spliced, this means they are subject to intron 
removal and ligation of exons in the order in which they appear in a gene, and 
so these specific exons are present in every mRNA produced from a pre-
mRNA (Will & Lührmann 2011). But the potential promotion or exclusion of an 
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exon by the splicing machinery can lead to deviations from this (WANG et al. 
2015). This is known as alternative splicing and leads to the formation of 
alternative mRNA with alternative arrangements of exons compared to the pre-
mRNA, this allows for a multitude of structurally and functionally distinct mRNA 
and protein variants from a single gene. Alternative splicing provides 
significant expansion of the proteome from relatively few genes and recent 
analysis indicates that 92-94% of human genes undergo alternative splicing 
and the majority of these transcripts are generated  in a tissue-specific manner 
(Wang et al. 2008; Lee & Rio 2015). Alternative splicing plays an important 
role in normal physiology mediating diverse biological processes, and as a 
result defects in alternative splicing have been linked to various diseases such 
as β-thalassemia, cystic fibrosis and schizophrenia (Gamazon & Stranger 
2014; Lee & Rio 2015).  
The most common method of endogenous alternative splicing in the human 
transcriptome is cassette exon inclusion, also known as exon skipping and 
accounts for over 40% of all alternative splicing events within the transcriptome 
(Gamazon & Stranger 2014; WANG et al. 2015). An exon which is not present 
in one or more transcripts of a gene, due to weak splice sites or silencer 
elements is defined as a cassette exon, and in exon skipping this cassette 
exon is excised from the transcript along with the flanking introns (Gamazon 
& Stranger 2014).  
Antisense oligonucleotide (ASO) technologies have been established as a 
technique that can be used to modulate alternative splicing (Evers et al. 2015). 
Introns and exons can be skipped or included depending on the splicing 
machinery, and therefore exon skipping can be used to correct a mutation in 
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an exon or skip an exon entirely by forcing cellular machinery to skip unwanted 
exons provided that the flanking exons restore the reading frame (Evers et al. 
2015). This can be done via the use of antisense oligonucleotides (ASOs) 
utilising the method of exon skipping. Exon skipping involves ASOs specific to 
regions of pre-mRNA binding to a specific site on an exon. Binding of an exon-
specific ASO to an ESE (exonic splicing enhancer) motif hides the exon from 
the splicing machinery leading to the exon not being incorporated in the 
mRNA, and hence skipping of that particular exon (Evers, et al. 2015). ASOs 
which are able to induce exon skipping must have specific properties in order 
to be used therapeutically. The activation of RNase H is useful only when 
downregulation of gene expression is required, but if exon skipping is required 
RNase H should not be activated (Verhaart & Aartsma-rus 2012). First 
generation PMOs worked through activation of RNase H and were therefore 
unsuitable for exon skipping, hence modified ASOs were designed to fulfil a 









1.10.4 ASO backbone modifications 
ASOs were first used in the form of synthetic unmodified DNA, however these 
types of oligonucleotides were very vulnerable to nucleases, and hence had 
very low half-lives. It was apparent that in order to be used in clinical trials their 
pharmacological profile would have to improve, therefore these ASOs were 
modified to make them more viable. Chemical modifications of ASOs fall into 
two categories: modifying the ribose ring, or alterations of the phosphate 
backbone (figure 1.6).  
The first generation of modifications provided protection against nucleases 
and involved the addition of a phosphorothioate (PS) backbone where a non-
bridging oxygen atom in the phosphodiester bond was replaced by a sulphur 
atom (figure 1.6). ASOs with this modification are more stable than typical DNA 
oligos, have increased half-lives and promote RNase H mediated cleavage of 
target mRNA. PS-modification is the most commonly performed chemical 
modification of ASOs in loss-of-function studies in vitro and in vivo (Chan, Lim 
& Wong 2006). 
Further improvement of ASOs to improve nuclease resistance and binding 
affinity for mRNA involved 2’-sugar modifications (Chan, Lim & Wong 2006). 
These were termed second generation ASOs, and include the 2’-O-Methyl (2’-
OMe) and 2’-O-Methoxyethyl (2’-MOE) modifications (Verhaart & Aartsma-rus 
2012; Chan et al. 2006; Evers et al. 2015). These 2’-sugar modifications do 
not support RNase H cleavage, and therefore cannot be used through this 
functional mechanism. In order to combat this, gapmer ASOs were developed. 
These gapmers contain modified 2’-sugar residues on either side of a stretch 
of unmodified PS residues, commonly known as the gap. These flanking 
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modified regions improve the binding and stability of the ASO, while the gap 
allows for the induction of RNase H activity. ASO effectiveness was further 
increased by modifications which limit nucleotide confirmation. Nucleic acids 
which have a methylene bridge connection between the 2’-oxygen and the 4’-
carbon of the ribose sugar are considered ‘locked’ and therefore these ASOs 
are referred to as locked nucleic acids (LNAs) (Scoles et al. 2019). LNAs are 
vastly resistant to nucleases, show improved hybridisation and do not induce 
RNase H, therefore they are viable ASOs for inducing exon skipping (Verhaart 
& Aartsma-rus 2012). However, LNAs appear to have severe toxicological 
problems and are therefore not the best options for therapeutic use (Verhaart 
& Aartsma-rus 2012). 
Further modification involved changes to the ASO backbone which were 
devised in order to facilitate functions through mechanisms such as translation 
inhibition or splice modulation. These modifications resulted in ASOs with high 
resistance to nuclease cleavage and inhibition of RNase H. Such ASOs 
include Peptide nucleic acids (PNAs) and Phosphodiamidate morpholino 
oligomers (PMOs). PNAs are generated by replacement of the sugar 
phosphate backbone with polyamide linkages (figure 1.5). They are still able 
to hybridize through Watson–Crick binding, are uncharged, and provide a high 
resistance to nuclease and degradation. As they are unable to activate RNase 
H, PNAs are mostly used in splicing modulation approaches. However, these 
ASOs have a poor cellular uptake, and are insoluble in water so are difficult to 




Phosphodiamidate morpholino oligomers (PMOs) are another type of ASO 
with a backbone modification. These are synthetic oligonucleotides of around 
25 subunits which are similar to DNA and RNA oligonucleotides, however they 
possess a Phosphodiamidate backbone instead of the naturally occurring 
phosphodiester linkage and a morpholine ring instead of a ribose ring (figure 
1.6). As a result of the modified backbone PMOs are extremely stable, and are 
resistant to endogenous nucleases which allow them to remain intact for 
longer (Eisen & Smith 2008). The neutral charge of PMOs means they are less 
likely to form interactions with cellular material, and therefore are less likely to 
cause toxicity (Eisen & Smith 2008). However, this neutral charge makes it 
particularly difficult to get them into cells, both in culture and in vivo. These 
PMOs therefore require a charged carrier in order to facilitate uptake into cells. 
One method which has been described to accomplish this involves using a 
charged cDNA molecule to leash the PMO, facilitating its uptake into cells (Lu 
et al. 2011). Relative to  
 
 
Figure 1.6: Chemical structure of modified antisense oligonucleotides. Taken from 




1.10.5 ASOs in disease  
In order to be used therapeutically, ASOs must be easily and effectively 
delivered to their target organs in sufficient concentration, whilst minimizing 
exposure to other tissues. In the case of ASO delivery, the pharmacodynamics 
and pharmacokinetics of the oligonucleotide is especially important. ASOs 
which contain negatively charged backbones act to bind plasma proteins 
which allows for tissue infiltration, whereas ASOs with neutrally charged back 
backbones, such as phosphorodiamidate backbones show more rapid 
clearance from the blood (Eisen & Smith 2008; Evers, Lodewijk J.A. Toonen, 
et al. 2015). The various ASO modifications that are available, including 
modifications to the backbone, the ribose sugar moiety and the nucleobases 
themselves can be employed to improve the properties of ASOs and enhance 
their delivery to their target organs (DeVos & Miller 2013; Juliano 2016; 
Roberts et al. 2020). One common method of ASO delivery involves 
subcutaneous or intravenous injection which is used to deliver these ASOs to 
the periphery, however most of these will not be able to cross the blood brain 
barrier (BBB) and reach the CNS, which poses the greatest hurdle which 
needs to be overcome in order for ASOs to be used therapeutically for 
neurodegenerative disorders (Kordasiewicz et al. 2012; Roberts et al. 2020). 
However, recent research has demonstrated multiple possible methods of 
ASO delivery which allow the therapeutic product to cross the BBB, and could 
therefore be used as effective routes of ASO administration in clinical trials 
(Miller et al. 2013; Evers, Lodewijk J.A. Toonen, et al. 2015; McCampbell et 
al. 2018). These delivery mechanisms include intrathecal, intramuscular, and 
intravenous delivery as well as through conjugation of ASOs to nanoparticles  
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(Siva et al. 2014; Aartsma-Rus & Krieg 2017; Lim et al. 2017). Through the 
use of these methods ASOs have been shown to be able to reach the CNS 
and produce their desired effect. 
1.10.5.1 Antisense Oligonucleotides in Alzheimer’s Disease 
One of the first approaches utilising ASOs in the treatment of AD employed 
the use of PS-ASOs targeted at the Aβ region of APP in order to reduce its 
expression and subsequently reduce the expression of Aβ (Farr et al. 2014; 
Evers, Toonen et al. 2015). This ASO, termed OL-1, was delivered alongside 
an Aβ antibody via intracerebroventricular administration in SAMP8 mice, a 
strain with a mutation causing spontaneous overexpression of APP, and 
subsequent Aβ plaque formation (Kumar et al. 2000). This study showed 
reductions in the levels of both APP and Aβ in specific brain regions including 
the amygdala and hippocampus (Kumar et al. 2000). Further work with OL-1 
ASO utilised Tg2576 mice, a model which is widely used in AD research and 
contains the APPswedish mutation which results in elevated Aβ levels and 
subsequent amyloid plaque deposition as well as increased 
neuroinflammation and oxidative damage (Farr et al. 2014). In this study the 
antisense was either delivered centrally into the lateral ventricle or 
intravenously via the tail vein. After behavioural testing these mice were 
sacrificed and evaluation of brain and cytokine levels were analysed (Farr et 
al. 2014). This analysis revealed that treatment with the OL-1 ASO was able 
to reverse the learning and memory deficits which are associated with Aβ 
deposition. This therapy also showed significant decreases in APP levels, as 
well as markers of neuroinflammation (Farr et al. 2014).  
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Another instance of antisense oligonucleotides being used therapeutically in 
AD was through the targeting of exon 19 of the Apolipoprotein E receptor 2 
(ApoER2) (Hinrich et al. 2016). In the brain ApoER2, through interactions with 
ApoE, Reelin and selenoprotein P, mediates a signalling cascade which leads 
to phosphorylation and activation of NMDA receptors which ultimately 
increases long term potentiation (LTP) (Herz & Chen 2006; Wasser et al. 
2014). Research has shown that this activation of NMDA receptors 
counteracts the NMDA receptor-dependent synaptic suppression that is 
induced by Aβ (Hinrich et al. 2016). ApoER2 signalling requires the presence 
of an alternatively spliced exon, this is exon 19 in mice, and exon 18 in 
humans. This exon mediates the interaction between ApoER2 with PSD-95, 
required for NMDA receptor activation, and the c-Jun amino-terminal kinase-
interacting proteins which are implicated in neuronal survival. Studies have 
reported a significant decrease in the abundance of ApoER2 mRNA isoforms 
that include exon 19 in autopsy brain tissue samples from AD individuals 
compared to patients with MCI and non-cognitively impaired patients, and 
research with mouse models of AD has demonstrated that a decrease in 
ApoER2 exon 19 inclusion is associated with AD (Hinrich et al. 2016). In this 
study ASOs were designed to target the intron upstream and downstream of 
exon 19 to block the activity of putative intronic splicing silencers that are 
located within the introns flanking this exon (Hinrich et al. 2016). The ASOs 
designed were 18-mers with 2’-MOE nucleotides. ASOs were tested in vitro 
and in vivo. In vitro testing was done in HeLa cells and into a mouse primary 
cell line derived from adult kidney cells, and in vivo testing was done in wild 
type (WT), non-transgenic mice by intracerebroventricular injection. RT–PCR 
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analysis of ApoER2 exon 19 splicing of RNA collected from tissues revealed 
a 65% increase in the percentage of ApoER2 mRNA transcripts that include 
exon 19, and similar effects on exon 19 inclusion were seen in vivo (Hinrich et 
al. 2016). The best ASO (ASO-21) was chosen to move forward and further 
test whether this ASO could increase exon 19 inclusion in the TgCRND8 
mouse model of AD which show rapidly developing amyloid pathology with 
amyloid plaques presenting in the cortex and hippocampus by 3 months of 
age and impaired learning and memory. (Janus et al. 2000; Hinrich et al. 
2016). RT-PCR analysis of these mice showed that there were significant 
increases in exon 19 inclusion in mice treated with the ASO-21 versus mice 
treated with a control ASO just 1 week after injection, and this increase was 
sustained up to 6 months. The increases in exon 19 inclusion also led to 
increases in increased ApoER1 protein that included the additional domain 
that is encoded for by exon 19 that was detectable by immunoblotting, 
however there was no significant difference observed in the levels of Aβ 
between these two treatment groups. The Morris water maze (MWM) was 
used to assess changes in learning and memory, and results showed there 
was significant correlation between the percent of ApoER2 mRNA with 
inclusion of exon 19 and performance in the MWM. This suggest that that the 
ASO21-mediated increase in exon 19 inclusion improved spatial memory 
learning and provided therapeutic benefit to AD mice (Hinrich et al. 2016). 
Another study which used ASOs in the development of a potential therapeutic 
for AD was in the use of splice switching ASOs (SSOs) in order to modulate 
APP splicing and reduce Aβ (Chang et al. 2018). SSOs can alter slice-site 
recognition and directly modulate splicing by base pairing to pre-mRNA and 
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blocking the interactions between RNA and RNA-binding (Chang et al. 2018). 
In this study these SSOs were designed to block APP exon 17 splicing and 
produce an alternatively spliced APP mRNA lacking exon 17. Removal of exon 
17 results in an in-frame deletion of 49 amino acids that form a site that is 
required for γ-secretase cleavage and is responsible for producing the toxic 
Aβ42 peptide. The SSOs used in this study were 2’-MOE 18-mers and were 
targeting to block the splicing of exon 17 of APP. Transfection of these SSOs 
in HEK293T cells followed by RNA extraction and RT-PCR confirmed that the 
2 of the 36 SSOs designed were able to induce exon skipping in a dose-
dependent manner. Further tests were undertaken in fibroblasts from Down 
Syndrome individuals. Down syndrome/Trisonmy 21 (DS) cells which contain 
3 copies of APP and therefore have an increase APP protein abundance, and 
higher Aβ42 abundance than non-DS cells making them a good model to 
assess Aβ changes. These DS cells were transfected with one of these SSOs, 
termed SSO 17-2, a dose-dependent decrease in full length APP mRNA, and 
an increase in APP mRNA lacking exon 17 was observed. Immunoblotting 
analysis of APP protein lysates from DS cells transfected with SSO 17-3 
demonstrated the same pattern as was observed at the mRNA level, and 
importantly SSO 17-3 treatment also demonstrated a 45% decrease in Aβ2 in 
the cell media of DS cells, resulting in levels that were comparable to 
karyotypically normal cells. In order to test these SSOs in vivo, SSOs were 
designed to target the murine APP exon 15 which is homologous to human 
APP exon 17. Administration of these SSOs to wild-type mice at post-natal 
day 1 or day 2 via intracerebroventricular injection, followed by RT-PCR 
analysis of the RNA isolated from both the cortex and hippocampus of these 
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mice 3 weeks after SSO administration demonstrated significant skipping of 
APP exon 15 in both of these brain regions. Brain tissue was also collected 
from wild-type mice after 3 months, a timepoint which is considered sufficient 
to allow normal accumulation of Aβ in wild type mice. This analysis suggested 
that SSOs were still present in the hippocampus and cortex of 4-month old 
mice that were injected with SSOs once at pre-natal day 1 or 2. RT-PCR of 
these tissue also showed similar levels of APP exon 15 skipping as was seen 
3 weeks after treatment, indicating long-term sustained effects of this SSO. 
ELISA analysis of the hippocampus revealed that SSO treatment resulted in a 
57% reduction in Aβ42 versus mice treated with a control SSO. These results 
confirm that these SSOs can be utilised in vivo and result in sustained, long 
lasting skipping of APP exon 15 and that these antisense technologies can be 
used effectively to reduce Aβ42 levels (Chang et al. 2018). 
These studies showed the applicability of ASO technologies to AD as potential 
therapeutics  
 
1.10.5.2 Exon skipping in Duchenne Muscular Dystrophy 
Duchenne Muscular Dystrophy (DMD) is a severe X-linked neuromuscular 
disorder which is characterised by muscle weakness which progresses over 
time, eventually reaching the diaphragm and respiratory muscles leading to 
respiratory failure. The disorder is caused by mutations in the dystrophin gene, 
coding for the protein dystrophin which is integral to muscle contraction. 
Mutations in dystrophin disrupt the reading frame, leading to non-functional 
transcripts or premature stop codons (Aartsma-Rus et al. 2003). ASOs can be 
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utilised to target exons, masking the exon-determining motifs and splicing out 
of these exons from the pre-mRNA. This approach has been shown to restore 
the disrupted reading frame, producing a shortened but functional dystrophin 
protein in DMD models (Rinaldi & Wood 2018). There are several ASO based 
DMD therapeutics which have entered clinical trials. Drisapersen is once such 
ASO, it is an 18-mer 2’O-methyl phosphorothioate ASO which targets exon 51 
of DMD gene for the induction of exon skipping. However, this treatment did 
not show any significant benefit over placebo in phase III clinical trials (Rinaldi 
& Wood 2018). Eteplirsen is another ASO based drug which utilises steric 
hindrance based exon skipping to skip exon 51 of the DMD gene has gained 
FDA approval for the treatment of DMD (Mendell et al. 2016; Lim et al. 2017). 
Eteplirsen is developed by Sarepta, it differs from Drisapersen in that it is a 
30-mer PMO and is therefore neutrally charged. Eteplirsen was granted FDA 
approval in 2017, making it the first FDA-approved drug for the treatment of 
DMD following clinical trials which demonstrated good outcomes and an 
acceptable safety profile (Mendell et al. 2016; Lim et al. 2017).  
In 2019 golodirsen became the second oligonucleotide drug to gain FDA 
approval for the treatment of  DMD (Aartsma-Rus & Corey 2020; Frank et al. 
2020). Golodirsen is a 25-mer PMO that was designed to skip exon 53 of 
dystrophin pre-mRNA and works to restore the open reading frame of DMD in 
patients with the aim of producing a shortened but functional dystrophin 
protein, slowing disease progression (Aartsma-Rus & Corey 2020; Frank et al. 
2020). This oligonucleotide gained approval based on the increases observed 
in overall dystrophin expression as a result of golodirsen treatment (Aartsma-
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Rus & Corey 2020; Frank et al. 2020). Skipping of exon 53 to restore the open 
reading frame of dystrophin is applicable to roughly 7.7% of patients with DMD.  
Viltolarsen is another oligonucleotide which was recently approved for the 
treatment of DMD. Viltolarsen gained approval  in March 2020 in Japan only. 
Viltolarsen is a 21-mer PMO and, similarly to golodirsen (Roshmi & Yokota 
2019; Dhillon 2020), functions by targeting and skipping exon 53 of the 
dystrophin gene. Viltolarsen again demonstrated exon skipping and increased 
expression of dystrophin protein as a result. Clinical trials of viltolarsen are 
continuing to be conducted in the USA prior to gaining approval (Roshmi & 
Yokota 2019; Dhillon 2020).  
 
1.10.5.3 ASOs and Spinal Muscular Atrophy 
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular 
disorder that affects motor neurones characterized by degeneration of the 
anterior horn cells in the spinal cord, resulting in progressive muscle weakness 
and atrophy. SMA is caused by a loss of function mutation in exon 7 of the 
survival motor neuron 1 (SMN1) gene (Neil & Bisaccia 2019). This loss of 
function of SMN1 is not fatal as this is compensated for to some extent by the 
SMN2 gene, a duplication of SMN1. SMN2 however contains a silent mutation 
within exon 7 which leads to its exclusion from most transcripts. This exon skip 
results in the formation of a truncated, and less functional SMN protein (Singh 
& Singh 2018). However, an ASO called Nusinersen was designed in order to 
target an intronic splicing silencer in the previous intron. This promotes the 
inclusion of exon 7 in the SMN2 transcript (Chiriboga 2017). Clinical trials 
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where this ASO was delivered intrathecally to patients suggested that there 
was long-lasting functional activity in a dose dependent manner, with levels of 
full-length functional SMN protein more than doubling after a single treatment 
with this ASO. Nusinersen  gained FDA approval in 2016 for the treatment of 
SMA (Neil & Bisaccia 2019). 
 
1.10.5.4 siRNA based gene therapies 
The mechanism of RNA interference (RNAi) was first discovered in 1998 by 
Fire et al. when double stranded RNAs (dsRNAs) were identified as being the 
causative agents for post-transcriptional gene silencing in Caenorhabditis 
elegans (Fire et al. 1998). This discovery showed that non-coding RNAs are 
central regulators of gene expression, and further research into this showed 
that these small non-coding RNAs could be used to induce specific RNAi 
silencing (Patil et al. 2014; Setten et al. 2019).  These small non-coding RNAs 
can be either small interfering RNAs (siRNAs) or microRNAs (miRNAs). 
siRNAs are molecules which have characteristic 3′ overhangs that allow 
recognition by the enzymatic machinery of RNAi, and eventually lead to 
homology-dependent degradation of the target mRNA, inducing gene 
silencing at the mRNA level. In cells, siRNAs are derived from cleavage of 
longer double stranded RNA (dsRNA) pre-cursors by cytoplasmic RNAse III 
family enzyme Dicer (Patil et al. 2014; Setten et al. 2019). The double stranded 
siRNAs are then incorporated into a multiprotein RNA-induced silencing 
complex (RISC). Another component of the RISC termed Ago-2 cleaves and 
separates the siRNA leading to an activated form of the RISC with the 
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antisense siRNA strand guiding the RISC to silence a target mRNA via 
degradation of the target RNA transcripts (Hu et al. 2020).  
miRNAs are endogenous duplexes that regulate gene expression through the 
formation of complexes with RISC and binding to the 3′ untranslated regions 
of target sequences (Lam et al. 2015; Setten et al. 2019). The primary 
mechanism of action of miRNAs are mRNA degradation and mRNA translation 
repression. The miRNA duplexes possess incomplete Watson-Crick base 
pairing, and the  miRNAs are endogenous substrates for the RNAi machinery 
(Gregory et al. 2005; Matranga et al. 2005; Leuschner et al. 2006). The 
miRNAs are primarily expressed as long primary transcripts (pri-miRNAs), 
which are processed within the nucleus into hairpins of 60–70 bp in length by 
a protein complex termed the microprocessor complex, which is made up of 
Drosha and DGCR8 into pre-miRNAs (MacFarlane & R. Murphy 2010). These 
pre-miRNAs are further processed in the cytoplasm by Dicer and one of the 
two strands is loaded into RISC, functioning to then silence genes. The 
differences between siRNAs and miRNAs means that siRNA are more efficient 
and can be more specifically targeted to induce gene silencing of a single 
gene, whereas one miRNA may affect the expression of several different 
genes (Lam et al. 2015). 
Soon after the discovery of RNAi, Elbashir at al. demonstrated successful 
silencing of the expression of specific genes in mammalian cells through 
utilizing chemically synthesised siRNAs (Elbashir et al. 2001). Since this time, 
further optimisation to siRNAs drug formulations were required to overcome 
pharmacodynamics-related and pharmacokinetic challenges in targeting 
specificity and cytotoxicity (Reynolds et al. 2004; Lennox & Behlke 2011; Ly et 
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al. 2017). These challenges have been addressed via optimisation of 
structural motifs, sequence selection, chemical formulation of RNAi triggers 
and engineering of delivery routes and excipients (Reynolds et al. 2004; Kim 
et al. 2005; Shukla et al. 2010; Kuwahara & Sugimoto 2010; Lennox & Behlke 
2011; Snead et al. 2013; Ly et al. 2017). These improvements have led to the 
formulation of siRNAs which have improved safety and potency while also 
enhancing the ease of delivery and reducing off target RNAi activity.  
In August 2018 the first siRNA based therapy gained FDA and European 
Medicines Agency approval (Hoy 2018). This was patisiran,  a double stranded 
siRNA encapsulated in a lipid nanoparticle for delivery to hepatocytes for the 
treatment of hereditary transthyretin amyloidosis with polyneuropathy in adults 
(Hoy 2018). Following this, the second RNAi based drug, givosiran, was 
approved by the FDA in 2019 and European Medicines Agency in 2020 (Scott 
2020). Givosiran is an siRNA drug which is covalently linked to a ligand to 
enable specific delivery of the siRNA to hepatocytes for the treatment of acute 
hepatic porphyria (AHP). Givosiran acts to down regulate aminolevulinate 
synthase 1 (ALAS1) mRNA and prevents accumulation of neurotoxic δ-
aminolevulinic acid and porphobilinogen levels that are associated with acute 










Aβ accumulation is crucial to the progression of AD and is implicated to be due 
to alterations in APP metabolism, expression, and processing. Analysis of APP 
protein and mRNA levels in AD patients show that there is an increase in the 
levels of KPI positive APP isoforms (APP770 and APP751), and a decrease 
in levels of APP695 compared to a healthy brain (Johnson et al. 1990). This 
loss of APP695 and the fact that this correlates with increased Aβ deposition 
suggests that the APP695 isoform confers protection to AD and that this loss 
of protection is one of the factors which contribute to AD. It is possible that 
these protective effects of APP695 are mediated through the AICD, which is 
preferentially produced from APP695. This project will further investigate 
whether PMOs can be utilised to induce alternative splicing of APP, the 
effects of modulating APP alternative splicing and whether APP695 does 
indeed provide protection against AD through the effects of the AICD. 
The objectives of this research project are:  
1) To design PMOs to prevent the inclusion of exons 7 and 8 of APP into 
the APP transcript 
2) To examine the effects of PMOs on manipulating APP splicing patterns 
at the RNA level in SH-SY5Y cells 
3) To examine the effects of PMOs on manipulating APP splicing patterns 
at the protein level in SH-SY5Y cells 
4) To examine whether increasing APP695 levels via exon skipping 
translates to detectable changes in the expression of  the AICD and 
other downstream genes related to the AICD 
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2 Materials and Methods 
2.1 Bioinformatics analysis 
2.1.1 Online resources  
 
Ensembl (www.ensemble.org)  
o Genomic sequences of APP 
Mfold (unafold.rna.albany.edu/)  
o RNA folding  
Sfold (sfold.wadsworth.org)  
o Thermodynamic calculations 
Human Splice Finder 3.0 (http://www.umd.be/HSF3/) 
o Determination of Splicing enhancers and silencers 
Basic Local Alignment Search Tool (www.ncbi/nlm.nih.gov/BLAST/) 
o Alignments of oligos and off target effect analysis 
RNAup WebServer 
(http://rna.tbi.univie.ac.at/cgibin/RNAWebSuite/RNAup.cgi)  






2.1.2 RNA sequences 
The RNA sequence for the APP transcript of interest was taken from the 
Ensembl genome database and exported in FASTA format. This sequence 
was used for subsequent analysis by either manually inputting the sequence 
into web servers or software, or by inputting the Ensembl transcript ID into said 
tool. Details of the transcript are described below. 
 
Gene Ensembl Entry 
Number 





3467 Protein coding 
 
Table 2.1: Table showing the details of the APP transcript from Ensembl which was 










2.1.3 RNA secondary structure 
In order to determine the secondary structure of the RNA molecules in the 
APP gene Mfold and was required. 
 
2.1.3.1 Mfold 
Mfold calculates the minimum free energy (MFE) structure for a sequence and 
has been previously used for RNA structure prediction in the PMO design 
process (Popplewell et al. 2009). On the Mfold website the RNA folding form 
function was used with default conditions. RNA folding temperature is fixed at 
37°C and ionic conditions of 1M NaCl was maintained. Loop sizes were set to 
a maximum of 30 bases by default, and there was no limit set on the maximum 
possible distance between paired bases. FASTA sequences of the whole APP 
gene, as well as specific regions of the gene (exons 7 and 8) were inputted, 
and the outputted secondary folding structures were saved as pdf format for 
analysis. Mfold has a limit of 9,000 base pairs for batch input on the entry form.  
 
2.1.4 Exon splicing enhancer and silencer sequences 
The Human Splice Finder 3.0 tool was used in order to determine where PMOs 
should be targeting within the APP exons of interest. Human splice finder 
analyses and gives information regarding the consensus values of potential 
splicing enhancer and silencer sites within and around exons of interest. The 
exons of interest in this case are exon 7 and exon 8. The APP Ensembl 
transcript ID used was ENST00000346798.7. This was inputted into the 
Human Splice Finder 3.0 tool and the exon to be analysed was specified. This 
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was done once for each exon, with 100bp of intron either side of the exon also 
being added for the analysis. 
 
2.1.5 PMO binding energies 
The Sfold web server was used to analyse the binding energies of potential 
PMOs. The SOligo tool on the Sfold web server was used in order to achieve 
this. The FASTA sequences of the specific exons with 100bp intron were 
inputted into the form. The only condition which was changed from the default 
was the preferred length of antisense oligo which was set to either 25 or 30 
bases instead of the default 20 bases. Once submitted the webserver 
calculated the data. There were two main output versions, oligo.out which was 
the complete output data, or Oligo_f.out which was the filtered version of the 
results. Oligo_f.out filtered results to remove any oligonucleotides with GC 
contents <40% or >60%, with binding energies <8kcal/mol and any GGGG 
repeats. We selected to use the data received from Oligo_f.out. The data 
produced was in the format of a table which showed the binding energies of 
each oligonucleotide that fit the requirements and was able to bind to the target 
sequence. Any oligonucleotide which showed potential for use was noted 





Figure 2.1: Sample SFold output. Demonstrates the target position, the target sequence, 
the PMO sequence, the GC content of the targeted sequence, and the oligo binding energy 
in kcal/mol. These factors were analysed in order to design functional PMOs, with the GC 
content and oligo binding energies being among the most important factors when considering 
PMO design. 
 
In order to calculate RNA-RNA interactions and determine the total free 
binding energy the RNAup server was used.  The sequence of the exon, and 
the potential PMOs were inputted into the online form on the RNAup website. 
Default settings were used except for the maximal length of the region of 
interaction which was adjusted to match the full length of the PMO. Once the 
server had modelled the interaction, data was received in form of text stating 
the total free energy of binding, the energy from duplex formation, the opening 
energy for the exon and the opening energy for the oligonucleotide. A 
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graphical representation of this is also given showing the position of the PMO 























2.2 Cell Culture 
2.2.1 Proliferation media  
o Dulbecco’s Modified Eagles Medium – high glucose (Sigma #D671)  
o Foetal Bovine Serum (FBS) (Gibco, #10500-064), final concentration 
10% 
o GlutaMAX (Gibco, #35050-061), final concentration 1x  
o Penicillin-streptomycin (Gibco, #15140122), final concentration 
100units/mL  
o Final volume was made up to 500ml. Media was filtered through a 
sterile 0.45µM filter (Thermo, #124-0045) before being aliquoted and 
stored at 4°C.  
 
2.2.2 Freezing media 
o Dulbecco’s Modified Eagles Medium – high glucose (Sigma #D671)  
o FBS, 20% final (Gibco, #10500-064) 
o Dimethyl sulfoxide (DMSO), 10% final (Sigma, #D8418) 
o Freezing media filtered through a 0.2μm filter and stored away from 
light at 4°C 





2.2.3 Cell lines 
Human neuroblastoma cell line SH-SY5Y was kindly provided by Professor 
George Dickson (Centre of Biomedical Sciences, Royal Holloway University 
of London). 
 
2.2.4 Thawing cells 
Stocks of SH-SY5Y cells were stored frozen in liquid nitrogen 1x106 cells/1mL 
freezing media (10% DMSO, 70% DMEM, 20% FBS). Stocks were thawed 
quickly by submersing in a 37°C water bath for approximately 1 minute. Once 
thawed, cells diluted to 5mL with proliferation media (DMEM/F12, 10% FBS, 
10% glutaMAX, 1% Pen/strep, 1% non-essential amino acids) and transferred 
to a 15ml falcon before being centrifuged 3000rpm for 5 minutes. Media was 
then carefully aspirated, and the pellet resuspended in 1ml of warm 
proliferation media before adding another 14ml of proliferation media and the 
cell suspension being seeded into a T75cm2 flask (Corning, #430372). Cells 
were incubated at 37°C, and 5% CO2 and subcultured at 70-80% confluency. 
 
2.2.5 Sub-culturing 
Cell confluency was checked daily and were subcultured when they reached 
70-80% confluency. All consumables were warmed to 37°C  in a water bath 
prior to use. The proliferation media from the T75cm2 flask (Corning, #430372) 
containing cells to be subcultured was aspirated and then cells were washed 
with 10ml of 1x DPBS (Dulbecco’s Phosphate buffer saline) (Gibco, #14190-
094). The cells were then detached from the flask by adding 1ml of TrypLE 
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Express (Thermofisher, #12604-021) and incubation at 37°C for 1-2 minutes. 
The flask was agitated to ensure cells detached and 9ml of culture media was 
added to neutralise the TrypLE and collect cells, this was transferred to a 15ml 
falcon and centrifuged at 3000 rpm for 5 minutes. The pellet was resuspended 
in 10ml of fresh culture media, and a 1:5 split of this solution was seeded into 
a new T75 cm3 flask (Corning, #430372). A further 14ml of pre-warmed growth 
media was then added, before cells were incubated at 37°C, 5% CO2 until 70-
80% confluency. 
 
2.2.6 Cryogenic storage of cell lines 
Once cells reached 70-80% confluency, media was aspirated, and the cells 
washed with 1x DPBS. Following this 1ml of 1x TrypLE was added in order to 
detach the cells from the surface of the flask. This was incubated at 37°C for 
1-2 minutes. TrypLE was inactivated by the addition of 9ml pre-warmed 
proliferation media, followed by counting of cells with a haemocytometer and 
centrifugation of cells at 3000rpm for 5 minutes to receive a cell pellet. Cells 
were resuspended at 1x105 cells per 1ml in freezing media. Cells were 
aliquoted at 1ml per vial into screw-top cryovials and cooled overnight at -








2.3 Cell Transfections 
2.3.1 Transient transfection of SH-SY5Y cells with Lipofectamine 
2000 
SH-SY5Y cells were seeded at a density of 5 x 105 cells/well in 6-well plates 
containing 2ml of proliferation media/well, and incubated at 37°C, 5% CO2 until 
they were 80-90% confluent, typically after 1 day of seeding. Once cells had 
reached 80% confluency, they were ready to be transfected. For SH-SY5Y 
cells a ratio of 1µl of lipofectamine 2000 (Thermofisher, #11668019) : 1µg of 
plasmid DNA was used per well. Both the lipofectamine 2000 and plasmid 
DNA were diluted in DMEM- high glucose (no additives) in separate Eppendorf 
tubes and incubated for 5 minutes at room temperature. The two separate 
tubes containing the plasmid DNA and transfection reagent were mixed 
together and incubated for a further 20 minutes at room temperature to allow 
for the formation of DNA-lipid complexes. After 20 minutes the mixture was 
then added slowly in a dropwise manner to the wells, and the plate was 
agitated to allow for proper mixing before incubating again at 37°C, 5% CO2. 
5 hours post transfection, the media from these wells was aspirated, and 
replaced with fresh pre-warmed proliferation media in order to reduce 
transfection-related toxicity and incubated for a further 24 hours before being 
extracted. Volumes used for plasmid-DNA and Lipofectamine 2000 were 




2.3.2 Transfection of SH-SY5Y cells with EndoPorter 
SH-SY5Y cells were seeded at a density of 2.5 x 105 in 12-well plates 
containing 500ml of proliferation media per well and incubated at 37°C, 5% 
CO2 until they were 80-90% confluent, typically after 1 day of seeding. PMOs 
purchased from GeneTools at stock concentrations of 1mM were diluted and 
maintained at a 100uM working concentration. These PMOs were transfected 
into cells at concentrations of 100-1000nM as required. Appropriate volumes 
of PMO were added to cells in each well, followed by 6µM of EndoPorter in 
DMSO (GeneTools). Plates were agitated to ensure adequate mixing before 
being incubated at 37°C, 5% CO2 for 24 hours prior to RNA being extracted.  
 
2.4 RNA extraction 
RNA was extracted from SH-SY5Y cells in 12 well plates using the RNeasy 
mini kit (Qiagen #74104). RLT buffer was added to wells, 350ul/well. This was 
pipetted up and down in order to lyse all cells. The homogenised sample was 
collected into QIAshredder centrifuge tubes and spun 13000x g for 1 minute. 
The collected solution was diluted in equal volumes of sterile 70% ethanol. 
The solution was then transferred to a RNeasy spin column placed within a 
2ml collection tube, and centrifuged for 15 secs at 8000x g. The flow through 
was discarded and 700ul of RW1 buffer was added to the column and again 
centrifuged for 15 seconds at 8000x g. The flow through was discarded and 
column was then washed twice with 500ul of RPE buffer which was diluted in 
ethanol prior to starting the RNA extraction. After the first wash the column 
was centrifuged for 15 seconds at 8000 x g and the second time for 8000 x g 
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for 2 minutes. The mini spin column was then placed in a 1.5ml collection tube 
and 30ul of RNase-free water was added and then was centrifuged for 1 

























2.5 Polymerase Chain Reaction  
2.5.1 Reverse Transcription cDNA Synthesis 
Synthesis of cDNA was carried out using the GoScript Reverse Transcriptase 
kit (Promega, #A5003) according to the manufacturer’s instructions. 500ng 
RNA was mixed with Oligo(dT)15 (Promega, #C1101)) and the final volume 
made up to 10µLwith nuclease free water in PCR tubes. PCR tubes were 
heated to 70°C for 5 minutes and then left at 4°C for a further 5 minutes. The 
reverse transcription master mix was prepared by mixing 4 µL of GoScript 5X 
Reaction Buffer, 1µL of MgCl2, 0.5 mM of dNTP (Promega, #U1511), 1 µL of 
GoScript Reverse Transcriptase and the volume of the master mix was made 
up to 15µL with nuclease free water. The master mix was then added to the 
RNA and placed in a G-storm 482 thermal cycler with the following 
programme: annealing at 25°C for 5 minutes, extension at 42°C for one hour, 










2.5.2 First Round and Nested Polymerase Chain Reaction    
PCRs were carried out for the amplification of APP, and two rounds of PCRs 
were carried out. Primers sequences are shown in table 2.1, and were ordered 
from Sigma Aldrich, before being diluted to working concentrations of 1µM for 
use in these PCRs.                                     
The GoTaq DNA Polymerase kit (Promega, #M3001) was used. A PCR master 
mix was prepared by adding 1x GoTaq Reaction Buffer, 1 mM MgCl2, 0.2 mM 
of each dNTP, 1 µM of each primer and 0.125 µL of GoTaq DNA Polymerase, 
where the final volume was made up to 25 µL with nuclease-free water. The 
PCR was run in G-storm 482 thermal cycler with the following program: 45° C 
for 30 min, initial denaturation 92 ° C for 2 min, 10 cycles of denaturation 92°C 
for 30s, annealing 62°C for 30s, extension 68°C for 45s, 15 cycles of 
denaturation 92°C for 30s, annealing 62°C for 30s, extension at 68°C for 45s 
+ 5 s/cycle, followed by final extension at 68°C for 10 min. Hold at 4°C infinite. 
A second round nested PCR was carried out in order to further increase gene 
amplification of APP transcripts. The master mix for the nested PCR was the 
same as the first round, with 1µl of the first-round product used as the template 
for this PCR. The PCR was performed in a G-storm 482 thermal cycler with 
the following program: Initial Denaturation 92 ° C for 5 mins, 30 cycles 
denaturation 92°C for 30s, annealing 60°C for 30s, extension 68°C for 45s, 








Table 2.2: Table showing the primers used for RT-PCR.  Forward and reverse primers 
are shown for both the first round and nested PCR 5’-3’. Primers were ordered form Sigma 
Aldrich.  
 
2.5.3 Agarose Gel electrophoresis 
Gel electrophoresis was used in order to analyse the effects of PMOs on 
modulating alternative splicing of APP and verify the presence of APP. TAE 
(40mM Tris, 20mM acetic acid, 1mM EDTA) was prepared as a 50x stock, and 
was diluted to 1x in order to prepare an agarose gel. The Agarose percentage 
of the gels used for electrophoresis ranged from 1-2.5% depending on 
separation level that were required, diluted in TAE buffer, with the volume 
made up to 120ml. The agarose/TAE mixture was heated until the agarose 
was fully dissolved, and then 10,000x SYBR Safe DNA gel Stain 
(Thermofisher, #S33102) was diluted down to 1x in the solution to allow for 
visualisation of DNA. The solution was poured into a gel casting tray with a  
comb inserted and the gel was left to set before being placed into an 
RT-PCR Primers 
APP forward 1 5'-GTGATGAGGTAGAGGAAGAGG-
3' 
APP reverse 1 5'-GTTGTAGAGCAGGGAGAGAG-3' 
Nested PCR primers 
APP forward 2 5'-CACAGAGAGAACCACCAGCA-3' 
APP reverse 2 5'-CTTGACGTTCTGCCTCTTCC-3' 
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electrophoresis tank. Once cool, 10µl of each sample was loaded onto the gel 
alongside 5µl of HyperLadder I (Bioline, #BIO-33025). Gels were run at 90V 


















2.6 Protein Analysis 
2.6.1 Buffers and solutions 
Solution Components 
NP40-based lysis buffer 20mM HEPES, 1mM EDTA, 150mM NaCl, 1% 
Nonidet P-40, 1mM dithiothreitol, 1 protease 
inhibitor tablet (#11873580001, Roche) per 50ml 
and 1 phosphatase inhibitor tablet 
(#88667SPCL, Pierce) per 10ml 
RIPA lysis buffer 150 nM NaCl, 1% Nonidet P-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 25 mM Tris pH 7.4, 1 
protease inhibitor tablet per 10 mL 
1X Tris-glycine transfer buffer 25mM Tris, 192mM glycine, 10% methanol 
1X Tris-glycine running buffer 25mM Tris, 192mM glycine, 0.1% SDS; pH 8.3 
4X Resolving buffer 1.5M Tris-base, 8mM EDTA, 0.4% SDS; pH 8.8 
4X Stacking buffer 0.5M Tris-base, 8mM EDTA, 0.4% SDS; pH 6.8 
1X Tris-buffered saline (TBS) 50mM Tris-base, 150mM NaCl 
1X Phosphate-buffered saline (PBS) 1 PBS tablet (Gibco, #003002) in 500ml of 
ddH2O 












Primary APP N-terminal 
22C11 
Mouse 1:1000 1:1000 Sigma, MAB348 
APP C -terminal 
A8717 
Rabbit 1:1000 1:1000 Sigma, A8717 
APP KPI Rabbit 1:500 - Merck, AB5302 
APP OX2 Rabbit 1:500 - Merck, 6B9289 
Anti-APP AICD 
Polly8119 
Rabbit 1:1000 1:1000 Covance, SIG-39148 
Anti-β-actin Mouse 1:5000 - Sigma, A1978 
Secondary  Anti-rabbit Goat 1:5000 - Cell Signalling, 5151S 



































2.6.3 Protein Extraction 
Following cell transfections in 6-well plates and incubation for 48-72 hours, 
cells were removed from incubator and kept on ice bucket. These wells were 
washed twice with ice-cold 1x PBS. Cells were lysed quickly using either ice-
cold RIPA lysis buffer, or NP40 lysis buffer, 100µl/well. Plates were tilted and 
scraped while still on ice in order to collect the protein lysate at the bottom of 
the well. Cell lysate was then collected and transferred to microcentrifuge 
tubes. Cellular debris was pelleted by centrifugation at 13250 rpm for 20 
minutes for the RIPA buffer, and 13250 rpm for 2 minutes for the NP-40 lysis 
buffer.  
 
2.6.4 DC Assay 
Concentrations of the protein extracts were measures using a DC protein 
assay (detergent compatible) (Bio-Rad, #5000111) as per the manufacturer’s 
instruction. Known concentrations of bovine serum albumin (BSA) or 0.2-1.5 
mg/ml were prepared for use as a standard curve. Following this, 20µl reagent 
S was added to each ml of reagent A that was required, this formed the reagent 
A’. 1µl of the standards and protein sample were added to wells in a 96-well 
plate. Reagent A’ was then added to each well, followed by the addition of 
reagent B. The plate was incubated for 15 minutes at room temperature away 





2.6.5 Protein Sample Preparation 
The required amount of protein was added to microcentrifuge tubes, and made 
up to 100µl with 4x LDS sample buffer (Invitrogen, #NP0008), 10µl NuPage 
reducing agent (Invitrogen, #NP0009) and volume was then adjusted to 100µl 
with lysis buffer that the lysates were extracted in. Samples were denatured 















2.6.6 Western Blotting 
2.6.6.1 Hand-cast Tris-glycine Sodium Dodceyl Sulphate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Resolving gel solutions were prepared for the separation for APP protein 
(recipes are shown in table 2.2). The resolving gel was prepared by casting 
the gel solution between two glass-plate cassettes of 1mm thickness (Mini-
PROTEAN Tetra handcast system, Bio-Rad) and overlaid with 100% 
isopropanol. The resolving gel was incubated at room temperature until set, 
followed by washing off of the isopropanol layer with dH2O. The next layer, a 
4% stacking gel solution was then prepared and cast (recipes shown in table 
2.2) followed by a comb being inserted into the glass-plate cassette.  Once 
this had set, the glass-plate cassette was transferred into a Mini-PROTEAN 
Tetra Electrode Assembly and then into a buffer tank. The buffer tank chamber 
was filled with 1x Tris-glycine running buffer and the comb carefully removed 
from the stacking gel in the glass-plate cassette. Protein was loaded into each 
well of the gel, alongside 1µl of BLUeye Prestained Protein Ladder 
(GeneFlow,#S60024) which was a reference for comparing protein size (kDa). 
The gel was then electrophoresed at 125V until the bromophenol blue dye ran 






 Resolving gel 
(16%) 
Resolving gel  
(10%) 






2ml 2ml 2ml - 
4x Stacking 
buffer pH6.8 
- - - 1ml 
30% Protogel 
(Bis-acrylamide 
solution ; National 
Diagnostics, 
#EC890) 
4.16ml 2.6ml 1.04 0.65ml 
ddH2O 1.84ml 3.4ml 4.96ml 4.6ml 
TEMED 6µl 6µl 6µl 20µl 
10% APS 40µl 40µl 40µl 160µl 
Total volume 8ml 8ml 8ml 6.25ml 







2.6.6.2 Pre-cast Bis-Tris SDS-PAGE 
4-12% NuPAGE Bis-Tris gels (Invitrogen, #NP0321) were trialled in order to 
best separate and examine APP from protein extracts of PMO transfected SH-
SY5Y cells. Bis-Tris gel cassette and the comb within the cassette was rinsed 
with ddH2O and the white tape at the bottom of the gel cassette was removed 
before placing the gel cassette in an XCell SureLock Mini-Cell gel running 
tank. The upper chamber of the tank was filled with 200ml of 1x NuPAGE MES 
SDS Running Buffer (Invitrogen, #NP0002)  containing 500µl NuPAGE 
antioxidant (Invitrogen, #NP0005). The rest of the chamber was filled with 
600ml of 1x NuPage MES SDS Running Buffer (no antioxidant). Protein 
samples were loaded into each well, alongside 1µl of BLUeye Prestained 
Protein Ladder (Geneflow, #S6-0024). The gel was electrophoresed at 200V 
until the bromophenol blue dye reached the bottom of the gel, typically 45 
minutes. 
 
2.6.6.3 Transfer of protein to nitrocellulose membrane  
Following protein electrophoresis, the transfer cassette was assembled. The 
gel was slowly and carefully removed from the glass-plate cassette and placed 
onto a nitrocellulose membrane with pore size of 0.2µM (Amersham, 
#15249794). This was then sandwiched between filter paper, 2 on either side 
of the membrane, followed by 2 blotting sponges on each side and soaked in 
1x Tris-glycine transfer buffer. Air bubbles were removed from this sandwich 
by applying pressure, and the transfer cassette was closed, and placed into a 
transfer tank filled with cold 1x Tris-glycine transfer buffer. The transfer tank 
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was submerged in wet-ice and the protein was transferred onto the 
nitrocellulose membrane at 10V overnight.  
 
2.6.6.4 Immunoblotting 
Following the protein transfer, the membrane was blocked with a blocking 
solution containing 5% dried non-fat milk (Marvel) in 1x TBS and 0.05% 
Tween-20. The membrane with blocking solution was agitated on a shaker for 
1.5 hours at room temperature. The membranes were then incubated with 
primary antibody diluted in 5% non-fat milk in 1x TBS, final volume 5ml 
overnight with gentle agitation. The membranes were then washed twice with 
1x TBS for 10 minutes each wash, followed by incubation with the appropriate 
secondary antibody diluted in 5% non-fat dried milk in TBS at a final volume 
of 5ml. This was incubated for 1 hour at room temperature away from light with 
gentle agitation. The two washing steps were then repeated, before the 
membrane was scanned using the Odyssey CLx Imaging system (Li-COR 
Bioscience). In some cases, the contrast of the images received from the 
Odyssey CLx Imaging system were manipulated to more clearly highlight the 
protein bands which were being analysed. Where there has been protein band 
contrast manipulation it is clearly stated. To visualise the protein bands, near 
infrared fluorescent detection at either 700nm or 800nm was used. After 







24-hours post transfection of SH-SY5Y  cells on cover slips in 12 well plates, 
cells were washed 3x with 1x PBS and then fixed with 500µl 4% PFA 
(Paraformaldehyde) (Agar Scientific, #R1026) per well for 8 minutes at room 
temperature. After fixing, cells were washed twice with 1x PBS before being 
blocked and permeabilised for 30 minutes at room temperature with 500µl of 
3% BSA in 1x PBS containing 0.02% Triton X per well.  Coverslips were then 
dried, and the appropriate primary antibodies were diluted in 100µl of 1% BSA 
in 1x PBS and added to each coverslip. Coverslips were incubated in a moist 
chamber for 2 hours at room temperature. Coverslips were then transferred to 
wells in a clean 12-well plate and washed three times with 1x PBS for 5 
minutes each with gentle agitation. Coverslips were then transferred back to 
the moist chamber, and appropriate secondary antibodies were diluted in 
100µl of BSA-PBS and incubated for 1 hour. Coverslips were then washed two 
times with 1X PBS as previously, and then incubated in a moist chamber for 1 
minute with 500μl of 1X Hoechst solution in order to stain the cell nuclei. 
Coverslips were then washed twice with 1x PBS for 5 minutes each to remove 
excess Hoechst staining. ProLong Gold Anti-Fade Mountant (Invitrogen, 
#P36930) was used to mount coverslips to microscope slides cell side down. 
Microscope slides were then incubated overnight at room temperature in a 
dark dry chamber until mounting media had set. Slides were transferred to 
either 4°C or -20°C for short- or long-term storage, respectively. Cells were 
visualised with a spinning disc confocal system (CARV II from Digital Imaging 
Solutions) with an EM-CD camera (QI Cam 3500) using Image Pro software. 
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2.7 Quantitative Reverse Transcriptase Polymerase Chain 
Reaction (qRT-PCR) 
RT-qPCR primers were adopted from a publication by Kerridge et al (Kerridge 
et al. 2014). For qRT-PCR, RNA was first generated using 0.5 μg of random 
primers (Invitrogen, #48190011) and 0.5 μg oligo(dT) (Promega, #C1101), 
600ng of RNA was used and the final volume was made up to 10 μL with 
nuclease free water in PCR tubes. The tubes were heated at 70°C for 5 
minutes and then incubated at 4°C for another 5 minutes. The GoScript 
Reverse Transcriptase kit (Promega, #A5003) was used to make a master mix 
consisting of 5x GoScript buffer, 2.5mM MgCl2, 0.5 mM dNTP, 8 units of 
reverse transcriptase, and RNA, the master mix was made up to 15µl with 
nuclease-free water. The RT-PCR was run in a G-storm 482 thermal cycler 
with the following programme cycle: annealing at 25°C for 5 minutes, 
extension at 42°C for 1 hour, and a final inactivation step of 70°C for 15 
minutes. The cDNA that was produced was diluted 1:50 in nuclease free water 
of use in qPCR reactions. Expression levels of target genes were assessed 
with qRT-PCR using the LightCycler 480 SYBR Green I Mastermix (Roche, 
#04887352001). 0.5μM of forward and reverse primer (table 2.5) were added 
to 5μl of LightCycler 480 SYBR Green I Mastermix before being mixed with 
diluted cDNA in a 384-well plate. The PCR reaction was conducted at 95°C 
for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 60°C for 15 
seconds, and 70°C for 15 seconds. All samples were amplified in technical 
triplicates. β-actin was used as a reference gene and expression levels of the 
genes of interest were compared against this. Gene expression was defined 
based on the threshold cycle (Ct), and relative expression levels were 
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calculated using the 2-ΔΔCt method, where foldchange was inferred from Ct 
level fluctuations of target genes made against reference genes. 
 
 




AQP1 ACTACACTGGCTGTGGGATT ATCCAGGTCATACTCCTCCA 
Actin CGCAGCAGTCAGGGACATTT TTCACATACAGCTTGGGAAGC 


















2.8 Data analysis and statistical analysis 
Densitometric analysis was conducted to quantify protein bands following 
western blots and RNA bands following RT-PCR using the Fiji image 
processing package (http://fiji.sc/). Individual bands were highlighted, and the 
fluorescence of each pixel was measured by the software. The software 
calculated the mean pixel value across the band and subtracted the 
background fluorescence. Further analysis was conducted using Microsoft 
Excel and GraphPad Prism 7.0. Percentage changes were calculated from 
raw values using Microsoft Excel using the following formula: Exon skipping 
percentage = fluorescence of exon skipped band / (fluorescence exon skipped 
band + fluorescence of non-skipped band) x100.  
Statistical significance was tested using one-way ANOVA followed by 
Dunnett’s multiple comparison test. EC50 values were calculated by fitting the 
Hill equation using GraphPad Prism 7.0. Graphs were plotted with GraphPad 
Prism 7.0, where all error bars show standard deviation.  
The method used for quantifying exon skipping has limitations due to the 
intrinsic biases that are present during the process of an RT-PCR. In an exon 
skipping PCR, it has been suggested that because the exon skipped amplicon 
is shorter than the non-skipped amplicon, the skipped amplicon is 
preferentially amplified in the PCR reaction, and will therefore be 
overestimated (Spitali et al. 2010; Verheul et al. 2016; Hiller et al. 2018). It has 
also been suggested that densitometric analysis could also negatively bias the 
shorter, exon skipped amplicon as the longer unskipped PCR amplicon will 
bind more intercalating SYBR Safe than the shorter skipped amplicon, leading 
to a brighter signal and therefore overestimation of the larger bands, and 
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underestimation of exon-skipping percentages as a result (Spitali et al. 2010). 
These biases in fragment size should be considered when performing exon 




















3 Design of antisense oligonucleotides for the purpose of 
inducing alternative splicing of APP exons 7 and 8 
3.1 Introduction 
Antisense oligonucleotide (ASO) mediated gene inhibition was first used in the 
inhibition of the replication and cell transformation of the Rous sarcoma virus 
through the use of a DNA molecule 13 nucleotide in length with 3’ and 5’ 
modifications (Stephenson & Zamecnik 1978). Modifications have since been 
made to the backbone and sugar component of ASOs to improve their 
specificity, binding strength, and stability. Subject to these modifications ASOs 
can alter RNA function through several distinct mechanisms, making them a 
diverse tool for gene therapy (WANG et al. 2015; Shen & Corey 2018). One of 
the most widely used mechanisms of action of ASOs is the induction of 
translational arrest via steric hindrance. ASOs can be directed to specific 
regions of the RNA transcript to block and disrupt the secondary structure of 
transcripts or blocking RNA binding proteins from carrying out their actions 
(Rinaldi & Wood 2018). The best-known application of steric hindrance is in 
modulating splicing events. ASOs can also be used to modulate alternative 
splicing through steric hindrance by targeting splice enhancer or splice silencer 
sequences, masking them from the splicing machinery promoting alternative 
splicing through exon skipping or exon inclusion respectively (Neil & Bisaccia 
2019). Alternative splicing is nature’s way of generating variations of a protein 
with different functions and modulation of alternative splicing with ASOs has 
been used in great effect in disease models such as Duchenne Muscular 
Dystrophy (DMD) where an antisense based therapy has gained clinical 
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approval  (Lu et al. 2014; Mendell et al. 2016; Aartsma-Rus & Krieg 2017; Lim 
et al. 2017).  
In the case of APP, alternative splicing of exons 7 and 8 naturally produces 
three major isoforms in the human brain, the APP770, APP751 and APP695. 
Exclusion of both exon 7 and 8 produces a functional APP protein termed 
APP695 which has relevance to AD. The progression of AD coincides with an 
increase in levels of APP770 and APP751 in the brain, whereas levels of 
APP695 are significantly decreased, because of this APP695 is implicated to 
have protective properties against AD (Johnson et al. 1990). Keeping this in 
mind one can use ASOs to force alternative splicing of APP so that increased 
levels of the APP695 isoforms are expressed and the effects of this can be 
observed in reference to AD (Evers, et al. 2015).  
Phosphorodiamidate morpholino oligomers are the ASO of choice which were 
used for this analysis. PMOs are a type of ASO which have been modified to 
contain a six membered morpholino ring instead of the ribose backbone and 
have the phosphodiester bonds replaced with phosphorodiamidate linkages 
(Aartsma-Rus & Van Ommen 2007). The PMO chemistry has specific 
properties which allow them to be used therapeutically. Typically, PMOs are 
resistant to nuclease and protease degradation meaning that PMOs will not 
be broken down before they are able to exert their effect (Verhaart & Aartsma-
rus 2012; Cirak et al. 2011). PMOs do not act through activating RNase H, 
therefore their effects are mediated through steric hindrance of translational 
arrest or by preventing proper RNA splicing events from occurring. PMOs carry 
an uncharged backbone meaning they are less likely to undergo non-specific 
interactions with other components of the cell making them less toxic, this has 
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also lead them to be used in clinical trials and shown to be safe and effective 
(Cirak et al. 2011). 
Retrospective analysis into PMO design parameters and variables by 
Popplewell et al demonstrated that active PMOs were longer, showed stronger 
binding to their targets, had target sites closer to the acceptor sites splice sites, 
could interfere with the binding of SR proteins, and overlapped with areas of 
open conformation (Popplewell et al. 2009). These were the only parameters 
which were shown to have an effect on PMO activity (Aartsma-Rus et al. 2009; 
Popplewell et al. 2009). In this chapter bioinformatic resources were used to 
analyse these parameters and the sequences of APP exon 7 and 8 in order to 














3.2 Design of PMOs against human APP exons 7 and 8 
The design parameters suggested by Popplewell et al were used in the design 
of PMOs for skipping of human APP exon 7 and 8 (Popplewell et al. 2009). 
Various bioinformatic software was used for this analysis.  
 
3.2.1 Targeting of splicing sites  
The first factor that needs to be considered when designing ASOs for exon 
skipping is the ability to target exon splice enhancers which usually act to 
facilitate the inclusion of an exon, while avoiding exon splice silencer 
sequences which usually act to exclude the exon during maturation of the pre-
mRNA, which is the aim of this project. The website Human Splice Finder 3.0 
(HSF) (http://www.umd.be/HSF/) was used for this as this online tool utilises a 
number of sources of motifs which includes ESE Finder and RESCUE-ESE 
databases (Desmet et al. 2009).  
On the online HSF tool, the analyse sequence option was selected and the 
APP sequence to be analysed was chosen using the Ensembl transcript 
number ENST00000346798 from the Ensembl genome browser 
(https://www.ensembl.org/) – and exon 7 or exon 8 were chosen respectively. 
Analysis by HSF automatically analyses the exon selected, plus the intronic 
sequence either side of the exon itself. For the HSF analysis, APP exon 7, the 
exon is 167bp in length, flanked with 100bp of intronic sequence at the 5’ and 
3’ end making the total input 367bp in length. For APP exon 8, the exon is 
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57bp in length flanked with 100bp on the 5’ and 3’ end making the total input 
257bp in length. 
A graphical output of the splice enhancer and silencer motifs from HSF 3.0 for 
exon 7 and 8 of APP are shown in figures 3.1 and 3.2. The RNA sequence (5’- 
3’) is shown on the 𝑥-axis. The grey box represents the exon (either APP exon 
7 or 8), and the black line indicates the intronic sequence on either side. The 
coloured lines above and below the line represent predicted cis-regulatory 
elements. Above the 𝑥-axis ESE motifs are depicted in red and pink. Below 
the 𝑥-axis ESS motifs are shown in blue and green. The y-axis depicts the 
strengths of these ESE and ESS motifs. Analysis of this graph revealed 
multiple potential sites throughout APP exon 7 (figure 3.1) and APP exon 8 
(figure 3.2) which can be targeted to achieve exon skipping. These readouts 
demonstrate that there are many predicted cis-regulatory elements throughout 
the sequences of APP exons 7 and 8, including both ESS and ESE sites. For 
APP exon 7, the analysis demonstrates (figure 3.1) that ESS sites are spaced 
throughout the exon; these are shown in blue and indicate areas where ASOs 
should not be designed to target as these regions promote exon exclusion 
which is our goal. ESE sites should be targeted in order to induce exon 
skipping. Analyses of APP exon 7 showed that there were ESE sites present 
throughout the exon, with four clusters of ESEs at the 5’, in the centre of the 
exon around the 60bp mark, one at the 3’, and one spanning the 3’ intron exon 
boundary which indicate potential targets for PMOs as blocking these 
enhancers could promote exon exclusion. Analysis of the ESS sites in this 
exon showed that there was a small cluster of ESSs at the 3’ end, with another 
small cluster in the middle of the exon, and no ESSs corresponding to the 5’ 
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ESE cluster. Analysis of APP exon 8 (figure 3.2) shows ESE sites in exon 8 
are concentrated primarily in the centre and at the 3’ end of the exon, with one 
major cluster seen in the centre and another smaller cluster seen at the 3’ 
exon intron boundary; ASOs designed to target these regions of the exon are 
more likely to be successful at inducing exon skipping. ESS sites in APP exon 
8 are also spaced throughout the exon; there are no clusters of ESS sites and 
therefore no obvious sites to avoid when designing ASOs.  
The HSF analysis also highlights potential putative exon splice enhancer 
(PESE) and putative exon splice silencer (PESS) octamers (Zhang & Chasin 
2004). PESE octamers were determined by identifying sequences which were 
overrepresented in noncoding exons compared to their prevalence in intronic 
sequences. PESS octamers on the other hand were determined by identifying 
sequences which were underrepresented in noncoding exons when compared 
to intronic sequences (Zhang & Chasin 2004). PESS octamers are shown on 
the HSF graph in dark green, with PESE octamers shown in pink. The 
graphical representation depicting APP exon 7 (figure 3.1) shows that there 
are no PESS octamers present in the exon, indicating that there are no region 
to avoid when designing ASOs in regard to PESS octamers. There was 
however a cluster of Fas ESS matrices present at the 3’ end of the exon, which 
potentially indicate regions to avoid when targeting ASOs. There are also 4 
major regions with clusters of PESE octamers, one at the 5’, one in the middle 
of the exon, and one at the 3’ end of the exon, and one at the 3’ end exon/intron 
boundary. These indicate regions with high signal strength which should be 
targeted with ASOs in order to potentially induce exon skipping and highlight 
potential regions which should be targeted for inducing skipping of this exon. 
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In the graphical representation for the splicing motifs in APP exon 8 (figure 
3.2) there was one cluster PESSs located at the 3’ end of the exon; this region 
should be avoided when designing PMOs because these PESS octamers 
naturally inhibit the inclusion of the exon which is our goal. It is also shown that 
there is only one cluster of PESEs present in this exon, these are located in 
the middle of the exon making this the optimal region to target when designing 
ASOs as this region shows the strongest strength of PESE binding. 
Of the different motifs, targeting of SC35 hexamers in particular has been 
demonstrated to be important in the design of ASOs for exon skipping,, so it 
was important to also look at targeting these sites within APP exons 7 and 8 
(Aartsma-Rus, van Vliet, et al. 2009). In these regions SC35 hexamers are 
shown in bright red. For the readout of APP exon 7 and surrounding introns, 
the SC35 hexamers are spaced throughout the exon; there are no particular 
peaks of SC35 signal strength. The readout for APP exon 8 and the 
surrounding introns again shows no peak of SC35 signal strength as these 
motifs are spread throughout the exon and surrounding introns. Therefore, 
there are no specific areas which should be targeted specifically for SC35 
signal motifs.  
The yellow line that is present in the Human Splice Finder readout shows the 
relative strength between the ESEs and ESSs. Peaks in this line above the 𝑥-
axis indicate an area which should be considered as a target for ASOs as this 
is considered to be an area with a high ESE/ESS ratio, whereas a peak below 
the 𝑥-axis indicates a silenced area which should be avoided. This again 
highlights the fact that there are 4 main regions in APP exon 7 which should 
be targeted in order to induce exon skipping as these correspond to 3 large 
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peaks in the ESE/ESS relative strengths. In APP exon 8 the single cluster of 
PESEs corresponds to the single peak of the ESE/ESS relative strength line 















Figure 3.1: Human Splice Finder analysis of ESE and ESS sites surrounding APP exon 7. The sequence for APP exon 7 and 100bp flanking 
intronic sequence were input into the Human Splice Finder 3.0 (http://www.umd.be/HSF/). The sequence runs  5' to 3' with the grey box indicating the 
exonic sequence, with intronic sequence on either side. ESEs motifs are shown above the 𝑥-axis as red and pink boxes, with ESS sites shown by 
blue and green boxes below the 𝑥-axis. ESE sites should be targeted for PMO design as blocking of these sites promotes exon exclusion, whereas 














Figure 3.2: Human Splice Finder analysis of ESE and ESS sites surrounding APP exon 8. The sequence for APP exon 8 and 100bp flanking 
intronic sequence were input into the Human Splice Finder 3.0 (http://www.umd.be/HSF/). The sequence runs  5' to 3' with the grey box indicating the 
exonic sequence, with intronic sequence on either side. ESEs motifs are shown above the 𝑥-axis as red and pink boxes, with ESS sites shown by 
blue and green boxes below the 𝑥-axis. ESE sites should be targeted for PMO design as blocking of these sites promotes exon exclusion, whereas 
ESS sites should be avoided. Black lines indicate regions which have been targeted for PMO design. 
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3.2.1.1 Secondary structures of APP exon 7 and 8 pre-mRNA 
For ASOs to be effective and bind to RNA, they must be able to access the 
complementary bases at their target site. The ability of the PMO to access its 
complementary bases is heavily influenced by the secondary structure of the 
pre-mRNA (Aartsma-Rus et al. 2009). This can be extremely complex due to 
the natural folding of RNA because of Watson-Crick base pairing forming 
areas of double-stranded sequence and areas of single stranded looped 
regions. If the ASO target region is within a region of double-stranded RNA it 
will be more difficult for the ASO to bind as it will need to compete with the 
RNA transcript for binding. Therefore, targeting open regions means there is 
less competition for binding and therefore the ASO is more likely to bind and 
have an effect. Targeting ASOs to the open regions of the RNA secondary 
structure has previously shown to correlate with ASO efficacy (Aartsma-Rus 
et al. 2009; Popplewell et al. 2009).  
The RNA secondary structures of APP exon 7 and 8 and surrounding introns 
were determined using MFold (http://unafold.rna.albany.edu/) (Zuker 2003). 
The sequence of each exon and 50bp surrounding intronic sequence were 
submitted separately into the RNA folding form of the MFold website. There 
was a total of 268 bases inputted for APP exon 7 (figure 3.3), and 158 bases 
inputted for APP exon 8 (figure 3.4). The MFold server produced multiple 
predicted secondary structures for each exon and the structure with the 
minimum free energy (MFE) for APP exon 7 (figure 3.3) and APP exon 8 
(figure 3.4) are shown below. With these MFE structures of these exons and 
introns PMOs can be designed to target single stranded regions of the RNA 
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structure which theoretically would allow the PMOs to more easily bind and 




Figure 3.3: Predicted Secondary structure APP exon 7 and flanking intronic sequence. The sequence of APP exon 7 and 50bp flanking intronic 
sequence was inputted into MFold (http://unafold.rna.albany.edu/) in order to generate a secondary structure prediction using the MFE approach. The 
predicted structure selected was that which showed to lowest free energy (ΔG) as this is the most likely to exist in nature. When designing PMOs for 
exon skipping  double stranded close confirmations should be avoided, and single stranded open confirmations should instead be targeted. The start 
and end of the exon are indicated with black triangles, and examples of these closed and open confirmations are also labelled with arrows. The regions 
which correlate with the peaks of ESE/ESS relative strength determined through HSF analysis are indicated in orange. Secondary structure analysis 
allows for manipulation of the specific sites where PMOs are being targeted to exploit the open confirmations instead of the closed confirmations whilst 



















Figure 3.4: Predicted Secondary structure APP exon 8 and flanking intronic sequence. The sequence of APP exon 7 and 50bp flanking intronic 
sequence was inputted into MFold (http://unafold.rna.albany.edu/) in order to generate a secondary structure prediction using the MFE approach. The 
predicted structure selected was that which showed to lowest free energy (ΔG) as this is the most likely to exist in nature. When designing PMOs for 
exon skipping  double stranded close confirmations should be avoided, and single stranded open confirmations should instead be targeted. The start 
and end of the exon are indicated with black triangles, and examples of these closed and open confirmations are also labelled with arrows. The regions 
which correlate with the peaks of ESE/ESS relative strength determined through HSF analysis are indicated in orange. Secondary structure analysis 
allows for manipulation of the specific sites where PMOs are being targeted to exploit the open confirmations instead of the closed confirmations whilst 
still targeting regions with high ESE/ESS relative strength. ΔG = -30.09.
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3.2.1.2 Binding Energy Determination  
After analysis of splice regulatory elements with HSF and analysis of the RNA 
secondary structure with MFold, the specific sequence of each exon which the 
ASO should be targeting was narrowed down to regions which overlap with 
ESE motifs, avoid ESS motifs and target single stranded open confirmations 
of secondary structure. The next step for ASO design was to calculate the 
binding energies of the different possible ASO sequences to their targets and 
determine which would have the highest binding energy efficiency to the pre-
mRNA transcript. In order to determine this the SOligo tool on the SFold 
website (http://sfold.wadsworth.org/) was used (Ding et al. 2004). This tool 
allows for the analysis of every complementary oligonucleotide of a specific 
length (either 25 or 30 bases in this case) along the gene sequence and 
calculates the intermolecular oligo dimer binding energy (kcal/mol) between 
the RNA sequence and its complementary sequence. A sample SFold SOligo 
output is shown in figure 3.5. This readout shows the target position, target 
sequence, antisense oligonucleotide complementary to this target sequence, 
GC content, and the oligo binding energy (kcal/mol). These results are filtered 
to show only the ASOs with GC content between 40- 60% as GC content has 
been shown to correlate with ASO-mRNA stability (Aartsma-Rus et al. 2009; 
Popplewell et al. 2009). Higher GC contents improves binding due to the 
strength of a GC bond, with ASOs with GC contents between 40-60% shown 
to be more effective. Results also filtered sequences which contained the 
GGGG run of bases as these have been shown to be associated with weaker 
ASO activity, and GeneTools are unable to synthesise PMOs with 4 
consecutive Gs (Chan, Lim & Wong 2006). Choosing the optimal sequence 
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for the ASO to be designed is based on covering the splice sites, blocking 
enhancer sequences, targeting single-stranded open looped regions, and 
finding the ASO which has the most negative intermolecular binding energy. 
 
 
Figure 3.5: Representative Sfold oligo output for the binding of potential PMOs to APP. 
The exonic sequence of either APP exon 7, or exon 8 plus 50bp flanking intronic sequence 
were inputted into SFold (http://sfold.wadsworth.org/) in order to generate this readout. The 
first column shows the target RNA sequence, the second column shows sequence of the PMO 
complimentary to the RNA sequence, the third column shows the GC content., previous 
research has suggested that PMOs with GC content of 40-60% allow for the best binding and 
most successful PMOs. The binding energy between the  potential PMOs and the RNA is 
shown in the fourth column, the more negative the binding the more likely the PMO is to be 
successful. Taking all of these into consideration with all the information of potential target 
positions from HSF and MFold we were able to select potential PMO sequences which had 
all of the required criteria.
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Utilising all of the information gathered through bioinformatic analysis and all 
of the previously discussed criteria, potential PMO sequences were selected. 
Once these PMO sequences were selected the next step was to calculate 
RNA-RNA interactions and determine the total free binding energy of the exon 
and RNA to see whether these PMOs had negative overall binding energies. 
In order to do this the RNAup server (http://rna.tbi.univie.ac.at/) was used 
(Gruber et al. 2008). RNAup models the total binding energy for an ASO RNA 
interaction at a particular site as , where 
 is the free energy required to make the binding region accessible in 
molecule A or B by removing intra-molecular structure, whereas  denotes 
the free energy gained from forming the inter-molecular duplex. This provides 
a more accurate prediction of ASO binding energy. The more negative the 
binding energy, the stronger the binding between the ASO and the RNA. 
Multiple PMO sequences were chosen for each of APP exon 7, and 8 but only 
those which showed the most negative binding energies were chosen to be 
tested experimentally. 
An example of the RNAup readout for a potential PMO designed to target APP 
exon 7 is shown below (figure 3.6) and shows data for the opening energy of 
the exon, opening energy of the oligonucleotide, energy formed from duplex 
formation and total free energy of binding. There is also a graphical 
representation of this showing the position of the PMO binding to the exon and 
the total free energy of binding (ΔGi) through the exon. The total free energy 
of binding was calculated for all potential PMOs using RNAup. The more 
negative the overall binding energy the stronger the binding between the PMO 
and the RNA transcript (Popplewell et al. 2009). The overall free binding 
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energies of the designed PMOs are all highly negative, which means they all 













Figure 3.6: Representative RNAup readout showing total binding of energy of PMO 
APP74/33 to its target. A sample readout from RNAup showing the total binding energy of the 
designed PMO to A) its target region on the exon  B) the whole exon and flanking introns. The 
black lines indicate the energy required to overcome the existing structures of the exon ΔGAu, 
and the red lines indicate the ΔGbinding. In this case RNAup gives a value of -44.29kcal/mol 
for the total binding energy of the PMO to its target. This is calculated by the formula 
ΔGbinding = ΔGAu + ΔGBu + ΔGh, where ΔGh denotes the free energy gained from forming 
the inter-molecular duplex, in this case -58.80 kcal/mol, and ΔGA,Bu is the free energy to 
make the binding region of the exon or PMO accessible. RNAup gives ΔGAu a value of 9.47 
kcal/mol and  ΔGBu  a value of 5.05 kcal/mol respectively. The ΔGbinding is therefore 9.47 + 









PMO ∆GAu ∆GBu ∆Gh Overall free binding 
energy (∆𝑮𝒊) 
APP74/33 9.47 5.05 -58.80 -44.29 
APP755/84 5.03 0.32 -43.21 -37.86 
APP795/124 13.10 4.18 -58.70 -41.42 
APP7125/154 12.29 4.39 -52.50 -35.82 
APP7164/+25 7.69 5.89 -52.41 -38.83 
APP8-12/13 5.09 1.82 -31.30 -31.30 
APP814/38 11.42 1.26 -48.20 -35.53 
APP839/+6 8.57 0.51 -46.92 -37.84 
APP8+7/+31 10.46 3.52 -49.91 -35.92 
 
Table 3.1: Overall free binding energies of PMOs. The overall free binding energies were 













3.2.1.3 ASO off target effects  
Once PMOs had been designed, it was vital to assess whether there were any 
potential off-target binding which would produce side effects. In order to do 
this each potential PMO sequence was run through the NCBI Basic Local 
Alignment Search Tool (BLAST) (https://blast.ncbi.nlm.nih.gov/) (Altschul et al. 
1990).  The BLAST output data was input into a table for PMO sequences for 
both APP exon 7 (table 3.2) and APP exon 8 (table 3.3). Each PMO sequence 
was put thought the BLAST software which was optimised for short- 
sequences against coding and non-coding human genome nucleotide 
collection databases (nr/nt) (Marsollier et al. 2016). Potential off-targets were 
assessed to determine their Expected-value (E-value), a parameter that is 
used to describe the number of hits that can be expected to be seen by chance 
when searching a database, it is therefore a measure of how significant a 
match is. According to BLAST, a very strong match is considered to have E-
value ≤1 × 10−4, whereas a poor match has E-value ≥1 × 10−3. For each PMO 
sequence, the two BLAST returns showing highest alignment scores (lowest 
E-values) were selected for further analysis. Table 3.1 and 3.2 show that for 
each PMO, the E-Value is only below the threshold (1e-4) for the binding of the 
PMOs to APP. All other off targets show E-values above the threshold (10−3) 
meaning that these bindings are likely to be by chance. It also shows that each 
PMO has a 100% overlap with APP, but none of the off-target genes show 
significant levels of overlap. For exon 7 targeting PMOs, each of the five PMO 
sequences which were analysed returned very strong matches to the desired 
APP transcript (E-value ≤7 × 10−8) whereas all of the off-target gene 
candidates returned high E-values (E-value ≥1.1). For exon 8, each of the four 
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PMO sequences which were analysed showed very strong matches to the 
APP transcript (E-value ≤3 × 10−5) whereas all of the off-target gene 
candidates analysed showed high E-values (E-value ≥0.63). Only predicted 
off-target sequences corresponding to the RNA transcript (negative strand) 
were selected for total free energy of binding calculations using the RNAup 
Server. RNAup calculated the overall free binding energy (∆𝐺𝑖) of each of the 
APP exon 7 (table 3.2) and exon 8 (table 3.3) targeting PMO sequences to be  
> -35.82 ∆𝐺𝑖 and > -31.30 ∆𝐺𝑖 respectively. These are considered to be highly 
negative and indicative of strong binding between the PMO and target 
sequence. Off-target interactions on the RNA transcript were detected for the 
majority of the PMO sequences tested, however these off-targets had lower 
overall free binding energies relative to the binding energies of the PMO 
sequences to APP. These off-target interactions also had major mismatches 
in their sequences leading to low sequence homology. The PMO sequences 
each show 100% homology to APP, however the highest level of homology 
between the APP exon 7 PMO sequences and off-targets was 73% homology, 
this included 8/30 base mismatches. For the APP exon 8 PMO sequences, all 
sequences showed 100%  with APP, however the highest homology to an off-
target sequence detected was 84%, this included 4/25 mismatches. This data 
suggests that there is a low probability of interference of any of the designed 
PMOs targeting APP with any off target RNAs. All of this indicated that our 






Table 3.2: BLAST analysis of potential APP Exon 7 specific PMOs. Prediction of the APP 
exon 7 PMO off target candidates. Shows the E-Value, % identity, number of base overlaps, 
homology with +/- strand, location of the target, whether the target is coding or non-coding 
and also the overall free binding energy of the potential off targets. ΔGi was only calculated 
only for the predicted targets that show sequence homology with the PMO on their negative 




























100% 30/30 -  Non-coding -44.29 
AHNAK2 17 53% 16/30 + Exon Coding N/A 
SACS 17 53% 16/30 + Intron Coding N/A 
APP755/84 APP 7e-
08 
100% 30/30 -  Non-Coding -37.86 
ACSS2 1.1 73% 22/30 - UTR Non-Coding -27.55 
LTBP2 4.3 56% 17/30 + UTR Coding N/A 
APP795/124 APP 8e-
08 
100% 30/30 -  Non-Coding -41.42 
NCAM1 13 53% 16/30 + Intron Coding N/A 
TRIOBP 199 46% 14/30 + Intron Coding N/A 
APP7125/154 APP 8e-
08 
100% 30/30 -  Non-Coding -35.82 
CNTN5 17 53% 16/30 - Intron Non-Coding -20.26 
GUCD1 17 53% 16/30 - Exon Non-Coding -18.28 
APP7164/+25 APP 7e-
08 
100% 30/30 -  Non-Coding -38.83 
CTNNA3 15 53% 16/30 + Intron Coding N/A 





Table 3.3: BLAST analysis of potential APP Exon 8 specific PMOs. Shows the E-Value, 
% identity, number of base overlaps, homology with +/- strand, location of the target, whether 
the target is coding or non-coding and also the overall free binding energy of the potential off 
targets. ΔGi was only calculated only for the predicted targets that show sequence homology 





































100% 25/25 -  Non-coding -31.30 
ATP2B2 2.5 84% 21/25 + Intron Coding N/A 
ABR 10 64% 16/25 - Intron Non-coding -22.75 
APP814/38 APP 4e-
05 
100% 25/25 -  Non-coding -35.53 
INSL6 0.63 72% 18/25 + UTR Coding N/A 
PC 2.5 68% 17/25 - Intron Non-coding -26.34 
APP839/+6 APP 4e-
05 
100% 25/25 -  Non-coding -37.84 
CNTNA
P2 
10 64% 16/25 - Intron Non-coding -21.74 
CUX2 40 60% 15/25 + Intron Coding N/A 
APP8+7/+31 APP 3e-
05 
100% 25/25 -  Non-coding -35.92 
TMEM4 2.5 68% 17/25 + Intron Coding N/A 
ELF5 2.5 68% 17/25 - Intron Non-coding -22.55 
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3.2.2 Final PMO designs 
Drawing from all the data collected, including the information from the predicted splice enhancer and silencer elements, the 
secondary structure, and binding energies PMO designs were finalised. The final designs are shown in Table 3.3 for APP 




Table 3.4: Final designs for PMOs targeted at APP exon 7.Table above shows the PMO length, target sequence, PMO sequence, GC content, 




PMO name Length Target 
Exon 












APP74/33 30bp 7 TGTGCTCTGAACAAGCCGAGACGGGGCCGT ACGGCCCCGTCTCGGCTTGTTCAGAGCACA 63.3 1 9.47 5.05 -58.80 -44.29 
APP755/84 30bp 7 GGTACTTTGATGTGACTGAAGGGAAGTGTG CACACTTCCCTTCAGTCACATCAAAGTACC 46.7 1 5.03 0.32 -43.21 -37.86 
APP795/124 30bp 7 TTACGGCGGATGTGGCGGCAACCGGAACAA TTGTTCCGGTTGCCGCCACATCCGCCGTAA 60 2 13.10 4.18 -58.70 -41.42 
APP7125/154 30bp 7 CTTTGACACAGAAGAGTACTGCATGGCCGT ACGGCCATGCAGTACTCTTCTGTGTCAAAG 50 0 12.29 4.39 -52.50 -35.82 




























Table 3.5: Final designs for PMOs targeted at APP exon 8. Table above shows the PMO length, target sequence, PMO sequence, GC content, 













PMO name Length Target 
Exon 












APP8-12/13 25bp 8 ttttttccatagTGTCCCAAAGTTT   AAACTTTGGGACActatggaaaaaa   32 0 5.09 1.82 -
31.30 
-31.30 
APP814/38 25bp 8 ACTCAAGACTACCCAGGAACCTCTT AAGAGGTTCCTGGGTAGTCTTGAGT 48 2 11.42 1.26 -
48.20 
-35.53 
APP839/+6 25bp 8 GCCCGAGATCCTGTTAAACgtacgt acgtacGTTTAACAGGATCTCGGGC   48 2 8.57 0.51 -
46.92 
-37.84 







































This chapter looked at the designs of ASOs to force the exclusion of APP 
exons 7 and 8 from the APP transcript through the use of a technique referred 
to as exon skipping.  
Previous research has supported the use bioinformatic software for ASO 
design (Aartsma-Rus,  et al. 2009; Popplewell et al. 2009). These studies have 
suggested parameters which should be considered, and these parameters 
compared to the efficacy of designed ASOs (Aartsma-Rus, van Vliet, et al. 
2009; Popplewell et al. 2009). Research of published ASOs for inducing exon 
skipping in the DMD gene to determine whether any ASO design guidelines 
can be extrapolated from these studies (Aartsma-Rus  et al. 2009). This work 
concluded that of the 156 ASOs analysed the best parameters for guide design 
were GC content and predicted binding energy. Other studies determined that 
targeting of exonic sequences compared to intronic sequences was more 
successful due to the greater GC content and therefore stronger binding 
(Aartsma-Rus et al. 2009). Popplewell et al reported the use of various other 
factors which should be considered in the design of effective ASOs. These 
include pre-mRNA folding, ASO length, ESE/ESS ratio and proximity of the 
target sequence to the exon acceptor site (Popplewell et al. 2009).  
The work presented here used a combination of design guidelines which were 
suggested by various groups. The first major step undertaken in the PMO 
design process was the prediction of binding sites for exonic splicing 
enhancers (ESE) and exonic splicing silencer (ESS) sites. According to Wang 
et al ESEs are more likely to be found at the 5’ end of an exon (Wang et al. 
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2006). However for APP exon 7, there were three major ESE clusters, one at 
the 5’, one at the 3’ and one in the middle ~60 bp into the exon (Wang et al. 
2006). There were no ESS motifs overlapping with the ESEs sites at the 3’ 
end, however there was a small cluster overlapping at the 5’ end, and a large 
ESS cluster in the middle of the exon. These regions are still the optimal sites 
for PMO targeting despite the ESS sites as these ESS clusters are relatively 
small compared to the strength and number of the ESE sites present in the 
same location. For APP exon 8, the cluster of ESEs are within the middle of 
APP exon 8, ~30 bps into the exon. There are no overlapping clusters of ESSs 
making this the optimal target for ASOs. PMOs were targeted at the peaks of 
ESE/ESS strength throughout both exons. 
The next step predicted the secondary structure of both APP exons to target 
open single stranded regions rather than straight double stranded regions. It 
was thought that PMOs which had ends in open looped regions were more 
likely to bind strongly and therefore had greater potential for inducing exon 
skipping. Of the PMOs which were designed for APP exon 7 skipping, one 
PMO (APP795/124) had both ends in open looped regions, with two PMOs 
(APP74/33 and APP755/84) having one end in an open loop and two PMOs 
(APP7125/154 and APP7164/+25) having no ends in open loops. Of these PMOs 
APP795/124 also had the most bases overlapping with open looped regions with 
17/30 bases of this PMO overlapping with a single stranded looped region. Of 
the PMOs designed for APP exon 8 skipping two PMOs (APP814/38 and 
APP839/+6) had both ends in open looped regions, one PMO (APP8+7/+31) had 
a single end in an open looped region, and one PMO (APP8-12/13) had no ends 
in open looped regions. Of all the PMOs, PMO APP839/+6 had the most bases 
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within open looped regions, with 17/25 bases in open single stranded looped 
regions. Based on the MFE prediction using MFold PMO APP795/124 and 
APP839/+6 are the two PMOs which are the most likely to be successful in 
strongly binding to the RNA transcript and potentially inducing exon skipping. 
However, we cannot predict this using just one software, the results from all 
analytical sources need to be aggregated to get a more reliable idea of which 
PMO will work the best.  
The next step was the prediction of binding energy of each PMO. In order to 
calculate the binding energy for each PMO sequence the intermolecular 
energy between the PMO and the RNA transcript was calculated using the 
SFold web server. This gave us an idea of the binding energy of the PMO to 
the target RNA transcript, the more negative this binding energy the stronger 
the PMO was able to bind. PMO lengths were adjusted during this analysis to 
try and maximise the strength of the PMO binding and therefore make it the 
most likely that PMOs will bind. Following this RNAup was used to calculate 
the total binding energy for each PMO binding to its complementary sequence 
on the RNA transcript taking into account the free energy required to remove 
intramolecular structures, and the free energy gained from forming the inter-
molecular duplex. These calculations showed that all PMOs had highly 
negative total binding energies. If just this information was taken into account, 
we can say that all of these PMOs are likely to bind efficiently and have the 
potential to induce exon skipping. Of all the PMOs designed for APP exon 7 
skipping PMO APP74/33 and APP795/124 had the most negative binding energies 
with ∆Gi of -44.29, and -41.42 kcal/mol respectively, meaning that these are 
the most likely to work successfully. For APP exon 8 PMOs APP839/+6 and 
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APP8+7/+31 had the highest binding energies with ∆Gi of -37.84, and -35.92 
kcal/mol respectively. Looking at the data for the predicted secondary structure 
and the total binding energies we can assume that both PMOs APP795/124 and 
APP839/+6 are the best for their respective PMO. This is because both of these 
PMOs had both ends in single stranded looped regions, the most bases in 
open looped regions, and the highest total binding energies (∆Gi) of all the 
PMOs which were designed.  
Due to the mechanism of action of ASOs, even a few mismatches between 
the oligonucleotide and the target sequence can lead to decreases in 
oligonucleotide activity or lead to the oligonucleotide having no effect at all 
(Moulton 2017; Fusco et al. 2019). Research has shown that when a 25-mer 
PMO has even a single mismatch with its target sequence the antisense 
activity is decreased significantly, although there are PMOs which have been 
shown to retain some activity despite mismatches (Khokha et al. 2002). 
Studies have shown that 14 continuous bases of homology is the minimum 
activating length for a PMO (Summerton 1999). Therefore, when designing 
ASOs the quality of the target sequence is something that needs to be 
seriously considered. In order to maximise the sequence specificity, and 
therefore the most efficacious ASO. it is thought that during the ASO design 
process, they should generally try to avoid polymorphic or mutated regions of 
the genome (Fusco et al. 2019). Targeting polymorphic or mutated genome 
regions increases the likelihood of there being SNPs or alterations in the 




For APP exon 7 the decision was made to optimise the length of the ASOs 
which were being designed. If the ASO is too long or too short some specificity 
could be lost. After careful analysis of exon 7 PMOs, the decision was made 
to use 30mer PMOs instead of 25mer PMOs, this was due to the differences 
in binding energies between the 30 and 25mers. Extending the PMO to a 
30mer instead of a 25mer allows for better blocking of the ESE sites, whilst 
allowing for coverage of single bonded looped regions, and significantly lower 
oligo binding energies all of which were significant enough to make this 
increase in oligo length necessary. Even though there are many ASO design 
guidelines which have been suggested, the only way to determine whether 
these guidelines correlate to the effectiveness of the designed ASOs is to 













4 Modulation of APP alternative splicing with the use of 
Phosphorodiamidate Morpholino Oligomers 
4.1 Introduction 
The spliceosome is a ribonucleoprotein megaparticle which is formed from 
various small nuclear ribonucleoproteins (snRNPs). These snRNPs recognise 
the 5’ splice site, the branch point sequence and the 3’ splice site to ultimately 
form a catalytically active spliceosome. The spliceosome and associated 
splicing factors are responsible of splicing the introns in an RNA transcript, 
these are able to bind to RNA and perform intron excision (Chen & Manley 
2009; Wang et al. 2014; Lee & Rio 2015). Splicing events at a junction can be 
constitutive or alternative (Siva et al. 2014). Constitutive splicing refers to 
splicing of introns or exons which are then expressed in all transcripts, 
whereas alternative refers to a splicing event where an exon may be skipped, 
or an intron retained in the mRNA sequence. In reference to alternatively 
splicing exons, they may be mutually exclusive, meaning only one of a group 
of exons can be present within a transcript, there may also be alternative 3’ 
splice sites, 5’ splice sites, or alternative first and last exons. The factors which 
determine whether a splice site is used are the strength of the splice site, which 
can be defined as strong or weak depending on their similarity to the 
consensus sequence, and the presence of splice regulatory elements which 
are either cis-acting of trans-acting (Roca et al. 2005; Gamazon & Stranger 
2014). Cis-acting elements are regulatory sequences in the RNA which recruit 
RNA-binding factors in order to aid or repress splicing (Bergsdorf et al. 2000; 
WANG et al. 2015). Cis-acting elements include hexamer recognition sites 
such as Exon Splice Enhancers (ESE) and Exon Splice Silencers (ESS) or 
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Intron Splice Enhancers (ISE) and Intron Splice Silencers (ISS). These factors 
play roles in splicing, as they are able to promote (splice enhancers) or inhibit 
(splice silencers) exon or intron inclusion. Trans-acting factors are the RNA-
binding elements which bind to cis-regulatory elements. This group is 
comprised of Serine-arginine (SR) proteins and heterogenous nuclear 
ribonucleoproteins (hnRNPs), both of which play roles in the determination of 
splicing (Ram & Ast 2007). SR proteins generally promote splicing through 
binding to ESEs and ISEs, whereas hnRNPs are generally antagonistic to SR 
proteins and are therefore negative regulators of splicing (Wang et al. 2014; 
Lee & Rio 2015). The balance between cis-acting splice enhancer and splice 
silencers, and the associated trans-acting SR proteins and hnRNPs help to 
determine whether a splice site is used or not. Alternative splicing provides 
significant expansion of the proteome allowing  a multitude of structurally and 
functionally distinct mRNA and protein variants to be produced from a single 
gene, and recent analysis indicates that 92-94% of human genes undergo 
alternative splicing and the majority of these transcripts are generated  in a 
tissue-specific manner (Wang et al. 2008; Lee & Rio 2015). The human brain 
expresses the highest proportion of alternatively spliced transcripts compared 
to any other tissue in the human body (Yeo et al. 2004). Neurones are 
particularly sensitive to alternative splicing, with numerous neurodegenerative 
and neurological diseases being associated with defective splicing (Nik & 
Bowman 2019). The most common of these splicing events in mammals is 
cassette exon exclusion, also known as exon skipping and accounts for over 
40% of all alternative splicing events within the transcriptome (Gamazon & 
Stranger 2014; WANG et al. 2015).  
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ASO technologies have been utilised to induce exon skipping, altering natural 
splicing patterns as a therapeutic avenue for the treatment of a variety of 
diseases. In the case of DMD, an ASO based therapeutic of the PMO 
chemistry has been granted FDA approval for the treatment of DMD. This drug 
named Eteplirsen functions by targeting and blocking the ESE sites within 
exon 51 of the DMD gene, reducing the inclusion of this exon and 
subsequently restoring the reading frame of the gene (Lim et al. 2017). The 
PMO chemistry is a type of ASO with a modified morpholine ring instead of a 
ribose ring and have been successfully used to modify splicing previously 
(Verhaart & Aartsma-rus 2012; Heemskerk et al. 2009; Evers et al. 2015). The 
PMO chemistry offers advantages over other ASO chemistries in terms of 
safety, this being one of the primary reasons this chemistry of ASO was 
selected. The safety of these PMOs is due in large to their uncharged 
morpholine backbone. This lack of charge means that these PMOs are 
incapable of interacting non-specifically with proteins such as nucleases and 
other cellular components (Lim et al. 2017). As a result PMOs may be less 
toxic, and are not subject to nuclease-mediated degradation making them 
highly stable in cellular environments (Lim et al. 2017). The lack of protein 
interactions means that PMOs are unable to bind and activate Toll-like 
receptors, which are receptors responsible for activating the innate immune 
response against pathogens (Lim et al. 2017). The fact that PMOs function 
independently of the RNase H pathway also lends to the improved safety of 
PMOs as it promotes specificity of PMO activity as their effects will be 
mediated through steric hindrance causing translational arrest or by 
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preventing RNA splicing, rather than degradation via RNase H (Lim et al. 
2017).  
In this chapter, the PMOs which were designed in order to exploit exon 
skipping as a potential therapeutic for AD were tested in order to determine 
the ability and efficacy of these PMOs in skipping exons 7 and 8 of APP and 
increasing the levels of relative APP695. Human neuroblastoma SH-SY5Y 
cells were used as a model for this because they endogenously express all 
three major APP isoforms, APP770, APP751 and APP695. Research has 
shown there is a shift in the pattern of APP isoforms present in the brains of 
AD patients with both APP770 and APP751 becoming more prominent, and 
APP695 which is the principal isoform expressed in a healthy brain shown to 
decrease (Johnson et al. 1990; Menéndez-González et al. 2006). Therefore, 
shifting the splicing back to a state where APP695 is predominant through the 
utilisation of exon skipping PMOs may offer some therapeutic benefits. This 
chapter aims to assess the modulation of alternative splicing by transfecting 
SH-SY5Y cells with various PMOs designed for skipping of APP exon 7 or 
exon 8, performing RNA extractions, followed by reverse transcriptase and 
nested PCRs. Data was semi-quantified using densitometric analysis to 
determine the changes in alternative splicing as a result of PMO treatment and 







4.2 Results  
 
4.2.1 Effects of PMOs on APP exon skipping 
PMOs designed to skip exon 7 or exon 8 of the human APP gene were 
transfected into SH-SY5Y cells using EndoPorter. These were incubated for 
24 hours before RNA was harvested from transfected cells. cDNA synthesis 
was performed utilising this RNA, and PCRs were conducted. These PCRs 
were conducted to analyse how effective these PMOs were at skipping exon 
7 or 8 respectively, and whether this was able to cause a detectable increase 
in APP695 at the RNA level. PCR primers were designed across APP exons 
6 to 10 in order to amplify all three APP isoforms that would be easily identified 
upon separation and quantification on an agarose gel. The three band sizes 
were APP770 (contains exon 7 and exon 8) – 1067bp, APP751 (contains exon 
7 only) – 1010bp, and APP695 (contains neither exon 7 nor exon 8) – 842 bp. 
There should be a shift towards more APP695 and less APP770/751 if the 








4.2.1.1 Concentration gradients of PMOs designed to target APP 
exon 7  
Five PMOs were designed to skip APP exon 7 (detailed in Chapter 3). These 
PMOs were designed to target different regions of APP exon 7 and the flanking 
introns, the PMOs were 30bp in length as these allowed for optimal coverage 
of ESE sites, and open looped regions as well as lower binding energies. and. 
These PMOs were transfected into SH-SY5Y cells at concentrations ranging 
from 0-1000nM in order to determine the concentration at which each PMO is 
most effective, as well as checking how efficacious each PMO was at 
modulating alternative splicing SH-SY5Y cells were transfected with the five 
different PMOs for APP exon 7 skipping - PMO APP74/33, APP755/84, 
APP795/124, APP7125/154, APP7164/+25.  PMOs were transfected into SH-SY5Y 
cells at concentrations of 0nM, 100nM, 250nM, 500nM, 750nM, and 1000nM 
respectively in order to determine which PMO, and which concentration of said 
PMO is best at modulating alternative splicing of APP. Appropriate volumes of 
the PMO were added directly to the cells in media, followed by 3µl of 
Endoporter (final concentration of 6 mM). RNA was harvested 24 hours post 
transfection, and RT-PCRs were conducted. Gel electrophoresis was 
performed on the PCR products and densitometric analysis was performed 
using ImageJ in order to analyse the isoform pattern of APP by comparing the 
intensity of each of bands representing the major APP isoform. The primers 
designed for this are able to detect all three APP isoforms, the APP 770 
isoform is represented by a band at 1067bp if both exon 7 and exon 8 are 
present. APP751 is detected at 1010bp, if there is exclusion of APP exon 8, 
and a band is detected at 842 bp if there is exclusion of both exon 7 and exon 
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8 of APP. There is also a fourth band present between the APP751 and 
APP695, this band is likely to be a form of APP produced in which only exon 
7 is skipped. This isoform is only present when SH-SY5Y cells are treated with 
high concentrations of exon 7 skipping PMOs and is only present at very low 
levels. This isoform is not a naturally occurring isoform, but rather only 
produced in this very specific case and therefore not a great deal is known 
about this isoform.  
The expression levels of each APP isoform are represented as percentages 
showing the amount of each APP isoform present out of the total amount of 
APP which is detectable in SH-SY5Y cells. Control SH-SY5Y cells are non-
transfected (0nM) meaning they have neither the PMO nor the Endoporter 
transfection reagent and therefore show baseline levels of expression of these 
APP isoforms. PMO APP74/33 (figure 4.1) demonstrates that these control SH-
SY5Y cells (0nM) show an expression profile of 30.5  5.1% APP770, 35.8  
1.3% APP751, and 33.6  5.9% APP695. Increasing the dose of APP74/33 
reduced the expression levels of both APP770 and APP751, however 
increased the expression of APP695 showing that this PMO was effective at 
inducing exon skipping. At a dose of 100nM it was clear that the PMO was 
able to modulate alternative splicing of APP. Expression levels of APP770 and 
APP751 decreased, whereas expression levels of APP695 increased 
compared to the control non-transfected cells (0nM) (APP770 24.2  3.7%, 
APP 751 34.2  2.4%, and APP695 41.6  6%). It was clear that an increase 
in PMO APP74/33 correlated with an increase in APP695 expression. The 
concentrations of 100nM showed significant increase in exon skipping and 
therefore APP695 levels (49.53  3.1%, ** = p<0.005) compared to control SH-
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SY5Y cells. Increasing the concentration further to 250nM increased APP695 
expression levels (54.47  5.6%, *** = p<0.0005) and 500nM (APP695 59.43 
 3.8%, **** = p<0.0001) both showed statistically significant increases in 
APP695 compared to blank SH-SY5Y cells. The highest levels of exon 
skipping and therefore APP695 were present in the cells transfected with the 
two highest doses of PMO APP74/33 used, 750nM (APP695 61.4  3.7%, **** = 
p<0.0001) and 1000nM (APP695 63.76  6.7%, **** = p<0.0001) with the 
absolute highest dose of 1000nM showing the greatest increase in APP695 
levels compared to blank SH-SY5Y cells. Analysis of PMO APP755/84 in figure 
4.2 showed that increases in the concentration of this PMO leads to 
subsequent increases in the expression of APP695 mRNA, and a decrease in 
expression of APP770 and APP751. This is because APP exon 7 is being 
effectively skipped by PMO APP755/84. Treatment with 100nM of APP755/84 
showed an increase in APP695 levels, with a subsequent decrease in levels 
of APP770, and APP751 compared to blank SH-SY5Y cells. This increase in 
APP695 was shown to be significant (APP695 48.45  3.5%, p<0.005). 
Increasing the concentration of APP755/84 to 250nM, 500nM and 750nM (250nM 
57.02  4%, **** = p<0.0001) (500nM 64.28  1%, **** = p<0.0001) (750nM 
66.7  4.1%, **** = p<0.0001) respectively lead to significant increases in exon 
skipping as can be seen by the increased intensity of the APP695 band at 
842bp relative to the untreated control SH-SY5Y cells (0nM). The largest and 
most significant increase in APP695 levels compared to blank SH-SY5Y cells 
were seen in the cells treated with 1000nM of APP755/84, this is the largest 
concentration of the PMO which was tested and increased APP695 levels to 
70.4  1.5% (**** = p < 0.0001). This shows that this PMO is effective at 
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inducing exon skipping at concentration of 250-1000nM as these all showed 
highly significant results.  
The gel image in figure 4.3 shows the effects of PMO APP795/124 at modulating 
alternative splicing of APP. This demonstrates that there is a large increase in 
APP695 levels as the concentration of PMO APP795/124  is increased, meaning 
that this PMO is effective at skipping of APP exon 7. The addition of 100nM of 
PMO APP795/124  lead to a significant increase in APP695 expression (48.88  
3.4%, * = p<0.05) compared to blank SH-SY5Y cells. Further increasing the 
concentration of PMO APP795/124  to 250nM lead to an increase in APP695 
levels with expression levels of 62.80  7.91% (**** = p < 0.0001) a moderate 
and significant increase compared to blank SH-SY5Y cells. Treating SH-SY5Y 
cells with 500nM of PMO APP795/124  showed a significant increase in exon 
skipping and APP695 levels (68.74  5.88%, **** = p < 0.0001) compared to 
blank SH-SY5Y cells. The levels of APP695 expression shown in the cells 
transfected with 500nM of PMO APP795/124   are similar to the levels shown with 
treatment of 1000nM of PMO APP795/124, and close to those of 1000nM of 
APP755/84, showing that this PMO is very effective at inducing exon skipping. 
When the concentration of this PMO was increased to 750nM the expression 
of APP695 increased to 78.10  5.58%, this is a significant increase when 
compared to control and shows greater skipping than any other exon 7 PMO 
at any concentration (**** = p<0.0001). The highest concentration of PMO 
APP795/124  lead to the highest levels of exon skipping compared to blank SH-
SY5Y cells, with the expression of APP695 increasing to 81.40  7.8%, this is 
statistically significant and makes this PMO very effective at modulating 
160 
 
alternative splicing (**** = p<0.0001). This PMO appears to be the most 
effective of the PMOs which were designed to skip APP exon 7 as it resulted 
in the highest expression level of APP695 being present. 
PMO APP7125/154 also demonstrated its ability to modulate alternative splicing 
through increasing APP695 expression (figure 4.4). Transfection of SH-SY5Y 
cells with 100nM PMO APP7125/154 showed a significant increase in APP695 
expression (100nM 50.62  10.9%, * = p<0.05). Further increasing PMO 
concentration to 250nM, 500nM, 750nM showed further increases in APP695 
expression levels which showed greater significance (250nM 61.1  13.3%, ** 
= p < 0.005) (500nM 61.23  10.6%, *** = p < 0.0005) (750nM 62.54  0.8%, 
*** = p<0.0005). The highest concentration tested showed the greatest and 
most significant increase in APP695 expression (1000nM 69  4.6%, **** = 
p<0.0001). This suggests that this PMO, while effective at inducing alternative 
splicing, it was less effective than APP795/124 at inducing exon skipping of APP 
exon 7 and thereby increasing levels of APP695. 
PMO APP7164/+25 was the final PMO which was tested for its ability to skip exon 7 of 
APP. This PMO was unsuccessful in modulating alternative splicing and 
skipping APP exon 7. As shown in the gel image (figure 4.5), there is no 
significant change in the expression levels of APP695 of any of the other APP 
isoforms compared to blank cells. Figure 4.5 supports this showing relatively 
consistent levels of APP695 at all concentrations of PMO APP7164/+25. The 
highest concentration of PMO APP7164/+25 (1000nM) demonstrated the amount 
of APP695 to 39.51   2.6%, an insignificant increase (p>0.05) when compared 
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to the control untreated cells. This PMO was the only PMO which showed no 





















Figure 4.1: Effects of different concentrations of PMO APP7 4/33 on APP alternative splicing. Shows the results of a concentration gradient of 
PMO APP74/33. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM PMO74/33. The different APP isoforms 
are labelled with arrows, with a red arrow denoting APP695. There is also a  fourth band present which correlates to the expected band size of only 
APP exon 7 being skipped. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and APP695 – 842 bp. The control is labelled 0nM as it 
is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment on the change in APP isoform levels from control 
(0nM) to 1000nM. Gel was run on a 2% Agarose gel with SYBR Safe in 1x TAE buffer, with 5ul of Hyperladder II (50bp, Bioline), visualised using the 




















Figure 4.2: Effects of different concentrations of PMO APP7 55/84 on APP alternative splicing. Shows the results of a concentration gradient of 
PMO APP755/84. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM PMO APP755/84. The different APP 
isoforms are labelled with arrows, with a red arrow denoting APP695. There is also a  fourth band present which correlates to the expected band 
size of only APP exon 7 being skipped. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and APP695 – 842 bp. The control is 
labelled 0nM as it is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment on the change in APP isoform 
levels from control (0nM) to 1000nM. Gel was run on a 2% Agarose gel with SYBR Safe in 1x TAE buffer, with 5ul of Hyperladder II (50bp, Bioline), 




















Figure 4.3: Effects of different concentrations of PMO APP7 95/124 on APP alternative splicing. Shows the results of a concentration gradient of 
PMO APP795/124. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM PMO795/124. The different APP 
isoforms are labelled with arrows, with a red arrow denoting APP695. There is also a  fourth band present which correlates to the expected band 
size of only APP exon 7 being skipped. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and APP695 – 842 bp. The control is 
labelled 0nM as it is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment on the change in APP isoform 
levels from control (0nM) to 1000nM. Gel was run on a 2% Agarose gel with SYBR Safe in 1x TAE buffer, with 5ul of Hyperladder II (50bp, Bioline), 





















Figure 4.4: Effects of different concentrations of PMO APP7 125/154 on APP alternative splicing. Shows the results of a concentration gradient 
of PMO APP7125/154. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM PMO APP7125/154. The different 
APP isoforms are labelled with arrows, with a red arrow denoting APP695. There is also a  fourth band present which correlates to the expected 
band size of only APP exon 7 being skipped. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and APP695 – 842 bp. The control is 
labelled 0nM as it is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment on the change in APP isoform 
levels from control (0nM) to 1000nM. Gel was run on a 2% Agarose gel with SYBR Safe in 1x TAE buffer, with 5ul of Hyperladder II (50bp, Bioline), 





















Figure 4.5: Effects of different concentrations of PMO APP7 164/+25 on APP alternative splicing. Shows the results of a concentration gradient 
of PMO APP7164/+24. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM PMO APP7164/+24. The different 
APP isoforms are labelled with arrows, with a red arrow denoting APP695. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and 
APP695 – 842 bp. The control is labelled 0nM as it is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment 
on the change in APP isoform levels from control (0nM) to 1000nM. Gel was run on a 2% Agarose gel with SYBR Safe in 1x TAE buffer, with 5ul of 
Hyperladder II (50bp, Bioline), visualised using the Ebox VX2 imaging system and quantified using ImageJ (N=3).
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4.2.1.2 Concentration gradients of PMOs designed to target APP 
exon 8 
Following this, PMOs for the induction of exon 8 skipping were tested by 
transfections of these PMOs individually into SH-SY5Y cells. The success of 
these PMOs will be measured by their ability to skip exon 8, and thus increase 
the levels of APP751. Control SH-SY5Y cells (0nM) showed an expression 
profile of 30.5  5.1% APP770, 35.8  1.3% APP751, and 33.6  5.9% 
APP695.  
The decision was made to analyse both the levels of APP695 and APP 751 in 
response to these exon 8 skipping PMOs. The primary measure of success 
for these PMOs was skipping of APP exon 8 and a detectable increase in the 
levels of APP751. As we previously observed spontaneous skipping of APP 
exon 8 in cells treated with APP exon 7 skipping PMOs the decision was made 
to analyse the levels of APP695 to determine whether skipping of exon 8 also 
leads to spontaneous skipping of APP exon 7, and therefore an increase in 
APP695. Therefore, APP695 levels were chosen as the secondary measure 
of success for these PMOs. 
Transfection of SH-SY5Y cells with 100nM and 250nM PMO APP8-12/13 (figure 
4.6) showed little changes in APP isoform expression, with APP751 remaining 
relatively consistent at 38.9  1.7%, and 40.1  0.1% respectively; both of 
these changes were non-significant (p > 0.05). This PMO was able to modulate 
APP751 levels, showing significant increases in APP751 expression when 
PMO concentration was increased further to 500nM  (500nM 43.3  0.1, ** = 
p < 0.0001). Further increases in PMO concentration demonstrated further 
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significant increases in APP751 expression (750nM 45.14  3.3, ** = p < 
0.0001) (1000nM 46.3  4.4, **** = p < 0.0001). However, if we look at APP695 
in particular, this PMO does not seem to be effective, showing numerical but 
non-significant changes (100nM 30.01  0.1%, 250nM 28.36  0.3%, 500nM 
33.05  4.9%, 750nM 35.79  0.7%, 1000nM 33.44  7.2%, ns = p>0.05). This 
indicates this PMO is effective at inducing exon skipping, although does not 
lead to an increase in APP695 because only exon 8 is being skipped. 
Transfection with different concentrations of PMO APP814/38 (figure 4.7) 
showed a similar pattern of APP695 expression, with no significant increases 
in APP695 seen as a result of PMO treatment  (100nM 31.93  0.2%, 250nM 
29.71  1.4%, 500nM 34.9  0.7%, 750nM 31.94  0.2%, 1000nM 30.5  0.6%, 
ns = p>0.05).  This PMO however showed its ability to induce exon skipping 
by increasing levels of APP751 as PMO concentration increased. Changes in 
APP751 levels detected in RNA extracted from SH-SY5Y transfected with 
100nM and 250nM of PMO APP814/38  were non-significant (100nM 36.3  
0.2%, 250nM 38.2  1%, ns = p>0.05). Transfection of SH-SY5Y cells with 
500nM, 750nM and 1000nM of PMO APP814/38 showed significant increases 
in APP751 expression (500nM 41.9  0.7%, *** = p < 0.0005) (750nM 43  
0.4%, **** = p < 0.0001) (1000nM 44.3  2.6%, **** = p < 0.0001). This PMO 
again showed its ability to modulate alternative splicing, however the change 
was not detected in APP695, but rather in APP751.  
PMO APP839/+6 (figure 4.8) again demonstrated its ability at modulating 
alternative splicing by significantly increasing levels of APP751, but also 
showed numerically higher values in APP695 expression even though these 
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were deemed non-significant. Concentrations of 100nM and 250nM showed 
non-significant changes in APP751 levels (100nM 36.84  0.7%, 250nM 38.93 
 0.7%, ns = p>0.05). Transfection of SH-SY5Y cells with 500nM, 750nM and 
1000nM of PMO APP839/+6 showed significant increases in APP751 
expression (500nM 40.76  0.3%, * = p<0.05) (750nM 43.46  0.4%, ** = 
p<0.005) (1000nM 47.84  2.9%, **** = p<0.0001). This changes seen with 
1000nM of PMO APP839/+6 showed the largest increase in APP751 of all the 
PMOs designed for APP exon 8 skipping. The effect of this PMO on APP695 
showed non-significant changes at all concentrations tested (100nM 31.5  
2.3%, 250nM 27.9  0.3%, 500nM 31.9  0.5%, 750nM 36.4  1.3%, 1000nM 
40.1  3.02%, ns = p>0.05). All of these changes were non-significant, 
however this PMO demonstrated the largest increase in APP695 expression 
levels of all the PMOs designed for the induction of APP exon 8 skipping.  
Transfection of SH-SY5Y cells with PMO APP8+7/+31 (figure 4.9) demonstrated 
no significant changes in either of APP751, or APP695 expression. This was 
the only PMO designed for APP exon 8 skipping which showed no ability in 






















Figure 4.6: Effects of different concentrations of PMO APP8 -12/13 on APP alternative splicing. Shows the results of a concentration gradient of 
PMO APP8-12/13. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM PMO APP8-12/13. The different APP 
isoforms are labelled with arrows, with a red arrow denoting APP695. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and APP695 
– 842 bp. The control is labelled 0nM as it is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment on the 
change in APP isoform levels from control (0nM) to 1000nM. Gel was run on a 2% Agarose gel run in 1x TAE buffer, with 5ul of Hyperladder II 





















Figure 4.7: Effects of different concentrations of PMO APP8 14/38 on APP alternative splicing. Shows the results of a concentration gradient of 
PMO APP814/38. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM PMO APP814/38. The different APP 
isoforms are labelled with arrows, with a red arrow denoting APP695. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and APP695 
– 842 bp. The control is labelled 0nM as it is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment on the 
change in APP isoform levels from control (0nM) to 1000nM. Gel was run on a 2% Agarose gel run in 1x TAE buffer, with 5ul of Hyperladder II 





















Figure 4.8: Effects of different concentrations of PMO APP8 39/+6 on APP alternative splicing. Shows the results of a concentration gradient of 
PMO APP839/+6. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM PMO APP839/+6. The different APP 
isoforms are labelled with arrows, with a red arrow denoting APP695. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and APP695 
– 842 bp. The control is labelled 0nM as it is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment on the 
change in APP isoform levels from control (0nM) to 1000nM. Gel was run on a 2% Agarose gel run in 1x TAE buffer, with 5ul of Hyperladder II 





















Figure 4.9: Effects of different concentrations of PMO APP8+7/+31 on APP alternative splicing. Shows the results of a concentration gradient of 
PMO APP8+7/+31. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM PMO APP8+7/+31. The different APP 
isoforms are labelled with arrows, with a red arrow denoting APP695. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and APP695 
– 842 bp. The control is labelled 0nM as it is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment on the 
change in APP isoform levels from control (0nM) to 1000nM. Gel was run on a 2% Agarose gel run in 1x TAE buffer, with 5ul of Hyperladder II 




4.2.2 Dose response curve of PMOs designed for APP exon 7 
skipping. 
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Figure 4.10: Dose response curves of log PMO concentration against % APP exon 7 
skipping. The EC50 was calculated from this dose response curve and is shown in the top left 
corner.  
 
After performing PCRs and analysing each PMO to determine ability to induce 
exon skipping a dose response curve was plotted to calculate the EC50 of each 
PMO. This is shown above in figure 4.10 with each line representing an exon 
7 skipping PMO. The EC50 value demonstrates the concentration of PMO that 
is required to produce skipping of exon 7 which is half of the maximum. 
Generally, the more effective a PMO is at inducing exon skipping, the lower its 
EC50 value is. As PMO APP795/124 demonstrated that it was the best PMO in 
terms of skipping exon 7 of APP it would be expected to have the lowest EC50. 
The results from the dose response curve (figure 4.10) support this, with PMO 
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APP795/124 showing an EC50 value of 249.5nM. PMO APP7125/54 had the next 
best EC50 number at 330nM, followed by PMO APP755/84 with an EC50 of 
336nM. PMO APP74/33 was calculated to have an EC50 of 416nM, making it 
the fourth best PMO for exon 7 skipping. An EC50 could not be calculated for 
PMO APP7164/+25 having little to no effect on exon skipping, making it the least 
effective PMO in terms of APP exon 7 skipping. This supports the previous 
data as it shows that PMO APP795/124 was the most effective for inducing exon 




























Figure 4.11: Figure summarizing designs for APP exon 7 skipping PMOs. A) Table 
summarizing the PMOs designed for skipping APP exon 7, including the GC content (%), the 
number of ends in an open loop, and the total binding energy (∆Gi) of each PMO binding to 
its specific target region. B) Figure depicting the predicted secondary structure of APP exon 7 
with each of the designed PMOs overlapping their target region. C) Bar graph summarizing 
the effect of PMO treatment on the levels of APP695 levels in SH-SY5Y cells transfected with 






4.2.3 Dose response curve for APP exon 8 skipping in SH-
SHY5Y cells following PMO transfection 
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Figure 4.12: Dose response curves of log PMO concentration against % APP exon 8 
skipping. The EC50 was calculated from this dose response curve and is shown in the top 
left corner. 
 
A dose response curve was also plotted to calculate the EC50 of each PMO 
which was designed to modulate skipping of APP exon 8. This is shown above 
in figure 4.12 with each line representing one of the exon 8 specific PMOs. 
The more effective a PMO is at inducing skipping, the lower its EC50 value is. 
PMO APP839/+6 was demonstrated to have the lowest EC50 value of the exon 
8 specific PMOs, with an EC50 of 371.9nM. PMO APP814/38  was calculated to 
have an EC50 value of 414.3nM, the second best put of all of the exon 8 PMOs, 
whereas PMO APP8-12/13 was shown to have an EC50 value of 445.6nM. An 
EC50 value could not be calculated for PMO APP87/+31 as it had no effect on 
exon skipping making it the least effective PMO for inducing skipping of APP 
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exon 8. This data along with the previous data (figure 4.13) suggest that PMO 











Figure 4.13: Figure summarizing designs for APP exon 8 skipping PMOs. A) Table 
summarizing the PMOs designed for skipping APP exon 8, including the GC content (%), the 
number of ends in an open loop, and the total binding energy (∆Gi) of each PMO binding to 
its specific target region. B) Figure depicting the predicted secondary structure of APP exon 
8 with each of the designed PMOs overlapping their target region. C) Bar graph 
summarizing the effect of PMO treatment on the levels of APP751 levels in SH-SY5Y cells 



















Figure 4.14: Effects of different concentrations of a combination of PMO APP7 95/124 and PMO APP8 39/+6 on APP alternative splicing. Shows the results of a 
concentration gradient of PMO APP839/+6. A) A representative gel image of RT-PCR products of SH-SY5Y cells treated with 0-1000nM of PMO APP7 95/124 and 0-1000nM of PMO 
APP839/+6in combination. The different APP isoforms are labelled with arrows, with a red arrow denoting APP695. The three band sizes are APP770 – 1067bp, APP751 – 1010bp, and 
APP695 – 842 bp. The control is labelled 0nM as it is untreated and shows base splicing levels. B) Bar graph depicting the effect of PMO treatment on the change in APP isoform 
levels from control (0nM) to 1000nM. Gel was run on a 2% Agarose gel run in 1x TAE buffer, with 5ul of Hyperladder II (50bp, Bioline), visualised using the Ebox VX2 imaging system 
and quantified using ImageJ (N=3). 
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Once the PMOs for the skipping of each of APP exon 7 and APP exon 8 had 
been assessed and the best PMO had been chosen for skipping of each exon, 
the next step was to test whether transfecting a combination of PMOs for APP 
exon 7 and exon 8 skipping together into SH-SY5Y levels would have a greater 
impact on APP exon 7 and 8 skipping, and as a result, a greater increase in 
APP695 expression compared to transfection with a single PMO alone. PMO 
APP795/124 and APP839/+6 were transfected together into SH-SY5Y at 
concentrations ranging from 0nM (control) to 1000nM of each PMO. This 
means that at the maximum dose tested, 1000nM of each PMO, and a total of 
2000nM of total PMO was used at the maximum dose. Increasing the dose of 
this combination of PMOs reduced the expression levels of both APP770 and 
APP751, increasing the expression of APP695 showing that this PMO was 
effective at inducing exon skipping. At a dose of 100nM there was a non-
significant, but numerical increase in the levels of APP695, and a slight 
decrease in APP770 and APP751 compared to controls (APP695 52.9  
16.3%, ns = p>0.05). Increasing the concentration further to 250nM increased 
APP695 expression levels, however these were again non-significant (60.4  
15.7%, ns = p>0.0005). Further increase to 500nM and 750nM of each PMO 
lead to significant increases in APP695 (500nM 71.4  18.5%, * = p<0.05) 
(750nM 70.6  10.5%, * = p<0.05) compared to control SH-SY5Y cells. The 
highest levels of exon skipping and therefore APP695 were present in the cells 
transfected with 1000nM of each of PMO APP795/124 and APP839/+6 (APP695 






The work presented in this chapter was performed in order to investigate the 
efficacy of the PMOs which were designed to modulate alternative splicing of 
APP pre-mRNA by excluding APP exons 7 or 8 from the mature RNA 
transcript. Alternative splicing of these exons produces three major isoforms 
of APP, APP770, APP751 and APP695. Exclusion of both exon 7 and exon 8 
produces the APP695 isoform, the principally neuronal isoform of APP. A 
decrease in the expression of this isoform has been seen to correlate with AD 
progression (Johnson et al. 1989). APP695 is thought to relay its protective 
effects through one of its cleavage products known as the amyloid intracellular 
domain (AICD). The AICD is produced from all isoforms of APP after 
processing via γ-secretase. Although the AICD can be produced from all 
isoforms of APP, it is only when it is produced from APP695 that it is able to 
have downstream effects through acting as a transcription factor for the 
activation of downstream genes.  
Four of the five PMOs which were designed specific to exon 7 of APP were 
successful in inducing exon skipping. The success of these PMOs at inducing 
exon skipping supports relying on bioinformatic resources for PMO design. 
These PMOs were designed based on information from a variety of 
bioinformatic resources. A major guide which was suggested to PMO design 
was the prediction of binding sites for exon splice enhancers (ESEs) and exon 
splice silencers (ESSs). The prediction of ESE and ESS sites was undertaken 
using the human splice finder (HSF). Results of the HSF analysis for APP exon 
7 and flanking introns showed that there were ESE sites present throughout 
the exon, with four major clusters of ESEs present. There was a single ESE 
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cluster present at the 5’, one in the centre of the exon around the 60bp mark, 
one at the 3’, and one spanning the 3’ intron exon boundary. These ESE 
clusters were generally strong, and showed little competition with ESS sites 
however the clusters present at the 3’ of the exon showed the strongest 
ESE/ESS ratio making them the most favourable targets (Aartsma-Rus, van 
Vliet, et al. 2009; Popplewell et al. 2009). The PMOs designed for APP exon 
skipping were designed to target all of these ESE/ESS peaks (Aartsma-Rus, 
van Vliet, et al. 2009; Popplewell et al. 2009). This bioinformatic analysis was 
supported by the in vitro work in this chapter as of the five PMOs designed to 
target the peaks in ESE/ESS peaks in relative energy in APP exon 7, only one 
PMO was ineffective at modulating alternative splicing. The ineffective PMO 
was PMO APP7164/+25 which was designed to target the ESE/ESS peak at the 
3’ exon/intron boundary and showed no ability to modulate alternative splicing. 
The two PMOs which showed the greatest ability to induce exon skipping were 
PMOs APP795/124 and APP7125/154 which targeted the weaker ESE/ESS 
relative strength peak in the middle of the exon, and the strong ESE/ESS peak 
at the 3’ end.  
For APP exon 8, there was one large, sustained peak of relative ESE/ESS 
strength throughout the exon, and another within intron 9 relatively close to the 
exon. PMOs were targeted throughout this exon, and in the 3’ intron. Of the 
four PMOs designed to target this exon, three were successful at inducing 
alternative splicing. The PMO which was the best at modulating alternative 
splicing was PMO APP836/+6 which targeted the ESE/ESS peak at the 3’ end 
of the exon overlapping with the intron. The only PMO which was unsuccessful 
at modulating alternative splicing which targeted this exon was targeting a 
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region within intron 9. It is probable that the failure of this PMO was solely due 
to it not targeting a region within the exon. 
From the success of the PMOs designed we can conclude that targeting of 
ESS sites of ESE sites through HSF analysis is a good guideline which should 
be followed in order to design successful PMOs.  
Another guideline for the PMO design process was regarding PMO binding 
energy. It has previously been reported that a PMO with more negative binding 
energy correlates with improved exon skipping (Popplewell et al. 2009). 
Therefore, another guide to PMO design was the prediction of the overall free 
binding energy (ΔG) of each PMO using RNAup, which uses the following 
formula ΔGbinding = ΔGAu + ΔGBu + ΔGh, where ΔGh denotes the free energy 
gained from forming the inter-molecular duplex, and ΔGA,Bu is the free energy 
to make the binding region of the exon or PMO accessible. Using this formula, 
the ΔGi for each PMO was calculated. These calculations showed that all of 
the PMOs which were designed for skipping of APP exon 7 had negative 
binding energies. PMO APP74/33 had an overall free binding energy of -
44.29kcal/mol which is the most negative binding energy detected, therefore 
this PMO would be predicted to show the greatest efficiency of exon skipping. 
This is not the case in practice as this PMO was in fact the third best PMO at 
inducing exon skipping. PMO APP755/84 was calculated to have a ΔGi of -
37.86kcal/mol, and PMO APP795/124 had a ΔGi of -41.42kcal/mol; these two 
PMOs showed the highest levels of exon skipping, however neither of their 
binding energies are significantly more negative than the other PMOs 
designed. PMO APP7125/154 had a binding energy of -35.82kcal/mol the lowest 
of all of the PMOs, and PMO APP7164/+25 , which was the PMO shown to be the 
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least effect in vitro was calculated to have a binding energy of -38.83kcal/mol. 
These results show that there is little correlation between the ΔGi of these 
PMOs, and their ability to induce exon skipping. These calculations also 
showed that all the PMOs designed for APP exon 8 skipping had highly 
negative binding energies. Of these PMOs the most successful PMO at 
inducing exon skipping, PMO APP839/+6 was calculated to have a ΔGi of -37.84 
kcal/mol, this was the most negative of the binding energies calculated for the 
exon 8 specific PMOs. The second most effective PMO, PMO APP814/38 was 
calculated to have a ΔGi of -35.53 kcal/mol and the third most effective PMO 
in terms of exon 8 skipping, PMO APP APP8-12/13 was calculated to have a ΔGi 
of -31.30.  PMO APP+7/+31 which was ineffective at inducing exon skipping was 
also the PMO which had the second highest ΔGi calculated at -35.92 kcal/mol. 
This is similar to the results seen for the APP exon 7 specific PMOs as it shows 
that there is little correlation between ΔGi and ability to induce exon skipping.  
As the overall binding energies do not seem to correlate with PMO efficiency, 
this could indicate that the predictions of the binding energies are not accurate 
to properly determine the required energy for PMO binding. This could also 
mean that there are other parameters which were not included in these binding 
energy calculations which are important in determination of PMO binding to 
the RNA. It could also be that as all of the PMOs designed had relatively similar 
binding energies the small differences between them was not significant to 
confer any additional benefit to PMO binding and efficiency. Research has 
previously discussed the link between negativity of binding energy and 
improved exon skipping (Aartsma-Rus et al. 2009; Popplewell et al. 2009). In 
this study effective PMOs were calculated to have binding energies of between 
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-30 kcal/mol to -40 kcal/mol, which is on par with the four successful and one 
unsuccessful PMOs designed in this chapter. Therefore, it possible that the 
tools used for the prediction of the PMO binding energies as well as the RNA 
folding are not good predictors of binding energy, or that binding energy in this 
case is not a strong determinant for PMO binding efficiency. 
The secondary structure of APP pre-mRNA was another parameter that was 
used as a guide for designing successful PMOs to modulate alternative 
splicing of APP. The secondary structure was predicted using the MFold web 
server, and the secondary structures were used to guide designs to single 
stranded regions of RNA. Based on this prediction, PMO APP74/33, APP755/84, 
and APP795/124 were designed to target open confirmations, with PMO 
APP74/33 and APP755/84 overlapping one open looped region, whereas PMO 
APP795/124 was designed to target two open looped regions. Comparing this to 
PMO APP7125/154, and PMO APP7164/+25 which both targeted regions of double-
stranded RNA. This adjustment was significant as the three PMOs which 
targeted open confirmations showed high exon skipping efficiency, while one 
of the two PMOs which targeted double stranded (PMO APP7164/+25)  showed 
no ability to induce exon skipping. It is unclear as to why APP7164/+25  produced 
no effect in terms of exon skipping (figure 4.11), as its design was similar to 
that of PMO APP7125/154 which showed the second highest overall ability to 
induce exon skipping. Both of these PMOs targeted the 3’ of the exon at 
regions of strong ESE/ESS relative strength, they both had relatively similar 
signal strengths (-35.82kcal/mol vs -38.83kcal/mol), and they both targeted 
double stranded closed confirmations. There are sure to be other factors which 
influence the difference between these two PMOs, however it would be 
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interesting to design a large number of PMOs targeted at the double stranded 
region to determine the effects of this on success of PMOs, and determine 
whether this is an important determinant of whether a PMO is successful.  
For APP exon 8 specific PMOs, PMO APP814/38, PMO APP839/+6, and PMO 
APP8+7/+31 all targeted open confirmations of RNA, with PMO APP814/38 and 
PMO APP839/+6 containing two ends in open looped confirmations and PMO 
APP8+7/+31 having one end in an open confirmation. PMO APP8-12/13 had no 
ends in open looped confirmation, targeting double stranded regions of RNA. 
Of the three PMOs with ends in open loops, two were successful in modulating 
alternative splicing. Both PMOs with two ends in open loops showed the 
strongest ability to modulate alternative splicing, and the one PMO which 
contained a single end in a loop being ineffective at inducing alternative 
splicing (figure 4.13). 
Looking at the PMO which were successful at preventing inclusion of APP 
exon 7 and 8, it can be concluded that targeting of predicted ESE binding sites 
and single-stranded RNA, while avoiding ESS binding sites and double-
stranded RNA are the most important factors to consider when designing 
PMOs, while binding energy predictions is not an accurate guide, and should 
not be relied upon. While this was true of the PMOs designed in this chapter, 
further testing of regions in other transcripts would be needed in order to rule 
out the use of binding energies as a guide to predict PMO targets. A much 
greater number of PMOs would also need to be tested in order to conclusively 
say which design parameters were the most predictive of more efficient PMOs. 
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Aartsma-rus et al. performed an analysis on previously published ASOs which 
function through exon skipping in the dystrophin gene in order to determine 
whether any guidelines could be extrapolated from these studies (Aartsma-
Rus, et al. 2009). Of these ASOs,104 were deemed successful, and 52 were 
deemed unsuccessful. The conclusions gathered from the 156 ASOs analysed 
in this published study contradict the results of this experiment as they 
concluded that the best parameters to use for ASO design were the GC 
content of the sequence, and its predicted binding energy, which were found 
not to be significant in the experiments conducted for the APP exon 7- and 8- 
specific PMOs. Their work also determines the majority of effective PMOs 
covered ESE sites, which agrees with the results shown in this experiment. 
Work by Popplewell et al. showed that a more accurate method for finding 
accessible bases is to use hybridisation array analysis. This method amplifies 
the target RNA sequence and subsequently exposes this RNA to possible 
hexamers (Popplewell et al. 2009). Binding of hexamers to RNA is detected 
through fluorescent labelling and biotinylated bases. Any potential binding is 
indicative of an accessible sequence of hexamers and these sequences could 
therefore be the targets for ASO targeting. This technique could improve ASO 
design, and due to the fact that these results are experimentally verified rather 
than relying on the assumptions of predictive software, this technique is much 
more reliable. 
As APP695 contains neither of APP exon 7 or 8, it was theorised that 
transfection of SH-SY5Y cells with a combination of PMOs which are able to 
induce skipping of both exons 7 and 8 would greatly increase the expression 
of APP695, above the levels seen in the experiments where cells were 
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transfected with APP exon 7, or exon 8 PMOs only. The PMOs which showed 
the best ability to skip their respective exon were chosen and transfected into 
SH-SY5Y levels in combination. Surprisingly, with 1000nM of each of PMO 
APP795/124 and APP839/+6, the levels of exon skipping observed (77.4  7.4%, 
** = p<0.005) were lower than that observed with transfection of PMO 
APP795/124  alone (81.40  7.8%, **** = p<0.0001), despite double the total 
PMO concentration being used. It is possible that this lack of increase is due 
to overloading of the SH-SY5Y cells with PMOs. Overall, we can conclude that 
the PMOs designed in this chapter were able to successfully fulfil the role 
which they were designed for, that is, to modulate the alternative splicing of 











5 Investigating the effects of modulating alternative splicing of 
APP on the expression pattern of the APP isoforms 
5.1 Introduction 
The amyloid cascade hypothesis was formed in 1992 to explain the 
relationship between Aβ and AD, and posits that Aβ accumulation and 
subsequent deposition are the initial steps which ultimately result in AD (Hardy 
& Higgins 1992; Selkoe & Hardy 2016). Since the inception of this hypothesis 
Aβ has been widely regarded as the principal neurotoxic agent implicated in 
AD pathology, however, as Aβ is produced through the proteolytic processing 
of the APP protein, it can be said that APP also plays a vital role in AD 
pathogenesis as the primary source of Aβ.  
The APP gene is located on chromosome 21 and is made up of 18 exons 
(Zhang et al. 2011). There are three major protein isoforms of APP expressed 
in the human brain, APP770, APP751 and APP695 with their diversity based 
solely on the alternative splicing of APP exons 7 and 8. APP770 is the full 
length variant of APP, containing both exons 7 and 8, whereas APP751 
contains only exon 7, both of these APP isoforms are expressed within the 
brain as well as in non-neuronal tissues such as in lymphocytes, platelets, 
heart muscle and the kidneys (Dawkins & Small 2014). APP695 contains 
neither exon 7 or 8 and is only expressed within the brain, and is principally 
neuronal (Dawkins & Small 2014). APP exon 7 encodes for a KPI domain, 
whereas APP exon 8 encodes an OX-2 domain (Sandbrink et al. 1996; Beilin 
et al. 2007). All three APP isoforms undergo proteolytic processing via two 
main pathways which are commonly termed the non-amyloidogenic and 
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amyloidogenic pathways (Zhang et al. 2011). Both of these pathways involve 
proteolytic processing with γ-secretase after initial cleavage with either α-
secretase for the non-amyloidogenic pathway, or β-secretase for the 
amyloidogenic pathway (Smith, Al Hashimi, Girard, Delay & Sébastien S. 
Hébert 2011). The amyloidogenic pathway of APP is named as such because 
processing of APP through this pathway releases the Aβ peptide. All isoforms 
of APP undergo processing through both of these pathways, and therefore all 
isoforms are able to produce Aβ. However, research has shown that the levels 
of KPI containing APP isoforms, namely APP770 and APP751 are increased 
in the brains of AD patients compared to physiological levels, whereas the 
neuronal isoform, APP695, shows decreased expression, correlating with an 
increase in Aβ deposition (Moir et al. 1998; Menéndez-González et al. 2006). 
This change in the expression levels of APP isoforms during AD which leads 
to increases in APP770 and APP751 whilst decreasing APP695 in the brain is 
thought to alter membrane proteolytic activity and play a role in deposition of 
Aβ, a key step in AD progression (Johnson et al. 1990).  This highlights the 
importance of the APP695 isoform and the balance between these APP 
isoforms in the progression of AD. Previously, we successfully demonstrated 
the ability of exon skipping PMOs designed to target APP exons 7 and 8 at 
increasing the levels of APP695 at the RNA level. This chapter aims to 
determine whether these PMOs through skipping of APP exons 7 and 8 are 






5.2.1 Optimisation of SDS-PAGE 
In order to determine whether induction of changes in pre-mRNA splicing 
translate to changes in protein expression of the APP isoforms, SDS-PAGE 
and western blotting analysis was performed. These westerns would be 
subject to densitometric analysis to compare the levels APP695 present in 
control SH-SY5Y cells and SH-SY5Y cells transfected with various PMOs for 
APP exon skipping.  In order to accomplish this, the first necessary step was 
to determine the optimal SDS-PAGE system to obtain the best possible 
separation of APP protein isoforms. The similarity in size between the three 
major APP isoforms makes this a challenging task, with only a small difference 
in the number of amino acids between the three isoforms of APP (19 amino 
acids between APP770 and APP751, and 56 amino acids between APP751 
and APP695) as well as the different levels of glycosylation of these proteins, 
and the differences in size due to this. Fully glycosylated proteins are 
considered mature, whereas partially glycosylated proteins are immature. 
Previous research has shown that these overlaps lead to the presence of three 
distinct protein bands, the mature APP751/ mature APP770 band, the mature 
APP695/ immature APP770/ mature APP751 band, and the immature 
unglycosylated APP695 band (Belyaev et al. 2010). 
In order to check the separation, hand-cast Tris-glycine gels of different 
percentages as well as pre-cast 4-12% gradient Bis-Tris gels were used for 
SDS-PAGE to separate protein extracts from control SH-SY5Y cells which 
were lysed with radioimmunoprecipitation assay (RIPA) buffer. Following 
electrophoresis, the transfer cassette was assembled. The gel was removed 
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from the plates of the SDS-PAGE cassette and was placed onto nitrocellulose 
membrane with a pore size of 0.2µM. This was sandwiched between filter 
paper and blotting sponges and submerged in Tris-glycine transfer buffer (see 
methods) before being inserted into a transfer tank full of transfer buffer. This 
was then transferred overnight at 10V, before being blocked with 5% dried 
non-fat milk in 1x TBS containing 0.05% Tween-20 for 1.5 hours.  The blots 
were then all probed with the commercial N terminal APP antibody 22C11 
which detects an epitope on the N- terminal of APP at amino acids 66-81 
(Hilbich et al. 1993). This is able to detect both the immature and mature 
variants of all three major isoforms of APP, APP770, APP751 and APP695 
(Hoffmann et al. 2000; Belyaev et al. 2010).  
Representative western blots from these gels are presented in figure 5.1. 
Representative western blots detected multiple APP bands between 93 and 
130kDa. These bands represent a cluster of the overlapping APP isoforms, it 
is not possible to visualise the three separate APP isoforms as three separate 
bands. The overlap between the isoforms of APP is due to the relatively similar 
sizes of the APP isoforms as well as the different levels of glycosylation of 
these proteins, and the differences in size due to this. Fully glycosylated 
proteins are considered mature, whereas partially glycosylated proteins are 
immature. The overlaps present lead to three distinct bands which are seen in 
these blots, the first band (top) is a mixture of the mature APP751 and the 
mature APP770, the next band (middle of the three) is a mixture of the mature 
APP695 with the immature APP751 and immature APP770, and the bottom 
most band is the single immature unglycosylated APP695 alone (Tomita et al. 
1998; Belyaev et al. 2010). If poor separation was demonstrated by the SDS-
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PAGE system used, it would become increasingly difficult to distinguish 
between and therefore perform analysis on these protein bands, hence the 
importance of optimisations to demonstrate clear separation. In order to do 
this, hand-cast Tris-glycine gels with varying acrylamide percentages, as well 
as a 4-12% gradient Bis-tris pre-cast gel were used to separate protein 
extracts from non-transfected (Blank) SH-SY5Y cells. 
The 10% hand-cast tris-glycine gel (figure 5.1A) was tested as these gels allow 
separation of mid-sized proteins. The western blot on blank (non-transfected 
control) SH-SY5Y protein extracts with the hand-cast 10% tris-glycine gels 
revealed a cluster of 3 bands at the predicted size, with adequate separation 
between these 3 bands which would allow for densitometric analysis of these 
bands. With this gel, the largest band which is detected (mature APP770/ 
mature AP751) is diffuse, whereas the other two bands are sharp and clear.  
The next SDS-PAGE system trialled was the hand-cast gradient 4-16% tris-
glycine gel (figure 5.1B). This gel system was trialled in an attempt to further 
improve separation and band clarity. The 4-16% tris-glycine gel system 
demonstrated three bands at the expected sizes, however there was poor 
separation demonstrated between the two largest bands (APP770/751/695 
matureAPP770/ mature APP751) as well as smearing of the protein towards 
the top of the gel where the acrylamide gel is at its most concentrated. This 
was not ideal as the poor separation meant that isolation and analysis of 
individual band would be difficult, and it was therefore decided that a different 
gel type would be trialled.  
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To enhance separation and resolution the decision was made to trial pre-cast 
4-12% Bis-Tris SDS-PAGE gels with MES buffer as the running buffer (5.1C). 
The Bis-Tris SDS-PAGE system was used since the combination of MES with 
a 4-12% polyacrylamide gradient is suitable for separation of proteins ranging 
from 3.5-160kDa. This range would allow for suitable separation of APP 
proteins, as well as allowing for the potential detection of smaller proteolytic 
fragments of APP such as the AICD which is to be analysed later. This gel 
demonstrated the best separation of the three gels trialled as this gel allows 
for isolation and analysis of each of the APP bands individually with no overlap 
between the bands. This gel also provided the best resolution of the three gels 
trialled showing three sharp easily identifiable bands. The decision was made 














Figure 5.1: Separation of APP protein with different SDS-PAGE systems and 
percentages. Representative western blots showing the separation of APP from non-
transfected SH-SY5Y cell extracted by RIPA buffer (in triplicate) by SDS-PAGE using different 
gel percentages and gel systems. Detection using the 22C11 N- terminal APP antibody 
1:1000. (A) 10% Tris-glycine gel, (B) 4-16% Tris-glycine gel, (C) 4-12% Bis-Tris gel with MES 
buffer. 20 µg of protein was loaded per well, against BLUeye Prestained Protein Ladder. Gel 










5.2.2 Protein lysis buffer and protein sample preparation 
optimisation 
The next goal was the optimisation of the protein extraction conditions that 
would allow detection of all three APP isoforms as well as possible proteolytic 
fragments produced. Optimisation of protein lysis buffer is important as this is 
the determining factor in terms of what proteins will be present in the lysate 
and subsequently used for analysis via western blotting. Two lysis buffers were 
compared, the NP-40 lysis buffer, and RIPA buffer.  
In parallel to the optimisation of lysis solutions, the impact of different reducing 
agents in the breakdown/separation of possible APP complexes were also 
analysed in the protein extracts. Such agents are required to reduce the 
intramolecular and intermolecular disulphide bonds in the protein samples, 
which is vital in preventing protein folding or aggregation, allowing the proteins 
to be denatured and migrate according to their MW through the gel. The two 
reducing agents trialled at the sample preparation phase were 10% DTT and 
NuPAGE Reducing Agent (RA). Protein samples for this experiment were 
prepared from blank, non-transfected SH-SY5Y cells. As a positive control 
protein extracts from SH-SY5Y cells transfected with an APP-695 
overexpression plasmid were prepared. Two different APP antibodies were 
used for this test, 22C11 and A8717. 22C11 is a monoclonal antibody raised 
in mice which detects an epitope between amino acids 66-81 on the N-terminal 
of APP. The A8717 is a rabbit polyclonal antibody which detects an epitope 
between amino acids 676-695 on the C-terminal of APP. Representative 
western blots presented in figure 5.2 show the four different combinations of 
lysis buffers and sample preparation used, NP40 + DTT (dithiothreitol), NP40 
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+ NuPAGE reducing agent, RIPA buffer + DTT, RIPA buffer + NuPAGE 
reducing agent. From the western in figure 5.2 it is clear that RIPA buffer is far 
superior to the NP40 lysis solution in terms of its ability to extract and allow 
detection of APP, as APP was readily detected at a much higher level in the 
protein extracted with RIPA buffer when compared with NP40 buffer. For both 
of the NP40 and RIPA buffer extracted protein, 20 µg of protein was loaded 
onto the SDS-PAGE gels, but the detection was seen to be at much higher 
levels in the RIPA buffer extracted protein. These APP protein bands were 
difficult to visualise with both the N- and C- terminal APP antibodies in the 
NP40 extracted samples but readily detected in the RIPA buffer extracted 
protein samples. As for the use of DTT or NuPAGE RA, no difference was 
observed for either the N-terminal or C-terminal antibodies between the two 
methods with both DTT and NuPAGE RA readily allowing visualisation of APP 
protein with both the N – and C – terminal APP antibodies. The NuPAGE RA 
ran with slightly less smearing compared with the DTT prepared samples, and 








Figure 5.2: Comparison of protein lysis buffers and sample preparation methods. 
Representative western blot using different lysis buffers and sample preparation to determine 
the best method of extracting and preparing protein extracts from SH-SY5Y cells to best 
visualise APP protein. Protein was extracted with either NP40 lysis solution or RIPA buffer 
followed by preparation with either DTT or NuPAGE reducing agent. Pre-cast 4-12% Bis-Tris 
gels were used for this gel with MES NuPage running buffer. 20 µg of protein was loaded per 













5.2.3 Baseline levels of APP at the protein level 
The next step in determining the effectiveness of PMOs at the protein level 
was to determine the baseline levels of APP and each of its 3 major isoforms, 
APP770, APP751 and APP695. Comparison of the levels of APP in protein 
extracts from control SH-SY5Y cells with the levels of APP from PMO 
transfected cells allows for determination of the change in APP isoform 
expression due to modulation of alternative splicing. Western blotting was 
conducted with protein extracts from two different control conditions, blank 
non-transfected SH-SY5Y cells, and SH-SY5Y cells transfected with a control 
PMO termed E2. This PMO was kindly provided by Dr. Linda Popplewell and 
had been previously researched in relation to DMD as an exon skipping PMO. 
The E2 PMO was designed to target a specific exon in the myostatin gene. 
This PMO was used as a control to demonstrate that non-specific PMO 
transfection had no effect on APP alternative splicing. The western blot of the 
blank non-transfected (figure 5.3) SH-SY5Y cells showed expression of the 
three major APP isoforms APP770, APP751 and APP695. However, it was 
difficult to determine the levels of the isoforms individually as there are 
overlaps between the sizes of the different APP isoforms. The overlaps 
present are between the mature APP751 and mature 770 (top band), between 
the mature APP695 with immature APP751 and APP770 (middle band). The 
only band that contains APP in a single isoform is the bottom most band which 
represents APP695 only. Densitometric analysis was used to compare the 
levels of expression of the single unglycosylated APP695 band as a 
percentage of the total amount of APP protein detected. The analysis showed 
that of the total APP in the Blank sample 15.26% ± 1.88% (N=3) was of the 
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APP695 isoform, compared to 16.48% ± 4.42% (N=3) present in protein 
extracted from the control PMO E2 transfected sample. From this we can infer 
that APP695 is the minority isoform present in SH-SY5Y cells with the 
remainder being of the APP770 and APP751 isoforms. This also confirmed 
that the control PMO, E2, had no effect on APP splicing as the change in 
APP695 levels were not significant (p>0.05). In the previous chapter it was 
demonstrated that the control PMO E2 had no effect on modulating APP 
splicing, and the results agree with this as there is no change in APP isoform 











Figure 5.3: Baseline levels of APP isoforms in control SH-SY5Y cells. Western blot and 
analysis showing the baseline levels of APP695 present in SH-SY5Y cells transfected with a 
control PMO (E2) and not transfected (Blank). Protein was extracted from SH-SY5Y cells with 
RIPA lysis buffer, and 20 µg of protein was loaded per well on an 4-12% Bis-Tris pre-cast gel 
run with NuPAGE MES buffer. Protein was run against BLUeye Prestained Protein Ladder. 
Gel visualised with the Odyssey CLx Imaging System (N=3). 
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5.2.4 Effects of PMOs on APP modulation at the protein level 
Previously we showed that the 3 major bands which correspond to 
combinations of the three major isoforms of APP were detectable in protein 
extracts from control SH-SY5Y cells.  In order to determine whether the 
designed PMOs were able to alter the levels of APP isoform expression, we 
transfected the designed PMOs into cultured SH-SY5Y cells. The cells were 
transfected with 1000nM PMO as this was shown to be the concentration 
inducing the highest exon skipping at the mRNA level in the previous chapter.  
The cells were then lysed with RIPA lysis buffer 48 hours post transfection and 
protein quantified with a DC assay. Protein samples were then prepared using 
LDS sample buffer and NuPAGE RA before boiling samples to denature. 
These samples were run on precast 4-12% Bis-Tris gels using MES buffer. 
SDS-PAGE and western blotting analysis was performed on protein extracted 
from SH-SY5Y cells from 6 different conditions; transfected with PMO 
APP795/124 for exon 7 skipping, transfected with PMO APP839/+6 for exon 8 
skipping, transfected with 1000nM of both PMO APP795/124 and PMO 
APP839/+6 for skipping APP exon 7 and 8, transfected with control PMO E2, 
and non-transfected blank SH-SY5Y cells. The combination of exon 7 and 8 
skipping PMOs were trialled together as it was expected that skipping both 
exons within the same sample with PMOs would lead to the largest increase 
in APP695 levels.  
These western blots were probed with the APP N – terminal antibody 22C11, 
as well as β-actin which acts as a loading control to normalise against and 
ensure that the equal levels of protein were loaded between wells. These 
westerns as well as results of densitometric analysis are shown in figure 5.4. 
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The western blot shows three distinct bands present at the expected size 
between 93-130 kDa for each condition, as expected. In western blots of 
protein samples extracted from both non-transfected blank SH-SY5Y cells and 
SH-SY5Y cells transfected with the control  PMO E2 APP695 accounted for 
12.63% ± 1.31% (N=3) and 12.06% ± 1.65% (N=3) of total APP detected 
respectively. In the positive control (SH-SY5Y cells transfected with an 
APP695 overexpression plasmid), the single, unglycosylated APP695 band 
accounted for the 59% ± 15.72% (N=3) of the total APP present. In protein 
extracts from cells transfected with PMOs for exon 7 skipping the single 
APP695 band accounted for 26.6% ± 2.68% (N=3)  (P<0.005, **) of the total 
APP expressed. Protein extracted from SH-SY5Y cells transfected with PMOs 
for exon 8 skipping, and a combination of PMOs for exon 7 and 8 skipping 
(7+8) showed that the single unglycosylated APP695 made up 20.31% ± 
4.27% (N=3) (P<0.05, *) and 29.11% ± 4.57% (N=3) (0.0005, ***) respectively 
of the total APP detected. All protein samples from SH-SY5Y cells transfected 
with PMOs designed to induce APP exon skipping lead to significant increases 
in the expression of APP695. The highest increase in intensity of the single 
APP695 band and therefore APP695 expression was demonstrated by the 
protein extracts from cells transfected with a combination of PMOs for exon 7 
and 8 skipping together. This western blotting analysis showed that the PMOs 
which were shown to have the best ability to modulate alternative splicing of 
APP at the mRNA level were also able to modulate the isoform expression 




Figure 5.4: Effects of PMOs on APP splicing at the protein level. Western blot showing 
the levels of different APP isoforms present in SH-SY5Y samples treated with PMOs for APP 
exon skipping, or controls. An APP695 WT overexpression plasmid was used as a positive 
control. The antibody used was 22C11 – which is an N-terminal APP antibody. Β-Actin is used 
as a loading control. Protein was extracted from SH-SY5Y cells with RIPA lysis buffer, and 20 
µg of protein was loaded per well on an 4-12% Bis-Tris pre-cast gel run with NuPAGE MES 
buffer. Protein was run against BLUeye Prestained Protein Ladder. Gel visualised with the 
Odyssey CLx Imaging System. (N=3). 
 
 
5.2.5 Confirming the identity of the APP695 
As previously described, it is challenging to distinguish the different APP 
isoforms and their glycosylated forms. We previously transfected SH-SY5Y 
cells with an APP695 expression plasmid as a means of identifying the 
APP695 band, acting as a positive control allowing us to compare this band 
against endogenously produced APP. Another way of confirming the identity 
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of the APP695 isoform was also examined, by means of a panel of epitope 
specific antibodies to confirm that we were are in fact analysing APP695 rather 
than a different isoform or another glycosylated form of APP. The two 
antibodies which were trialled for this were the Anti-APP 770 domain, which is 
specific to the OX2 domain present in APP770, a putative glycosylation 
domain encoded for by exon 8 of APP, and the Anti-APP KPI  domain (Smith 
et al. 2011), which is specific to the Kunitz protease inhibitor (KPI) domain 
encoded for by exon 7 of APP. The OX2 domain is present only in the APP770 
isoform, but is absent from both the APP751 and APP695 isoforms of APP. 
The KPI domain is present in APP770 and APP751 but is absent from APP695 
as this isoform is the only one which does not contain exon 7, which encodes 
this domain. Therefore, these antibodies should be able to detect the APP770 
and APP751 isoforms more specifically, and therefore confirm the identity of 
the APP695 protein band.  
Representative western blots probed with the OX2 antibody on protein 
extracted from SH-SY5Y cells on 4-12% Bis-Tris gels are shown in figure 5.5. 
The western blot was probed with the Rb X APP OX2 and the 22C11 APP NT 
antibody. Probing of this western with the 22C11 N- terminal antibody detected 
three major bands detected in the protein samples extracted from blank control 
SH-SY5Y cells, as well as the protein extracted from the SH-SY5Y cells 
transfected with the control PMO E2. These three bands correspond to the 
mAPP770/m751, imAPP770/im751/m695 bands and the single 
unglycosylated imAPP695, as has been shown previously. When the blot was 
probed with the OX2 specific antibody only two bands were detected, these 
two bands correspond to the top two bands which were detected with the 
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22C11, the mAPP770/m751, imAPP770/im751/m695. The mAPP770/m751, 
imAPP770/im751/m695 band was detected due to the overlap in size between 
the APP770/751 with the APP695  even though the OX2 antibody cannot 
detect the OX2. However, there was no sign of the bottom most band which is 
the single unglycosylated APP695. This confirmed our hypothesis as it shows 
that OX2 is only detected where APP770 is present due to the inclusion of the 
OX2 domain within APP exon 8 and confirms that the bottom most band is the 










Figure 5.5: Differential detection of APP with the 22C11 and OX2 antibodies. 
Representative western blot probed with the 22C11 N- terminal APP antibody, OX2 specific 
APP antibody and β-actin demonstrating the differences in APP detection. Protein was 
extracted from SH-SY5Y cells with RIPA lysis buffer, and 20 µg of protein was loaded per well 
on an 4-12% Bis-Tris pre-cast gel run with NuPAGE MES buffer. Protein was run against 





Representative western blots probed with the KPI antibody on protein 
extracted from SH-SY5Y cells on 4-12% Bis-Tris gels are shown in figure 5.6. 
This western blot was also probed with the APP N- terminal antibody 22C11, 
as well as β-actin as a loading control. A 4-12% Bis-Tris gel with NuPAGE 
MES buffer was used for this purpose. The KPI domain which this antibody is 
specific to is encoded by APP exon 7, and therefore can be detected in both 
of the APP770 and APP751 isoforms, but not in APP695. This antibody can 
again be used to confirm the identity of the APP695 band. Figure 5.7 shows 
that the bands which were detected by the KPI antibody corresponds to the 
mAPP770/m751 band, and the imAPP770/im751/m695 bands which 
correspond to the same bands with the 22C11 antibody. Again, the only band 
which was not detected was the unglycosylated immature APP695 band. This 
confirms that the band which have been used for analysis thus far were indeed 
the APP695 rather than a different isoform or glycosylated version of APP. 
With all these different means of confirming the identity of APP695 we can 
move forward with confidence that this band can only be APP695. This means 
that the analysis conducted in this chapter is reliable validating the fact that 
these PMOs are able to modulate alternative splicing, and these changes are 












Figure 5.6: Differential detection of APP with the 22C11 and KPI  antibodies. 
Representative western blot probed with the 22C11 N- terminal APP antibody, KPI specific 
APP antibody and β-actin demonstrating the differences in APP detection. Protein was 
extracted from SH-SY5Y cells with RIPA lysis buffer, and 20 µg of protein was loaded per well 
on an 4-12% Bis-Tris pre-cast gel run with NuPAGE MES buffer. Protein was run against 











The purpose of the work conducted in this chapter was to determine whether 
the effects of the PMOs which were designed to modulate the exon skipping 
of APP at the pre-MRNA level are detectable as changes in APP protein 
expression. In order to analyse APP protein western blotting was conducted 
as previous research had shown this method to be effective at measuring 
levels of APP protein (Belyaev et al. 2010). 
Optimisation of the SDS-PAGE system and protein preparation was required 
in order to determine the best method to adequately measure APP protein. 
Comparisons were done between hand-cast Tris-glycine gels, and pre-cast 
Bis-Tris gels at different acrylamide percentage in order to determine the 
optimal conditions for APP separation. The major difference between these 
two systems was the operating pH, with the Tris-glycine system running at a 
pH of 9.2, while the Bis-Tris runs at a more neutral pH of 7.2. The more neutral 
running pH of the Bis-Tris gels have been shown to promote increased sample 
integrity and gel stability which results in better resolution and protein 
separation, therefore it was assumed that the Bis-Tris gel would show optimal 
conditions for separation (Hachmann & Amshey 2005). When comparing gel 
percentages, the 10% Tris-glycine gel showed the least separation of the three 
polyacrylamide percentages tested, followed by the 4-16% Tris-glycine and 
the 4-12% Bis-Tris which showed the best separation. The 4-12% Bis-Tris 
allowed for the optimal separation of the APP bands which cluster between 
93-130 kDa as it is has a lower percentage at the top end where this separation 
takes place, and the gel percentage increases slower going down the gel 
compared to the 4-16% gels. Following this the two lysis buffers were tested, 
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the RIPA buffer and the NP40 lysis solution. The NP-40 lysis solution is 
generally considered to be a milder lysis buffer and is generally used when 
lysates of whole cell proteins are required, whereas RIPA buffer is considered 
harsher as it contains SDS, this means it is able to break down the cell nucleus 
and solubilise nuclear proteins. The western blots comparing the RIPA buffer 
and NP40 lysis solution suggest that RIPA buffer allows for the extraction and 
subsequent detection of more APP compared to the NP40 lysis solution as the 
three major APP bands are sharper and appear to be detectable at higher 
amounts. This could be as a result of the SDS containing RIPA lysis buffer 
releasing nuclear APP which would otherwise not be extracted with the NP40 
lysis solution. Belyaev et al demonstrated the separation of APP using SDS-
PAGE, the system used differed with that which were used in this chapter as 
higher percentage acrylamide gels were used (7-7% polyacrylamide gels vs 
4-12% Bis-tris gels) and more protein was loaded onto these gels (30-40µg of 
protein compared with 20µg of protein). Despite the differences in the systems 
used, Belyaev et al demonstrated similar levels of expression as well as 
separation of the APP isoforms. Belyaev et al also demonstrated the detection 
of three major APP protein bands, the matureAPP770/mAPP751, the 
immatureAPP770/imAPP751/mAPP695, and the mAPP695 through western 
blotting analysis with the 22C11 antibody (figure 5.5). This pattern of APP 
protein banding had previously been demonstrated using the 22C11 antibody, 
and showed a similar pattern of APP isoform expression to the controls in 
figure 5.3  (Belyaev et al. 2010). The work conducted by this group 
demonstrated an increase in APP695 protein levels by 2-fold through 
transfection with an APP695 overexpression plasmid compared to control 
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mock transfected cells. This is identical to the fold-change shown in the protein 
extracts from SH-SY5Y cells transfected with a combination of PMO 
APP795/124 + PMO APP839/+6 showing that PMO transfection is a good way to 
increase levels of APP695.  
The work presented here as well as previous work have demonstrated the 
difficulty in detecting single APP isoforms due to the overlaps in the sizes of 
mature and immature APP isoforms which have been previously described. In 
order to confirm the identity of the APP695 isoform and confirm that the protein 
band which is being analysed is in fact the APP695 multiple methods were 
used. Protein was extracted from SH-SY5Y transfected with an APP695 
overexpression plasmid. These samples were used to confirm the identity of 
the APP695 by determining which APP protein band increased as a result of 
the treatment. The analysis showed that the there was an increase detected 
in the strength of the two bottom protein bands, which is expected as they both 
contain mature or immature APP respectively. However, this method was 
unable to confirm whether the bottom most band was solely the APP695, and 
therefore another method was used to further narrow down the identity of the 
APP695.  
The APP OX2 specific antibody and the APP KPI specific antibody were used 
to differentially determine the identity of APP695 as neither of these antibodies 
is able to detect the APP695. As APP695 contains neither of the exons which 
are associated with the KPI or OX2 domains which these antibodies are 
specific to, western blotting with these antibodies should be unable to detect 
this isoform and therefore confirm the identity of the single unglycosylated 
imAPP695 band. Figures 5.5 and 5.6 show the representative western blots 
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using the OX2 and KPI antibodies, respectively. The OX2 antibody, which is 
able to detect mature and immature APP770, shows detection of two of the 
three major APP bands, with the single immature APP695 protein band not 
being detected by this antibody. The KPI antibody, which is able to detect 
mature and immature APP770 and APP751, again shows detection of the 
same two APP bands between 93-130kDa, with only the bottom most band 
being absent. This means this bottom band cannot contain either of APP770, 
or APP751 and therefore can only be the APP695. From the data gathered by 
the relative size of this band, the positive control, the OX2 antibody, and the 
KPI antibody we can confirm that the bottom most APP band around 93kDa 
can only be the unglycosylated imAPP695, and we can continue this analysis 
with confidence.   
The data presented in this chapter confirms the ability of PMOs designed for 
the induction of exon skipping of exon 7 and 8 of APP at also inducing a 
change in the expression of APP695 protein. These results show similarity to 
the results demonstrated at the RNA level in chapter 4. The largest increase 
in the expression of APP695 was demonstrated in the RNA extracts from SH-
SY5Y cells which were transfected with PMO APP795/124, which showed an 2-
fold increase in APP695 levels compared to control SH-SY5Y cells (83.94.6% 
compared with 42.27.4%), the fold increase here is similar to that shown in 
the change in APP695 protein in SH-SY5Y cells transfected with this PMO 
compared to controls (26.6% ± 2.68% compared with 12.63% ± 1.31% in 
control cells). At the RNA level, the use of a combination of PMOs was unable 
to increase the expression of APP695 to the same levels as the best exon 7 
skipping PMO, PMO APP795/124, alone . However, at the protein level, a 
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combination of PMOs APP795/124 and APP839/+6 showed the largest increase 
in APP695 protein level (29.11% ± 4.57%), a 2.3-fold increase in APP695 
expression compared with controls. However there does not appear to be  
correlation between the changes in the levels APP695 before and after PMO 
transfection between the mRNA and protein. This is likely due to the generally 
weak correlation between mRNA and protein expression profiles. Studies of 
mRNA expression have shown that the correlation between mRNA and protein 
expression account for only ~40% of explanations (Koussounadis et al. 2015). 
It is possible that certain genes, such as such as cell cycle and secreted 
proteins, show higher levels of correlations (Koussounadis et al. 2015). 
Although it is accepted that the nucleotide sequence of a gene determines the 
sequence of its mRNA, and in a similar manner the sequence of the mRNA 
determines the amino acid sequence of the resulting protein, various studies 
have shown that this relationship between the transcript and protein 
expression go beyond just transcript concentration (McManus et al. 2015). 
Processes which affect protein expression other than the transcript 
concentration include; rate of translation of the protein, modulation of 
translation through non-coding RNA binding, relative transcript availability, 
modulation of protein half-life, protein synthesis delay and protein transport 
(Liu & Aebersold 2016). Therefore, comparisons between proteins and mRNA 
expression are not always directly applicable. Overall, this chapter succeeded 
in proving that PMOs designed for the induction of exon skipping of APP exons 
7 and 8 are able to increase the expression of the APP695 protein isoform. 
However, in order to gain a clearer insight of the effects of PMOs on APP695 
expression at the protein level, experiments such as PMO concentration 
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gradients could be conducted. This could give greater insights into the 
maximal concentration of PMO that can be administered without inducing 
toxicity, and also the maximal increase in expression that can be achieved 
using these PMOs. Another experiment that could be conducted is a time 
course of transfections, incubating SH-SY5Y cells for various time points post 
transfection before protein extraction. This could provide better understanding 














6 Downstream effects of APP alternative splicing 
6.1 Introduction 
Processing of APP occurs via either of two main processing pathways which 
involves the sequential processing of APP with two different secretases. These 
pathways are often termed the α- or β-secretase pathways, and both pathways 
utilise processing via γ-secretase as their second step (Zhang et al. 2011). 
The γ-secretase complex is an aspartyl protease which has been 
demonstrated to induce a process commonly referred to as regulated 
intramembrane proteolysis (RIP) and has been commonly associated with 
important cellular signalling pathway processes (Zhang et al. 2011; Grimm et 
al. 2013). Many type-1 membrane proteins such as Notch and APP undergo 
processing via this pathway which has been shown to lead to the release of 
the intracellular domains (ICDs) of these substrates (Grimm et al. 2013; 
Kerridge et al. 2014). In the processing of APP, γ-secretase processes the C-
terminal fragment (CTF) of APP that is produced through either α- or β-
secretase, often termed the α-CTF or β-CTF, depending on which secretase 
they were first cleaved by. Proteolytic processing of the either the α-CTF or β-
CTF of APP by γ-secretase release the amyloid intracellular domain (AICD). 
Interestingly, the processing of Notch through RIP leads to the release of the 
Notch intracellular domain (NICD), a small peptide which has been 
demonstrated to have the ability to translocate into the nucleus, and regulate 
gene transcription for various genes which are critical in developmental 
pathways (Ross & Kadesch 2001; Zhang et al. 2011). Both APP and Notch 
undergo RIP, are proteolytically processed by γ-secretase in a similar manner, 
and release ICDs through their processing. As a result of this analogous 
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nature, it was proposed that the AICD acted in a similar manner to the NICD 
with its ability to translocate to the nucleus, and act as a transcriptional 
regulator (Kerridge et al. 2014; Pardossi-Piquard & Checler 2012). In fact, the 
term AICD was initially coined due to this similarity to the NICD (Belyaev et al. 
2010).  In recent years research has confirmed a signalling pathway involving 
the AICD interacting with the adaptor protein Fe65, translocating to the 
nucleus and forming a complex with a histone acetyltransferase (Tip60) and 
direct regulation of multiple genes and signal transduction by this complex 
(Müller et al. 2008; Belyaev et al. 2009; Zhang et al. 2011). Some of the genes 
known to be regulated by the AICD include APP, neprilysin (NEP), 
transthyretin (TTR), aquaporin-1 (AQP1), GSK-3β, and p53 (Zhang et al. 
2011; Grimm et al. 2013; Kerridge et al. 2014). Most important among these 
genes are Neprilysin (NEP), an enzyme which acts to degrade Aβ, the 
principal neurotoxic peptide in AD, this makes it of great importance to AD 
(Belyaev et al. 2009; Schmidt et al. 2009; Belyaev et al. 2010; Kerridge et al. 
2014). It has been shown that AICD binds directly to the NEP promoter 
causing transcriptional activation and an increase in NEP mRNA, protein and 
activity levels (Belyaev et al. 2009; Belyaev et al. 2010). This increase in NEP 
expression was shown to be primarily neurone specific, with transcriptionally 
active AICD up-regulating NEP demonstrated to derive only from the neuronal 
isoform of APP, APP695, whereas the APP751 and APP770, produced mainly 
cytoplasmic AICD which showed no transcriptional activation (Belyaev et al. 
2010; Kerridge et al. 2014). As NEP is a key contributor to the degradation of 
Aβ, its up-regulation through the effects of APP695, and therefore the AICD 
represents a potential therapeutic avenue for the treatment of AD (Belyaev et 
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al. 2009;  Belyaev et al. 2010). AQP1 is another gene which is regulated by 
the AICD, it is a membrane water channel protein that has been seen to be of 
relevance to AD (Misawa et al. 2008; Hoshi et al. 2012). In the brain, up-
regulation of AQP1 expression has been observed in the early stages of AD, 
and in these brains AQP1 was demonstrated to be expressed by astrocytes 
located in close proximity to senile amyloid plaques (Huysseune et al. 2009).. 
Furthermore, recent research by Park et al. demonstrated that ectopic 
expression of AQP1 in human neuroblastoma cells lines which contain the 
APPswedish mutation, and therefore overexpress Aβ, reduced the levels of 
BACE1-mediated cleavage of APP, thus decreasing the levels of Aβ 
production (Park et al. 2021). It was also demonstrated that knockdown of 
AQP1 in cells increased BACE1 activity and Aβ production. These results 
suggest a role for AQP1 inhibiting the interaction between BACE1, and makes 
this an important target for assessment (Huysseune et al. 2009; Park et al. 
2021). TTR is yet another gene which is regulated by the AICD; it is a major 
Aβ binding protein, which facilitates the clearance of Aβ preventing the toxicity 
which is associated with Aβ (Kerridge et al. 2014).  TTR has been shown to 
be regulated at both the mRNA and protein levels by direct AICD binding to 
gene promoters as a result of APP695 overexpression (Kerridge et al. 2014).  
The AICD exists as multiple peptides which vary in length. This diversity is due 
to multiple factors which include the fact that APP processing via the α- and β-
secretase pathways are localised to different subcellular compartments, and 
importantly, the imprecise nature of γ-secretase (Grimm et al. 2015; Bukhari 
et al. 2017). The multiple cleavage sites of γ-secretase result in the production 
of AICD peptide fragments of different sizes. The AICD57 and AICD59 are two 
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such peptides which are generated due to this imprecise cleavage. Both of 
these peptides encompass the 47 amino acid APP cytoplasmic region and 
either 10 or 12 amino acids of the transmembrane domain (Kerridge et al. 
2014). Cleavage of APP at the ε-cleavage site leads to the formation of the 
AICD50 and/or AICD51 peptides (Kerridge et al. 2014). The AICD50 is thought 
to be the main species of AICD that is produced is the, and this is considered 
the typical form of the AICD (Chow et al. 2010; Pardossi-Piquard & Checler 
2012). 
These are but a few of the genes which are regulated by the AICD, and they 
have shown clear relevance to AD through either acting to clear or degrade 
Aβ, thus the upregulation of this AICD may be a potential therapeutic target in 
AD. A study by Kerridge et al showed that up-regulation of NEP and TTR 
through overexpression of APP695 significantly decreased the levels of Aβ in 
SH-SY5Y cells (Kerridge et al. 2014). Therefore, in terms of potential 
therapeutic approaches in AD, targeting APP695 in order to increase the levels 
of the AICD could provide a significant benefit in reducing Aβ load on the brain. 
We have previously shown the ability of PMOs which were designed to skip 
APP exon 7 and 8 to modulate the splicing of APP in SH-SY5Y cells RNA, and 
the effect of this on increasing the expression of APP695 protein. 
Theoretically, this increase in APP695 should lead to a subsequent increase 
in the transcriptionally active AICD. In this chapter, we attempt to 
experimentally confirm whether increasing APP695 through the modulation of 
APP alternative splicing leads to increases in the levels of AICD, and whether 
this AICD is transcriptionally active and able to modulate gene expression of 




6.2.1 Immunocytochemical analysis of APP N and C terminal 
The data presented in the previous chapter showed that PMOs designed to 
modulate APP alternative splicing were successful and lead to substantial 
increases in the levels of APP695. The largest increase in APP695 levels 
when compared to control SH-SY5Y cells was observed in protein samples 
extracted from cells transfected with a combination of PMO APP795/124 and 
PMO APP839/+6 designed for the modulation of APP exon 7, and exon 8. The 
next highest increase in APP695 expression was seen in the protein samples 
extracted from SH-SY5Y cells transfected with PMO APP795/124, followed by 
the extracts from cells transfected with PMO APP839/+6.  The extracts from the 
samples which were transfected with the control PMO E2 showed no increase 
in APP695 with the levels being similar to those of blank control SH-SY5Y 
cells. As previously stated, one of the biologically active peptides formed from 
APP cleavage is the AICD, and when this is specifically cleaved from APP695 
the AICD which is produced is able to translocate to the nucleus and act as a 
transcription factor for various genes (Słomnicki & Leśniak 2008; Pardossi-
Piquard & Checler 2012). In order to investigate whether there was indeed an 
increase in in the levels of AICD due to the increase in APP695 expression 
seen in the previous chapters, SH-SY5Y cells were transfected with PMOs for 
APP exon skipping, followed by double immunolabelling of these SH-SY5Y 
cells with specific APP N and C terminal antibodies followed by confocal 
microscopy. 
SH-SY5Y cells transfected with 1µM of PMO APP795/124, PMO APP839/+6, and 
a combination of PMOs  APP795/124 and APP839/+6 as well as Blank control, and 
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E2 control SH-SY5Y cells were immunolabelled with the 22C11 APP N 
Terminal, and A8717 APP C Terminal antibodies (Ge et al. 2004; Huang et al. 
2006; Chua et al. 2013; Kerridge et al. 2014; Maloney et al. 2014). The 22C11 
antibody recognition epitope is between amino acids 66-81 of APP at the N 
terminal and therefore should be able to detect all three major isoforms of APP, 
whereas the recognition epitope of the A8717 antibody is in a region between 
676-695 amino acids of the C-terminal of APP and therefore should also be 
able to detect all three isoforms of APP, but also has the ability to detect the 
AICD fragment which is cleaved from APP. If there was indeed an increase in 
AICD which is cleaved specifically from the APP695, this should be detectable 
in the nucleus of these SH-SY5Ys given the ability of APP695 derived AICD 












Figure 6.1: Immunofluorescence images showing the distribution of APP N- and C- 
terminal staining in SH-SY5Y cells. Representative images of immunolabelling with the Anti-
APP N-terminus specific 22C11 antibody (Red) and the Anti-APP C-terminus specific A8717 
antibody (Green) in SH-SY5Y cells. Cells were seeded in 12-well plates containing coverslips 
with 200,000 cells/well and incubated for 24 hours before being transfected with 1µM of the 
appropriate PMO, either PMO APP795/124, PMO APP839/+6, or a combination of PMO APP795/124 
and PMO APP839/+6. Cells were fixed with 4% PFA before being immunolabelled with the 
appropriate antibodies and Hoechst for nuclear staining. Cells were mounted onto microscope 
slides with ProLong Gold Anti-Fade mountant. Cells were visualised with a spinning disc 
confocal system (CARV II from Digital Imaging Solutions) with an EM-CD Camera using the 






As shown in figure 6.1, staining with the 22C11 N-terminal specific antibody 
revealed staining distributed throughout the cell membrane as well as strong 
perinuclear staining for SH-SY5Y cells under all conditions. A similar 
distribution was also observed for the A8717 C-terminal specific APP antibody. 
These observations were consistent for all PMO transfected SH-SY5Y cells, 
as well as control cells. These results suggest that the proteins detected by 
these antibodies are confined to the same cellular compartments, meaning 
that no nuclear translocation of the AICD can be observed. This could 
potentially be due to the levels of the AICD being too low to be detectable. 
Previous research has also reported that the AICD is rapidly degraded under 
normal conditions, which could potentially explain the results seen here. 
As there were no clear differences detected between the localisation or pattern 
of staining of the different conditions between the two antibodies used, and 
there was no significant increase in the staining within the nucleus when 
comparing control SH-SY5Y cells to transfected cells, immunolabelling with 
another C- terminal specific antibody was performed. The anti-AICD Poly8119 
antibody used here was epitope specific to the AICD (figure 6.2), and 
therefore, unlike the A8717 C-terminal APP antibody, should show only the 
specific AICD staining and no APP staining when used for 
immunocytochemistry (Stieren et al. 2011; Tampellini et al. 2011). This 
antibody was specific to the C50 and C53 variants of AICD but does not react 
with C57 or C59 variants. Immunocytochemistry with this antibody revealed a 
different staining profile compared to the A8717 C-terminal APP antibody in 
figure 6.1. A strong concentrated dotted staining within the nucleus of the SH-
SY5Y cells and more granular staining was detected throughout the SH-SY5Y 
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cells in blank, and the PMOE2 control SH-SY5Y cells as well as in the SH-
SY5Y cells transfected with 1µM of PMO APP795/124, PMO APP839/+6, and a 
combination of PMOs  APP795/124 and APP839/+6 together (figure 6.2). The 
strong dotted staining within the nuclei of these SH-SY5Y cells suggests the 
presence of transcriptionally active AICD that has translocated to the nucleus. 
This staining does not co-localise with the APP N- terminal staining of the 
22C11 antibody. However, as this dotted staining in the nucleus of the SH-
SY5Y cells is present in all PMO transfected cells as well as in control SH-
SY5Y cells (E2, blank), it can be concluded that the AICD visualised within the 
cell nuclei were not solely present as a result of the increased APP695 
expressed as a result of modulating APP alternative splicing with exon 
skipping PMOs. 
However, to further investigate if induction of exon skipping affects the levels 
of nuclear AICD, quantification of nuclear staining was undertaken. To do so, 
at least 100 cells per condition on multiple coverslips were counted and the 
percentage of cells under each condition which show red nuclear AICD 
staining was calculated (figure 6.3). This analysis showed that for the controls 
45.2% of all cells counted showed red nuclear staining. Comparing this to the 
PMO transfected cells, cells transfected with PMO7 showed the highest 
percentage staining with 42.15% (p>0.05, non-significant) of cells showing red 
nuclear staining, PMO8 having 41.9% (p>0.05, non-significant) of cells with 
red nuclear staining, and PMO7+8 combined showing the lowest percentage 
staining with 36.5% of cells showing this staining (p>0.05, non-significant). 
Statistical analysis was undertaken by a one-way ANOVA followed by a 
Tukey’s multiple comparison test and showed no significant difference in the 
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AICD levels between SH-SY5Y cells transfected with PMOs, and control SH-
SY5Y cells (p>0.05). From this analysis it can be concluded that PMO 
transfection and increases in APP695 have no effect on the number of cells 
with nuclear AICD staining detected by anti-AICD antibody. Even though there 
appears not to be extensive colocalization between the staining of the anti-
AICD antibody and the staining of the 22C11 N-terminal specific antibody, it is 








Figure 6.2: Immunofluorescence images showing the distribution of APP N- and C- 
terminal staining in SH-SY5Y cells. Representative images of immunolabelling with the Anti-
APP N-terminus specific 22C11 antibody (Green) and the Anti-AICD Poly8119 antibody (Red) 
in SH-SY5Y cells. Cells were seeded in 12-well plates containing coverslips with 200,000 
cells/well and incubated for 24 hours before being transfected with 1µM of the appropriate 
PMO, either PMO APP795/124, PMO APP839/+6, or a combination of PMO APP795/124 and PMO 
APP839/+6. Cells were fixed with 4% PFA before being immunolabelled with the appropriate 
antibodies and Hoechst for nuclear staining. Cells were mounted onto microscope slides with 
ProLong Gold Anti-Fade mountant. Cells were visualised with a spinning disc confocal system 
(CARV II from Digital Imaging Solutions) with an EM-CD Camera using the image pro 












Figure 6.3: Bar chart demonstrating the percentage of SH-SY5Y cells which were 
counted to contain nuclear AICD staining. Images were taken of 100 SH-SY5Y cells for 
each condition, and the number of cells which showed evidence of nuclear AICD staining were 
counted as positive, with the remaining counted as negative. The number of cells which were 






























































6.2.2 Western blotting to detect downstream effects of PMOs 
As the data collected via immunocytochemistry was inconclusive in terms of 
detecting the AICD within SH-SY5Y cells western blots using the same 
antibodies were then conducted in an attempt to detect the presence and 
quantify the levels of the AICD peptide levels.  
SH-SY5Y cells were either left non-transfected as a control (blank), 
transfected with the control PMO (E2), transfected with an APP695 
overexpression plasmid as a positive control or transfected with PMOs for APP 
exon skipping. Protein was extracted from these SH-SY5Y cells 48-hours post 
transfection, and western blotting was performed using the NuPage 4-12% 
Bis-Tris gel system with MES buffer. This system with MES buffer allows for 
the optimal separation of both large and small proteins, allowing for the 









Figure 6.4: AICD detection using the APP N- and C- terminal antibody. Representative 
western blotting images comparing the APP N- terminal antibody 22C11, and the APP C- 
terminal antibody A8717 and their ability to detect APP and the AICD in control and PMO 
transfected cells. SH-SY5Y cells were transfected with PMO APP795/124, PMO APP839/+6, or a 
combination of PMO APP795/124 and PMO APP839/+6,the control PMO E2,left non-transfected 
(blank) as controls, or transfected with an APP695 overexpression plasmid as a positive 
control. A.) Immunoblotting of APP using the APP N- terminal antibody 22C11 showing the 
detection of APP between 93-130kDa, and the lack of detection of any AICD at 6kDA B.) 
Immunoblotting of APP using the APP by the C- terminal antibody A8717 again showing 
expression of APP between 93-130kDa and the detection of a band at 6kDa for the +ve control 
transfected cells, and potential faint expression in the protein extracts from PMO transfected 
cells  C.) Overexpressed version of image of  the bottom region of the APP C- terminal blot 
with contrast manipulated to more clearly show the proteins that are present at very low levels 
at 6kDa for the protein extracts from SH-SY5Y cells transfected with PMO APP795/124, PMO 
APP839/+6, and a combination of PMO APP795/124 and PMO APP839/+6. Protein was extracted 
from SH-SY5Y cells with RIPA lysis buffer, and 20 µg of protein was loaded per well on an 4-
12% Bis-Tris pre-cast gel run with NuPAGE MES buffer. Protein was run against BLUeye 







As previously described, there was strong detection of all three isoforms of 
APP by the 22C11 APP N- terminal antibody between 95-130kDa (figure 
6.4A). However due to the similarity in sizes between the three isoforms, and 
the overlaps between the mature/immature variants of these proteins, three 
major bands were detected. In the protein extracts from the positive control, 
intense banding representing the immatureAPP695 band and 
imatureAPP770/imatureAPP751/matureAPP695 bands were detected with 
the N-terminal APP antibodies. These three major bands were present in 
protein extracts from all conditions. A closer inspection around the 6kDa mark 
where the AICD would be present revealed that no bands were detected with 
the APP N-terminal antibody as expected.  
Immunoblotting with the APP C- terminal antibody A8717 (figure 6.4B) 
detected products similar to those of the N- terminal antibody for the three 
major APP isoforms in all conditions. However, at the 6kDa mark, the C- 
terminal antibody detected a single band which is evident in the protein 
samples from cells transfected with the APP695 overexpression plasmid (+ve 
control). There appears to be no detection of AICD in the PMO transfected or 
control protein extracts, however upon overexposure of this blot (figure 6.4C), 
the presence of bands of similar sizes could also be seen in protein samples 
from cells transfected with the PMOs but not in samples of control cells. This 
western shows us that detection of AICD is possible in these conditions, 
however, these results should be interpreted with caution since the levels of 
the AICD fragments are very low.  
As low levels of the AICD peptide were detected in protein extracts from PMO 
transfected SH-SY5Y cells with the APP A8717 C- terminal antibody these 
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westerns were repeated with the AICD specific Poly8119 antibody. This 
antibody was used as it was previously successful in detecting the AICD 
through immunocytochemistry and therefore may allow for greater specificity 
and provide better detection of the AICD protein through western blotting. 
Immunoblotting with this antibody showed a single band was present between 
95-130kDa, this was interesting as this antibody is supposed to be specific to 
only the AICD C50 and C53, which would result in a protein band around 6kDa, 
and therefore the identity of the single protein band remains unclear. Around 
the 6kDa mark where the AICD was expected to be detected, there were no 
bands present for the blank control, E2 control as expected (figure 6.5). 
Analysis of the extracts from PMO transfected SH-SY5Y cells showed no clear 
signs of AICD present around the 6kDa mark, this was unexpected and 
opposed the results demonstrated by immunoblotting with the A8717 C-
terminal APP antibody. Protein extracted from SH-SY5Y cells transfected with 
the APP695 overexpression plasmid (positive control) showed no indication of 
AICD protein at the 6kDa mark, this is in contrast to the A8717 C- terminal 
APP antibody, as this sample showed the highest expression of AICD protein 
with this antibody, therefore it was expected that AICD would also be the most 






Figure 6.5: AICD detection using the AICD specific APP antibody. Representative 
western blots of protein extracted from SH-SY5Y cells were transfected with PMO APP795/124, 
PMO APP839/+6, or a combination of PMO APP795/124 and PMO APP839/+6,the control PMO 
E2,left non-transfected (blank) as controls, or transfected with an APP695 overexpression 
plasmid as a positive control. Blots were probed with the AICD specific antibody Poly8119. 
Shows the presence of a single band present between 95-100kDa, and a lack of detection of 
any protein at 6kDa, and therefore a lack of the AICD. Protein was extracted from SH-SY5Y 
cells with RIPA lysis buffer, and 20 µg of protein was loaded per well on an 4-12% Bis-Tris 
pre-cast gel run with NuPAGE MES buffer. Protein was run against BLUeye Prestained 

















6.2.3 Functional assay for the detection of AICD function 
As detection of the AICD through immunolabeling was inconclusive, but  
western blotting was able to detect the AICD, the next step involved 
investigating whether induction of exon skipping with PMOs was associated 
with an increase in the expression of known downstream targets. Therefore, 
RT-qPCRs were conducted and utilised in order to analyse specific genes that 
have been shown to be transcriptionally regulated by the AICD and determine 
whether the expression levels of these genes increase or decrease in relation 
to transfection with our PMOs modulating the alternative splicing of APP. RT-
qPCRs were performed on mRNA extracted from SH-SY5Y cells that have 
been transfected with PMOs for skipping exon 7, 8 and 7+8 combined, as well 
as the control PMO E2 and a blank non-transfected control. The two genes 
which were analysed for changes in expression pattern were neprilysin (NEP) 
and aquaporin-1 (AQP1). β- Actin was used as a housekeeping reference 
gene.  
RT-qPCRs of RNA extracted from SH-SY5Y cells transfected with 1µM PMO 
APP795/124, revealed differences in the expression levels of NEP by 7.16 ± 
1.87-fold compared to the expression levels in non-transfected control cells 
(blank) (normalised to 1; figure 6.6a). This was a significant increase 
(p<0.0001, ****) suggesting that AICD levels were increased, most likely as a 
consequence of an increase in APP695 due to PMO APP795/124 modulating 
the splicing pattern of APP, increasing APP695. RT-qPCRs in RNA extracted 
from SH-SY5Y cells transfected with 1µM PMO APP839/+6 revealed differences 
in the expression of NEP by 4.45 ± 0.99-fold compared to the expression levels 
in control cells only (normalised to 1) this was also a significant increase 
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(p<0.01, **). RT-qPCRs of RNA extracted from SH-SY5Y cells transfected with 
1µM PMO APP795/124 and PMO APP839/+6 combined demonstrated changes in 
expression levels of NEP by 1.72 ± 0.58-fold compared to control cells; this 
change was non-significant (p>0.05), this suggests that there was not a 
significant increase in levels of AICD in these samples, and therefore not a 
significant increase in NEP.  Performing RT-qPCRs with RNA extracted from 
SH-SY5Y cells  transfected with the control PMO E2 revealed differences in 
the expression levels of NEP by 1.06 ± 0.14-fold compared to control, non-
transfected cells only, this change in NEP expression was non-significant 
(p>0.05) and only marginally increased compared to the blank cells which 
were normalised to 1. The results obtained for NEP with these RT-qPCRs 
were similar to those obtained for the expression levels of APP695 at the RNA 
level in chapter 4. As the transfection of SH-SY5Y cells with PMOs for the 
induction of APP exon skipping were able to increase APP695 levels, and 
were now demonstrated to increase the levels of NEP, we can therefore 
extrapolate that this increase in NEP expression is due to the change in 
APP695 increasing transcriptionally active AICD. 
RT-qPCRs of RNA extracted from SH-SY5Y cells transfected with 1µM PMO 
APP795/124, revealed differences in the expression levels of AQP1 by 11.39 ± 
4.9-fold compared to the expression levels in blank cells (figure 6.6b). This 
was a significant increase (p<0.0005, ***) suggesting that AICD levels were 
increased as a consequence of PMO treatment modulating APP alternative 
splicing. RT-qPCRs in RNA extracted from SH-SY5Y cells transfected with 
1µM PMO APP839/+6 revealed differences in the expression of AQP1 by 4.49 
± 0.15-fold compared to the expression levels in blank SH-SY5Y cells 
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(normalised to 1) although this showed an increase in AQP1 expression, this 
was shown to be non-significant  (p>0.05). qPCRs of RNA extracted from SH-
SY5Y cells transfected with 1µM PMO APP795/124 and PMO APP839/+6 
combined demonstrated changes in expression levels of AQP1 by 3.28 ± 0.53-
fold compared to control cells, this change was also non-significant (p>0.05), 
even though an increase was demonstrated.  Performing RT-qPCRs with RNA 
extracted from SH-SY5Y cells  transfected with the control PMO E2 revealed 
negligible increases in the expression levels of AQP by 1.15 ± 0.11-fold 
compared to blank cells, this change in AQP1 expression was non-significant 
(p>0.05). The results obtained for AQP1 with these RT-qPCRs were similar to 

















Figure 6.6: RT-qPCR analysis of NEP and AQP1 expression in SH-SY5Y cells. RT-qPCR 
analysis of mRNA extracts from SH-SY5Y cells transfected with 1µM PMO795/124, 839/+6, a 
combination of these two (7+8), E2, or non-transfected cells (blank) as a negative control. A) 
RT-qPCR showing the expression of NEP in SH-SY5Y cells transfected with PMOs 7, 8, 7+8 
combined and E2. Expression levels are compared to control non-transfected SH-SY5Y cells. 
B) RT-qPCR showing the expression of AQP1 in SH-SY5Y cells transfected with PMOs 7, 8, 
7+8 combined and E2. Expression levels are compared to control non-transfected SH-SY5Y 
cells. All samples were amplified in technical triplicates. β-actin was used as a reference gene 
to compared expression levels against. Gene expression was defined based on the threshold 
cycle (Ct), and relative expression levels were calculated using the 2-ΔΔCt method, where 











Agarose gel electrophoresis was performed on qPCR products to ensure that there 
was only a single product being produced and detected rather than multiple PCR 
products, or any primer dimers being formed that would have interfered with the 
results obtained from the qPCR (figure 6.7). The gel electrophoresis showed that 
there was a single distinct band detected for both the NEP, and AQP primer sets at 
the expected band sizes. This validates the results of the qPCR as it proves that the 










Figure 6.7: Validation of NEP and AQP1 primers. Representative gel image of the qPCR 
products for NEP and AQP1 qPCRs run on a 2% agarose gel with 1x TAE buffer. After 
completion of the qPCR cycle, 384-well plate was quickly removed from LightCycler480 qPCR 
machine and samples were prepared by the addition of 5x loading dye and  loaded onto a 2% 











The aim of this chapter was to describe the downstream effects of modulating 
the alternative splicing of APP in SH-SY5Y cells on the AICD, and in particular 
transcriptionally active AICD. Previously,  research has suggested that the 
AICD which is produced through the proteolytic processing of the APP695 
isoform is transcriptionally active and acts as a transcriptional regulator for a 
variety of genes (Belyaev et al. 2010). Genes which are regulated by the AICD 
include NEP; a key Aβ degrading protein, and AQP1; a water channel protein 
which has been shown to play a role in the clearance of Aβ from the AD brain 
(Hoshi et al. 2012). The ability of the PMOs designed in this thesis in regard 
to induction of alternative splicing and increasing APP695 have been 
demonstrated at the RNA level (chapter 4) and  this change in alternative 
splicing has been shown to change the isoform expression pattern of APP 
protein through western blotting (chapter 5). According to the literature, this 
should therefore lead to a subsequent increase in transcriptionally active AICD 
(Belyaev et al. 2010).  
Initial efforts to verify this increase in AICD were based on research which 
suggested that transcriptionally active AICD is able to translocate to the 
nucleus (Słomnicki & Leśniak 2008; Pardossi-Piquard & Checler 2012). 
Therefore, immunocytochemistry was conducted utilising three different 
antibodies which were specific to different epitopes of APP, an N-terminal 
specific APP antibody (22C11), a C-terminal APP antibody (A8717) and an 
antibody which was specific to the AICD peptide itself (Poly8119). The 22C11 
and A8717 antibodies showed identical staining profiles with the staining of 
both of these antibodies showing co-localisation (figure 6.1). This was 
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unexpected, as the A8717 C-terminal antibody detects an epitope which 
allows for the detection of all three APP isoform (APP770, APP751, APP695), 
but also the AICD, whereas the 22C11 antibody is only able to detect the three 
APP isoforms but not the AICD as this is cleaved from the C-terminus of APP. 
These results were negative for the detection of AICD, but APP detection was 
demonstrated suggesting that the A8717 antibody was potentially not sensitive 
enough to detect the AICD or that the staining of the APP, which is much more 
highly expressed, was masking the staining of the AICD which was expressed 
at much lower levels. Research has also stated that the AICD is rapidly 
degraded in the cytoplasm of cells after its production by the Insulin-Degrading 
Enzyme (IDE) making detection of AICD difficult (Edbauer et al. 2002). 
Previously a study by Kerridge et al showed that the A8717 antibody was able 
to detect low levels of nuclear AICD in the nuclei of SH-SY5Y cells which were 
transfected with an APP695 overexpression plasmid (Kerridge et al. 2014). 
The PMOs which were designed for the induction of APP exon skipping 
increase the expression levels of APP695 by skipping of exons 7 and 8 
preferentially producing more APP695 relative to APP770 and APP751 whilst 
maintaining the same levels of total APP as are normally produced within the 
cell. The APP695 overexpression plasmid on the other hand increases 
APP695 and total APP levels hence producing more AICD than PMO 
treatment explaining the visualisation of AICD staining. This group also utilised 
NH4Cl, an alkalising agent, and the tyrosine kinase inhibitor Gleevec, both of 
which are thought to stabilise the AICD, delaying its rapid degradation and 
allowing for better visualisation of AICD within cell nuclei (Kerridge et al. 2014). 
According to this research, utilisation of these compounds alongside the 
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A8717 antibody should allow for better visualisation of the change in AICD 
expression as a result of the PMOs designed in this thesis. 
Immunostaining with the Poly8119 anti-AICD antibody (figure 6.2) 
demonstrated strong distinct nuclear staining in all samples, which did not co-
localise with the staining of the 22C11 antibody. This staining was indicative 
of AICD, but its presence in all samples including the controls meant that either 
the staining with this antibody was not specific, or that there was no correlation 
between APP695 expression and transcriptionally active nuclear AICD. The 
latter is unlikely however, as the correlation between transcriptionally active 
AICD and APP695 has been thoroughly researched (Belyaev et al. 2010; 
Nalivaeva & Turner 2013). Therefore, the more likely explanation was that the 
nuclear staining seen was non-specific. Previous research had confirmed the 
ability of this antibody to detect nuclear transcriptionally active AICD and 
therefore the results demonstrated here are unexpected (Tampellini et al. 
2011). 
Western blotting conducted to detect the AICD utilised the 22C11, A8717 and 
Poly8119 antibodies, these were used as alternatives to 
immunocytochemistry. Westerns utilising the 22C11 antibody were as 
expected and were unable to detect the AICD, as this antibody recognises an 
epitope on the N-terminal of APP whereas the AICD is cleaved from the C-
terminal. The A8717 antibody however showed clear indication of the AICD 
peptide detected in the protein extracted from SH-SY5Y cells transfected with 
the APP695 overexpressing positive control, and on overexposure of this blot 
revealed indications of very low levels of AICD present in protein extracts from 
the samples transfected with PMOs for APP exon skipping (figure 6.4). This 
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was an expected result as this increase in AICD demonstrated in those 
samples which showed increases in APP695, but not in control cells. This is 
in agreement with previous research, and further confirms the theory that 
increases in APP695 lead to increases in AICD levels as a result. Although the 
AICD levels expressed here are low, it is confirmation that the detection of the 
AICD is possible, and that the PMOs modulating alternative splicing are able 
to increase AICD levels.  
The Poly8119 antibody was also used in western blotting, and showed a single 
band for APP, while showing no indications of AICD protein (6.5). This 
antibody when used for immunocytochemistry demonstrated nuclear staining 
indicative of AICD in SH-SY5Y cells under all conditions, PMO transfected and 
controls. However, upon the quantification of the cells which contained nuclear 
staining it appeared that there was no correlation between APP695 expression 
and AICD expression. The results of both of these experiments suggest that 
this antibody is not specific to the AICD, as it opposes the results 
demonstrated by the A8717 antibody, and the results shown in previous 
research (Kerridge et al. 2014; Grimm et al. 2013).  
Previous studies have demonstrated transcriptional activity of the AICD which 
is produced through APP695 proteolytic processing and its ability to regulate 
multiple genes which are relative to AD (Belyaev et al. 2010; Kerridge et al. 
2014; Shu et al. 2015). RT-qPCRs have been conducted on samples where 
AICD has been upregulated and looked at the effect this has on NEP and other 
downstream targets of the AICD (Kerridge et al. 2014). Here a similar strategy 
was used, RT-qPCRs were conducted on RNA extracts from PMO transfected 
cells to determine NEP and AQP1 expression levels and how the expression 
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levels of these genes changed in control vs PMO transfected cells. This 
allowed us to look for changes in the expression levels of these AD relevant 
genes as a direct consequence of exon skipping from our PMOs, but also 
allowed for investigation into the possible changes in transcriptionally active 
AICD given that the expression levels of NEP and AQP1 are regulated by the 
expression levels of APP695 dependent AICD. RT-qPCR analysis with NEP 
specific primers showed an increase in the expression levels of this gene, 
suggesting that there was an increase in the transcriptionally active AICD in 
the PMO transfected cells when compared to control non-transfected cells 
(figure 6.6). The biggest increase in transcriptionally active AICD was seen in 
the SH-SY5Y cells which were transfected with PMOs for exon 7 skipping, 
followed by exon 8 and then the combination of PMOs 7+8 together. The 
pattern shown for RT-qPCR using the AQP1 specific primers also shows the 
same pattern. These results confirm that PMO transfection increasing APP695 
does indeed increase transcriptionally active AICD. This increase in 
expression transcriptionally active AICD and subsequent increases in 
downstream genes which are relevant to AD such as NEP and AQP1. The 
accumulation, aggregation and deposition of Aβ is implicated as one of the 
first steps in the progression of AD and leads to the atrophy which spreads 
throughout the brain and leads to the deficits which are seen in AD (Folch. et 
al 2015). The clearance of Aβ through the regulation of Aβ related genes such 
as AQP1 and NEP is a potential therapeutic strategy for the treatment AD, and 
the work presented in this chapter confirms the ability of the APP exon skipping 
PMOs designed here to increase the expression of these genes through 




The work conducted here utilised antisense oligonucleotide technology. 
Antisense oligonucleotides are useful tools in molecular biology due to their 
specificity, limited off-target effects, and resistance to degradation, which allow 
for prolonged interactions. Antisense technologies are commonly used in exon 
skipping, where the oligonucleotide influences splicing machinery to alter 
patterns of exons (Verhaart & Aartsma-rus 2012). This work aimed to exploit 
antisense technology to manipulate the splicing machinery to induce exon 
skipping in the APP gene. PMOs were designed based on information from a 
variety of bioinformatic resources such as prediction of splice regulatory 
elements, secondary structure of the RNA transcript and binding energies 
(Aartsma-Rus, van Vliet, et al. 2009; Popplewell et al. 2009). Using all of this 
data, a total of 9 PMOs were designed, 5 for the targeting of APP exon 7, and 
4 for the targeting of APP exon 8. Analysis of these PMOs through RT-PCR 
showed variable ability of these PMOs to induce exon skipping and shifting the 
splicing pattern to increasing the expression of APP695. Further work 
conducted confirmed these changes in mRNA splicing translate to changes in 
APP isoform expression at the protein level and a subsequent increase in 
APP695 protein. These increases in APP695 which are detected after PMO 
treatment could have important implications in terms of AD. Research has 
shown that APP695 leads to the production of Aβ through its preferential 
processing via β-secretase, and research by Belyaev et al. in particular 
showed a 2-fold increase in Aβ levels in SH-SY5Y cells which were generated 
to overexpress APP695 (Cordy et al. 2003; Ehehalt et al. 2003; Belyaev et al. 
2010). However, previous research has demonstrated decreases in the 
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principally neuronal APP695 isoform, and increases in APP770 and APP751 
have been detected in the brains of AD patients, and a corelation of this 
change in APP isoform expression with increased deposition of Aβ, suggesting 
that this change away from the physiological expression of APP isoforms has 
detrimental effects on the brain and aids progression of synaptic dysfunction 
in AD (Johnson et al. 1990; Menéndez-González et al. 2006). This correlation 
can be explained through the production of a small peptide which is produced 
from the processing of APP, the AICD. Previous research has confirmed that 
the AICD peptide, when specifically produced from the processing of APP695, 
is transcriptionally active, and is able to translocate to the nucleus and regulate 
the expression of many genes which are related to the clearance or breakdown 
of Aβ (Belyaev et al. 2010; Nalivaeva & Turner 2013; Kerridge et al. 2014). 
Research by Kerridge et al. showed that when increasing the expression of 
the AICD, subsequent upregulation of NEP and TTR is detected, which 
correlates to significant reductions in Aβ (Kerridge et al. 2014). This could 
suggest that although APP695 was shown to produce high levels of Aβ, the 
regulation of these levels by the AICD in the brain prevent their over 
accumulation, and acts to prevent the toxicity caused by Aβ. The detrimental 
effects associated with this loss of APP695 in the brain could be due to this 
loss of regulation of Aβ by the AICD, and not solely the levels of Aβ that are 
present.  
There are also many other genes that have been shown to be regulated by 
the AICD, and the interactions of the AICD with these genes will need to be 
studied in greater depth to fully understand how these may play a role in AD. 
One such downstream target is glycogen synthase kinase 3 (GSK3). Studies 
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have shown that the AICD induces upregulation and increased activation of 
GSK3β (von Rotz et al. 2004; Spears et al. 2014). GSK3β typically acts to 
phosphorylate substrates, including important proteins related to AD such as 
tau (Spears et al. 2014). A consequence of tau phosphorylation by GSK3 is 
an increase in hyperphosphorylated tau, and a decrease in the interaction 
between tau and microtubules, leading to an increase in self aggregation as a 
result. Studies with GSK3-overexpressing transgenic mice suggest that 
inhibition of GSK3β prevent the formation of tau aggregate, and studies in 
transgenic Drosophila models revealed that tau phosphorylation correlates 
with tau aggregation (Pérez et al. 1996; Jackson et al. 2002; Noble et al. 2005). 
These results suggest that increased AICD could lead to increased 
hyperphosphorylated tau and lend to worsening AD phenotype. This is a 
potential limitation of this study, as the downstream effects of increasing the 
AICD via shifting the alternative splicing of APP has yet to be researched in 
great detail and will need to be researched further to assess whether there are 
any other risk genes which are upregulated in response to the increased AICD. 
This work was able to confirm the ability of the PMOs designed to increase the 
expression of the AICD, as well as the expression of Aβ clearing genes NEP 
and AQP1 and implicate this as a possible therapeutic.  
Current therapeutics for AD focus on ameliorating the symptoms of AD, 
however prevention and reversal of AD is not yet possible. Mainline drugs for 
AD treatment are based on cholinesterase inhibitors (CIs) and N-methyl-D-
aspartate (NMDA) antagonists (Mendiola-Precoma et al. 2016). Cholinergic 
systems in the basal forebrain are affected in AD, including loss of cholinergic 
neurones, loss of enzymatic function for acetylcholine synthesis and 
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degradation (Yiannopoulou & Papageorgiou 2013; Mendiola-Precoma et al. 
2016). This results in memory loss and deterioration of other cognitive and 
noncognitive functions such as neuropsychiatric symptoms, in order to 
enhance the cholinergic transmission CIs are able to delay the degradation of 
acetylcholine between the synaptic cleft (Yiannopoulou & Papageorgiou 2013; 
Mendiola-Precoma et al. 2016). As of now, 3 CI based drugs have been 
approved for the treatment of mild to moderate AD: donepezil, galantamine 
and rivastigmine. A therapeutic for moderate to severe AD is memantine, an 
NMDA antagonist which acts to protect neurones from excitotoxicity, with this 
drug leading to improvements in cognition in patients with severe AD 
(Yiannopoulou & Papageorgiou 2013; Mendiola-Precoma et al. 2016). Much 
of the current research into potential AD therapeutics have aimed at directly 
reducing overall Aβ levels, such as BACE1 and γ-secretase inhibitors. These 
therapeutics have generally not fared well in terms of their ability to modify the 
pathological processes underlying AD progression, and have generally failed 
at the clinical trial stage (Yiannopoulou & Papageorgiou 2013; Graham et al. 
2017; Panza et al. 2019). This may be due to the fact that under physiological 
conditions, Aβ plays various important physiological functions such as 
regulating synaptic function, promoting recovery from brain injury, and 
protecting the body from infection, with some researchers suggesting Aβ 
deposition to be a compensatory mechanism in response to the neuronal 
damage associated with AD, rather than a factor which is causative of the 
disease (Crdenas-Aguayo et al. 2014; Brothers et al. 2018). Therefore, the 
absolute reduction of Aβ may interfere with vital regulatory processes in the 
brain and could be a reason for the failure of these therapies. The PMO based 
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therapy designed here shows significant advantages over other Aβ targeting 
therapies as they do not focus solely on increasing the clearance, or 
decreasing the production of Aβ but rather work on multiple levels to restore 
and maintain the physiological levels of the APP isoforms, and therefore 
restore the brains homeostatic regulation of Aβ. These PMOs act to induce 
APP alternative splicing, thereby restoring and reversing the APP splicing 
pattern to that which is seen at physiological levels in the brain (high APP695, 
low APP770/APP751) rather than that which is seen during AD (low APP695, 
High APP770/APP751). This increase in APP695 directly influences the 
transcriptionally active AICD which under physiological conditions acts to 
regulate various genes, including those involved in the transport and clearance 
of the Aβ peptide.  
Several antisense oligonucleotide therapies have been approved for clinical 
use in recent times. Most notably, Eteplirsen, a 30-nucleotide exon-skipping 
PMO designed for the treatment of Duchenne muscular dystrophy (DMD) was 
granted accelerated approval by the US Food and Drug Administration (FDA), 
however, even with this drug there were major issues regarding attaining 
sufficient levels of ASO distribution and high uptake into the target organ 
(Evers et al. 2015; Lim et al. 2017; Rowel et al. 2017). Neurodegenerative 
disorders are at an advantage in terms of ASO uptake and distribution as 
research has suggested that ASOs of most chemistries are readily taken up 
by neurones and glia once reaching the nervous system (Evers et al. 2015). 
Uptake is suggested to take place through nucleic acid channels, but these 
mechanisms are not fully understood (Evers et al. 2015). Once in the nervous 
system vascular barriers prevent ASOs from entering the periphery thus 
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reducing breakdown by the kidney or liver allowing them to reach clinically 
effective concentrations (Evers et al. 2015). These factors increase the viability 
of ASO based therapies for the treatment of AD, such as the PMOs designed 
in this work. Despite this, delivery of these ASOs to the nervous system is a 
challenge which must be overcome, and the best delivery route needs to be 
found in order for ASO based therapeutics to be used effectively. In order to 
reach the nervous system drugs will need to cross the BBB, or blood-spinal 
cord barrier (BSCB) (Evers et al. 2015). These barriers prevent most 
molecules from entering the nervous system from the blood circulation, limit 
transport to/from the brain and separates the peripheral immune system from 
the brain. Therefore, ASOs would find it very difficult to cross these vascular 
barriers when delivered systemically, even though this method of delivery is 
generally thought to be less invasive than direct delivery. There have however 
been many promising potential delivery methods which have been the focus 
of recent research. One such ASO delivery method is the use of modified 
ASOs known as cell-penetrating peptide (CPP) delivery systems (Stalmans et 
al. 2015). CPPs are a group of peptides which are able to cross cell 
membranes more easily than normal, non-modified ASOs, without causing 
membrane damage (Stalmans et al. 2015). The general mechanism of entry 
of CPPs is not fully understood, however there is consensus that this 
mechanism involves both endocytosis and a direct penetrative mechanism, 
and these pathways vary based on cell types and cargos (El-Andaloussi et al. 
2005; Bechara & Sagan 2013; Copolovici et al. 2014). CPPs can be up to 30 
amino acids in length and can carry different cargo. Systemically delivered 
ASOs tagged with arginine rich CPPs have been shown to be able to cross 
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the BBB in vivo and lead to wide distribution throughout the brain of wild-type 
mice, making this a promising delivery system for ASOs to the CNS (Du et al. 
2011). Although there are many advantages of systemic ASO delivery there 
are also several disadvantages. These disadvantages include the fact that the 
majority of systemically delivered ASOs end up in the liver and kidney and are 
subsequently broken down (Sazani et al. 2002; Aartsma-Rus & van Ommen 
2009). Another major disadvantage is that the dose required to be delivered 
to allow the ASO to cross the BBB and reach the CNS at a therapeutically 
effective concentration is approximately 100-fold higher than if the ASO was 
delivered directly into the CNS making this method far more expensive and 
increasing the risks of toxicity (Banks et al. 2001; Erickson et al. 2012).  As an 
alternative to this, delivery of ASOs via the nasal passage provides a non-
invasive method of bypassing the BBB while avoiding the toxicity of systemic 
delivery. Intranasal delivery has previously been shown to be an effective 
method for drug delivery in the past and clinical trials have reported positive 
data regarding this, with intranasally administered insulin having been 
thoroughly  researched (Benedict et al. 2007; Benedict et al. 2011; Craft et al. 
2012; Claxton et al. 2013). Research of intranasal drug delivery has 
demonstrated that intranasal administration leads to greater tissue-to-blood 
concentration ratios in the brain over 2 hours as compared to intravenous 
administration, and increased drug targeting to the brain and spinal cord by 5- 
to 8-fold (Dhuria et al. 2009). Meta-analyses of the safety and side-effects of 
intranasally administered drugs therapeutics such as insulin, steroids, and 
oxytocin show that favourable safety profiles, even compared to the same 
compounds being intravenously infused (Nathan 2011; Shemesh et al. 2012). 
248 
 
For example, insulin when administered intravenously leads to elevated blood 
pressure, and enhanced hypothalamo–pituitary–adrenal secretory activity 
(Fruehwald-Schultes et al. 2001; Kern et al. 2005). However, intranasal 
administration of insulin has not been associated with blood pressure changes 
or no increased hypothalamo–pituitary–adrenal secretory activity (Benedict et 
al. 2004; Benedict et al. 2005). Intranasal delivery has also been shown to 
allow ASOs to cross the BBB. The 13-mer GRN163 oligonucleotide is a 
telomerase inhibitor and a potential therapeutic for brain tumours. Research 
has shown that  intranasal delivery of this ASO led to favourable distribution 
and efficacy of the therapeutic in vivo and supports the efficacy of intranasally 
administered ASOs to be used cross the BBB and reach the CNS at 
therapeutic levels (Hashizume et al. 2008). 
Direct delivery methods can bypass vascular barriers through direct infusion 
into the cerebrospinal fluid (CSF). ASOs can be infused 
intracerebroventricularly (ICV) directly into the CSF in cerebral ventricles or 
intrathecally into the subarachnoid space of the spinal cord (Soderquist & 
Mahoney 2010; Evers et al. 2015). These methods have advantages over 
systemic delivery. Administration results in immediate high levels of the 
administered drug in the CSF, meaning that lower doses can be used and 
there is a lower risk of toxicity as a result. Also, as there is free exchange 
between the CSF and the cells of the brain and the BBB, this will act to prevent 
the transport of these ASOs out into the peripheral circulation, so direct 
delivery can relatively rapidly result in a therapeutic drug concentration in the 
CNS, and these levels can be sustained for relatively long periods (Soderquist 
& Mahoney 2010; Evers, Lodewijk J.A. Toonen, et al. 2015). The intrathecal 
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and ICV methods of drug delivery have been implemented in human clinical 
trials for ALS and SMA, as well as in vivo in mice models of Huntington’s 
disease, all of which have shown promising results and a good safety profile 
(Passini et al. 2011; Miller et al. 2013; Østergaard et al. 2013; Rigo et al. 2014; 
Chiriboga 2017). Nusinersin, an ASO based therapy for SMA was also 
delivered through intrathecal injections, and has shown promising results and 
has now gained FDA approval for the treatment of SMA, making this a viable 
route for future ASO based therapies to be delivered to the CNS effectively 
(Ottesen 2017). 
ASOs and their ability to interfere with pre-mRNA splicing has been thoroughly 
researched as potential therapeutics for disease such as spinal muscular 
atrophy (SMA) and familial hypercholesterolaemia. SMA is an autosomal 
recessive disorder caused by a mutation in the survival motor neuron 1 
(SMN1) gene with the most common mutation leading to a deletion in exon 7 
of this gene resulting in the formation of a truncated and non-functional SMN 
protein (Rinaldi & Wood 2018; Gidaro & Servais 2019). One such ASO drug 
named nusinersen gained FDA approval in 2016 becoming the first drug 
approved for the treatment of SMA (Neil & Bisaccia 2019). Nusinersin is a 2’-
O-methoxyethyl (2’-MOE) which was delivered by intrathecal injection for the 
purpose of blocking ESS and ISS motifs promoting the inclusion of exon 7 of 
SMN1 into the mRNA effectively restoring the expression of functional SMN  
(Neil & Bisaccia 2019). Mipomersen is another such ASO that has gained FDA 
approval as a therapeutic (Hair et al. 2013). Mipomersen is a second 
generation ASO that is designed for the treatment of familial 
hypercholesterolaemia by binding to and subsequently degrading 
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apolipoprotein B through activation of RNase H activation, inhibiting 
apolipoprotein B protein (Raal et al. 2010). This strategy effectively leads to 
reduction in the concentrations of apolipoprotein B and proves successful in 
treating familial hypercholesterolaemia (Hair et al. 2013). 
Antisense oligonucleotides which reached clinical trials have generally shown 
good safety profiles and are well-tolerated by humans, in general showing only 
mild adverse effects such as flu-like symptoms or reactions around the site of 
administration such as post-lumbar puncture syndrome or back pain (Miller et 
al. 2013). Elevated transaminases, a possible indication of liver damage, have 
also been reported in some clinical trials with Mipomersen, but not in all studies 
(Raal et al. 2010). Considering that ASOs have been thoroughly researched 
and utilised to correct aberrant pre-mRNA splicing in other diseases, using 
ASOs for exon skipping to restore the physiological expression of APP695 has 
great potential for use in AD therapy.  
As previously mentioned, there have been multiple ASOs researched for their 
potential to be used as therapeutics in AD. One such ASO which is of particular 
interest as it targeted APP, was the PS-ASO termed OL-1, which was 
designed to target the Aβ region of APP in order to reduce its expression (Farr 
et al. 2014; Evers, Toonen et al. 2015). This ASO was delivered via 
intracerebroventricular administration alongside an Aβ antibody in SAMP8 
mice which show spontaneous overexpression of APP, subsequent Aβ plaque 
formation (Kumar et al. 2000). Treatment in this model demonstrated 
reductions in the levels of both APP and Aβ (Kumar et al. 2000). Further 
research with this antisense utilised Tg2576 mice, a mouse model containing 
the APPswedish mutation, and therefore demonstrating age-related 
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impairment in learning and memory, elevated brain levels of Aβ, decreased 
efflux of Aβ from the brain, and increased neuroinflammation and oxidative 
damage (Farr et al. 2014). The antisense drug was either delivered centrally 
into the lateral ventricle or intravenously via the tail vein and mice were tested 
for changes in learning and memory via the T-maze foot shock avoidance test, 
the novel object recognition test and the elevated plus maze test before being 
sacrificed and the brain and cytokine levels were analysed (Farr et al. 2014). 
In mice treated with the OL-1 ASO  there were significant decreases in APP 
levels, significant decreases in markers of neuroinflammation, and reversal of 
learning and memory deficits (Farr et al. 2014). The major disadvantage of the 
OL-1 ASO is that it is a  phosphorothiolated ASO, which utilises RNase H in 
order to reduce expression of APP, which reduces total APP. This is significant 
as APP has been shown to play a variety of roles in the brain, including 
neuronal growth, neuronal calcium homeostasis, transcriptional regulation and 
synaptic functions (Berridge 1998; Octave et al. 2013).  
Another important study which utilized ASOs in the development of a potential 
therapeutic for AD through targeting APP was the study by Chang et al. in 
which SSOs) were used to modulate APP splicing and reduce Aβ (Chang et 
al. 2018). In this study 2’-MOE 18-mers SSOs were designed to block APP 
exon 17 splicing with the aim to produce an alternatively spliced APP mRNA 
lacking exon 17, which theoretically should  prevent  γ-secretase cleavage of 
APP, and therefore prevent the production of the Aβ42 peptide. Analysis of 
these SSOs in HEK293Tcells and in DS cells, which contain 3 copies of APP 
and therefore an increase APP and Aβ42 protein abundance. RT-PCR 
analysis of cells transfected with these SSOs demonstrated effective exon 
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skipping, and via immunoblotting it was confirmed that these SSOs reduced  
Aβ42 levels by 45%.  In vivo testing of these SSOs involved designing SSOs 
to the murine APP exon 15 as this is homologous to human APP exon 17 
(Chang et al. 2018). Administration of these SSOs to wild-type mice via 
intracerebroventricular injection, followed by RT-PCR analysis of the RNA 
isolated from the cortex and hippocampus of these mice demonstrated 
significant skipping of APP exon 15 in both of these brain regions after 3 
weeks. SSO levels were sustained in the brain of these mice up to 3 months 
post-injection, and levels of  Aβ42 were reduced by 57% compared to mice 
treated with a control SSO (Chang et al. 2018). These results are again 
promising, as they confirm the use of antisense therapies in vivo, and show 
that therapeutically relevant concentrations of antisense therapies can reach 
the CNS and have sustained, long-term effects.  
As with all studies, there are limitations to the study that is presented in this 
thesis which will affect the ability to definitively address the questions being 
asked. The major restrictions to this experiment were the restrictions in terms 
of cell culture models available for use, and the limit on the number of and 
types of ASO tested. The use of cell culture models in this study were 
necessary and allowed for the elucidation of significant answers to the 
questions posed. However, the drawbacks to the SH-SY5Y cell model which 
were used in this study are that only one type of cell exists in the system as 
opposed to having mixed populations of cells as would be present in vivo. Cells 
in these systems generally do not necessarily behave in the same way as in 
vivo, and therefore results seen in these cell lines do not always translate to in 
vivo. Use of in vivo models would overcome these limitations and make the 
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results more predictive of therapeutic applications. Despite these drawbacks, 
cell culture is and will remain the preliminary model for many areas of research 
in molecular biology due to relatively low cost, ease of replicability and the 
ease of manipulation, all of which cannot be matched by other model systems.  
In this project several PMOs were designed targeted at specific sites, this 
required the use bioinformatic tools in order to assess the target sequences 
for PMO binding. In order to make concrete conclusions about the success of 
the PMOs in vitro compared to the predicted success in silico a much larger 
number of PMOs are required than were designed. Despite this, in silico 
predictions were sufficiently successful to produce PMO sequences that 
induced APP exon skipping. 
The method used for quantifying exon skipping also has limitations due to the 
intrinsic biases that are present during the process of an RT-PCR. In an exon 
skipping PCR, it has been suggested that because the exon skipped amplicon 
is shorter than the non-skipped amplicon, the skipped amplicon is 
preferentially amplified in the PCR reaction, and will therefore be 
overestimated (Spitali et al. 2010; Verheul et al. 2016). However, the degree 
of bias depends on a variety of factors including the pre-amplification 
stoichiometry of the transcripts with and without the exon skip, the length 
difference between the transcripts with and without the exon skip, and the total 
number of PCR cycles performed (Verheul et al. 2016). Generally, the degree 
of amplification bias of shorter products vary, but typically do tend to 
overestimate the levels of induced exon skipping (Spitali et al. 2010; Verheul 
et al. 2016; Hiller et al. 2018). It has also been shown that in some cases 
densitometric analysis could also negatively bias the shorter, exon skipped 
254 
 
amplicon as the longer unskipped PCR amplicon will bind more intercalating 
SYBR Safe than the shorter skipped amplicon, leading to a brighter signal and 
therefore overestimation of the larger bands, and underestimation of exon-
skipping percentages as a result (Spitali et al. 2010). Due to these biases, RT-
PCR and densitometric analysis may not be the best methodology for 
assessing changes in exon skipping levels. A multicenter comparison of exon 
skipping quantification methods by Hiller et al. showed that the gold standard 
for exon skipping quantification was the digital droplet PCR (ddPCR) system 
(Hiller et al. 2018). This system works by detecting single nucleic acid 
molecules compartmentalized in droplets and this method is highly sensitivity 
and precise. The major disadvantage of this technique is represented by the 
high costs associated with the ddPCR machine and the reagents, all of which 
limit the availability of this method (Verheul et al. 2016; Hiller et al. 2018). 
Compared to this, a single round of PCR combined with quantification with an 
Agilent 2100 Bioanalyzer resulted in a 2.3-fold overestimate in exon skipping 
compared to ddPCR, an overestimation that was said to acceptable (Hiller et 
al. 2018).  
Hiller et al. also showed that the use of nested PCR followed by densitometry 
via ImageJ, as was used throughout this thesis, led to a 2.6-fold exon skipping 
over estimation compared to ddPCR (Hiller et al. 2018). This method showed 
large variation between the exon skipping results which were obtained via this 
method from each of the different labs that took part in this study and 
demonstrated that when a single operator processed all the acquired images, 
exon skipping levels showed less variation (Hiller et al. 2018). This could mean 
that this method, when results are processed consistently via a single 
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individual could lead to a lower than 2.6-fold overestimation in exon skipping 
levels, potentially making this method as good as the Agilient bioanalyzer 
method, which showed a 2.3-fold over estimation in exon skipping compared 
to ddPCR (Hiller et al. 2018). In terms of the research conducted in this thesis, 
all data was process by a single operator, and although this is method is not 
the best possible method of quantifying exon skipping, the low cost, ease of 
access and the fact that it could be used systematically and consistently 
throughout this study meant that it was the best possible method of exon 
skipping quantification that we had available at the time. 
Following the work discussed in this thesis, future work would include 
performing RT-qPCRs for other Aβ related genes which are regulated by the 
AICD peptide. This includes genes such as  transthyretin which is known to 
play a role in the removal of Aβ from the brain (Kerridge et al. 2014). These 
would consolidate the findings already shown and demonstrate a broad 
pathway of Aβ regulation by the transcriptionally active AICD produced 
through alternative splicing modulation increasing relative APP695 levels. 
Another crucial step to determining the effectiveness for these PMOs 
therapeutically would be to characterise the effects of these exon skipping 
PMOs on levels of Aβ, through performance of an ELISA in order to determine 
whether these increases in expression seen in the Aβ clearing genes as a 
result of PMO treatment result in functional decreases in the levels of Aβ 
(Schmidt et al. 2005). Further work in the immediate future would be to 
characterise the effects of these PMOs in a more relevant model such as 
induced pluripotent stem cell-derived neurones and potentially patient cell 
lines. This would be the most accurate cell culture model possible to ascertain 
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the full effects of these PMOs, however, ultimately, with appropriate peptide 
conjugations these PMOs would need to be tested in vivo to assess the true 
effect of exon skipping on APP695, AICD and more broadly on AD progression 
and pathology. In terms of models to be used for future research, there are 
two major candidates. The first candidate for in vivo study of these PMOs is 
the Tg(APP)8.9Btla mouse model (Lamb et al. 1993). This mouse model 
contains a stably integrated insert of the entire, unrearranged 400 kb human 
APP gene. This model is perfect for proof-of-concept experiments to show that 
the results demonstrated by these PMOs in cell models can translate to in vivo 
experiments, and to experiment on the best method in order to deliver these 
PMOs to the CNS (Lamb et al. 1993). The other mouse model which could be 
considered when testing these PMOs in vivo is the J20 mouse model (Mucke 
et al. 2000). This transgenic mouse model expresses a mutant form of the 
human APP with both the APPswedish and the Indiana mutations. This model 
shows progressive deposition of Aβ as they age and would be useful as they 
allow us to test the PMOs designed in this study for their efficacy in vivo as 
proof of concept, but also allow us to assess the therapeutic applicability of 
these PMOs by assessing the effects of these PMOs on the levels of Aβ, AICD 
and downstream genes such as neprilysin (Mucke et al. 2000). 
As of 2015, it is estimated that 46.8 million people worldwide are living with 
AD, with cases expected to grow to 74.7 million in 2030 and 131.5 million in 
2050 (Prince et al. 2015). If the PMO based therapeutic which was designed 
in this study were to translate to a clinical setting, it is possible that this therapy 
could be amenable to this entire population of patients because this treatment 
is not specific to a single mutation, or a single type of AD, but rather could be 
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applied to the broad population of AD patients in order to attempt and restore 
the APP splicing pattern to that which is observed under physiological 
conditions. The delivery method for PMOs is also something which would need 
to be considered, and as previously discussed this is one of the great 
challenges for ASO based therapies for neurodegenerative diseases. In terms 
of delivery for the PMOs based therapy designed in this study, the most 
promising route of delivery is intrathecal delivery. As previously mentioned, 
this route of delivery has been thoroughly researched and has proven to be 
effective for the delivery of Nusinersen, an ASO based therapy for SMA which 
has gained FDA approval (Neil & Bisaccia 2019).  
In terms of economic cost, it is estimated that the global cost of AD was US 
$818 billion in 2015, and over US $1.1 trillion in 2018 (Prince et al. 2015). The 
current first line treatments for AD are donepezil, galantamine, rivastigmine 
and memantine, and these cost between £50-100 per month, however, these 
drugs provide symptomatic relief, but are not able to modify the pathological 
processes underlying the disease and do not appear to alter disease 
progression. These AD drugs are relatively cost-effective when compared to 
ASO based therapies such as Nusinersen, which has a yearly cost of between 
US $258,448 and US $907,665 per year, or Eteplirsen which costs US 
£300,000 per year (Lim et al. 2017; Dangouloff et al. 2021). When considering 
the PMO based AD therapy designed in this study, it is likely that this will cost 
more than the currently approved AD drugs, and potentially closer to the price 
of nusinersen and eteplirsen, however, when considering the economic 
burden of AD globally, it is possible that this treatment, if effective, could add 
real economic value, and benefit the quality of life of patients. 
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